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ABSTRACT 
 
Clostridium difficile is a spore-forming anaerobic bacillus and a leading cause of nosocomial 
diarrhoea. C. difficile infection (CDI) occurs often following antibiotic treatment leading to 
alteration of the gut microbiota enabling C. difficile to thrive and cause a range of 
symptoms from asymptomatic carriage to severe diarrhoea, pseudomembranous colitis 
(PMC) and death. C. difficile virulence is associated with production of toxins (A, B and 
binary CDT) nonetheless this bacteria harbours an array of other virulence factors. The role 
of toxins has been well studied by utilising purified/recombinant toxins however it is 
unknown how the gastrointestinal mucosa responds to bacterial cell. 
In the present study, C. difficile-mediated innate immunity response was investigated 
primarily utilising four different C. difficile strains including: R20291 a hypervirulent strain 
(A+B+, CDT+), 630 a fully sequenced strain (A+B+) and variant strains M68 and CF5 (A-B+). 
Initial studies showed that under laboratory conditions all strains shared comparable 
survival and sporulation capacity (in an aerobic environment), whereas strains R20291, 
M68, and CF5 achieved similar growth kinetics.   
Bacterial adherence to human intestinal epithelia cell (IEC) study revealed that strain 
R20291 adhered significantly to Caco-2 cells compared to other strains. Although an 
equivalent adherence level was noted with strains 630, M68 and CF5 but it did not 
correlate with downstream cellular responses. While R20291 was the most potent, 630 and 
M68 were found to be as cytotoxic, leading to significant cell apoptosis. Furthermore, these 
strains showed an extensive IEC tight junction disruption leading to paracellular 
permeability, detected as occludin redistribution, transepithelial electrical resistance (TEER) 
and FITC-dextran influx. In contrast, strain CF5 had the least effect on cell death, IEC barrier 
integrity and showed less Rac1 glucosylation when compared with strain M68. Although all 
four strains induced antimicrobial immunity and pro-inflammatory cytokines, CF5 mediated 
the least pro-inflammatory responses. Similar findings were also observed in an ex vivo 
model of infection utilising human colonic explants.   
Noting the anaerobic nature of C. difficile, experiments conducted in an Ussing vertical 
chamber system showed significant increase in antimicrobial and pro-inflammatory 
responses and a rapid TEER loss.  
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C. difficile-mediated dendritic cell (DC) activation established in murine model system 
demonstrated up-regulation of co-stimulatory molecules leading to a predominant anti-
inflammatory IL-10 secretion. Similar results were also detected with human monocyte-
derived DCs. Despite a significant IL-10 expression in infected murine DCs, which is known 
to suppress IL-12 and IL-23 induction, it was detected that C. difficile may generate a 
cytokine milieu that favours dual Th1/Th17 immunity. Moreover, C. difficile strains 
triggered an ASC-containing inflammasome causing the activation of caspase-1 and release 
of mature IL-1β.   
Utilising R20291 and 630 isogenic mutants the role of toxins in murine and human DC 
function was investigated observing DC activation and cytokine production in a toxin-
dependent and independent manner. These findings indicated that multiple bacterial 
factors may play a role in initiating host innate immune responses to C. difficile infection.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
ACKNOWLEDGEMENTS 
 
Firstly, I would like to thank Dr. Mona Bajaj-Elliott my primary supervisor, for providing me 
with the opportunity to pursue research as part of her team and for her support and 
guidance. I also would like to thank my second supervisor, Dr. Elaine Allan for her help and 
advice. 
I also thank Dr. Lisa Dawson and Dr. Richard Stabler for all their guidance and advice, Prof. 
Nigel Minton and Dr. Sarah Kuehne for providing me with C. difficile isogenic mutant strains 
and Dr. Bertrand Vernay for carrying out the time-lapse and confocal microscopy. 
I am very grateful and appreciate all the help and support given to me throughout my 
studies by Lindsey, Marianne, Hannah, Holly, Anna, Mark, and Nayani. I also thank all other 
members of both 5th and 6th floor labs at ICH for making the long hours in the lab an 
enjoyable experience. 
I would like to express my gratitude to everyone at Eastman Dental Institute for being very 
accommodating over the course of my project. I particularly thank Dr. Haitham Hussain for 
his invaluable help, and Kat and Mike for sharing their experiences of working with C. 
difficile. 
Finally, I owe my deepest and foremost gratitude to my parents and my brother for their 
love and support, especially my mother and brother, who gave me endless support and 
encouragement after our sad loss. To my family, I dedicate this thesis. Last but not least, I 
thank Mohammad for sharing this journey with me and always being there when I needed.  
 
 
 
 
 
 
 
 
6 
 
TABLE OF CONTENTS 
 
DECLARATION .......................................................................................................................... 2 
ABSTRACT ................................................................................................................................ 3 
ACKNOWLEDGEMENTS ........................................................................................................... 5 
TABLE OF CONTENTS ............................................................................................................... 6 
LIST OF FIGURES .................................................................................................................... 11 
LIST OF TABLES ...................................................................................................................... 14 
PUBLICATIONS & ABSTRACTS ............................................................................................... 15 
ABBREVIATIONS .................................................................................................................... 17 
Chapter 1 ............................................................................................................................... 22 
1.1 Clostridium difficile ................................................................................................ 23 
1.1.1 Introduction ................................................................................................... 23 
1.1.2 C. difficile Virulence Factors ........................................................................... 24 
1.1.3 C. difficile Pathogenesis ................................................................................. 32 
1.1.4 Risk Factors .................................................................................................... 33 
1.1.5 Treatment ...................................................................................................... 34 
1.1.6 Epidemiology .................................................................................................. 35 
1.1.7 The Evolution of C. difficile ............................................................................ 37 
1.1.8 The Animal Models of C. difficile Infection .................................................... 39 
1.2 Host Immune Response ......................................................................................... 40 
1.2.1 Innate GI Mucosal Response(s) ...................................................................... 40 
1.2.2 Acquired Mucosal Immune Response............................................................ 50 
AIMS & HYPOTHESIS ............................................................................................................. 55 
Chapter 2 ............................................................................................................................... 56 
2.1 Bacterial Culture .................................................................................................... 57 
2.1.1 Bacterial Strains and Growth Conditions ....................................................... 57 
2.1.2 Bacterial Stock Culture Preparation ............................................................... 57 
2.1.3 C. difficile Growth Kinetics ............................................................................. 59 
2.1.4 C. difficile Survival under Aerobic Conditions ................................................ 59 
2.1.5 C. difficile Sporulation .................................................................................... 59 
2.1.6 C. difficile Toxin Gene Detection .................................................................... 60 
2.1.7 C. difficile Toxin Detection by Western Blotting ............................................ 62 
7 
 
2.1.8 C. difficile Toxin Cytotoxicity Assay ................................................................ 64 
2.1.9 Analysis of Rac1 Glucosylation and Inflammasome Activation ..................... 64 
2.2 Mammalian Cell Culture ........................................................................................ 67 
2.2.1 Mammalian Cell-lines ..................................................................................... 67 
2.2.2 Lactate Dehydrogenase (LDH) Release Assay ................................................ 67 
2.2.3 Ethidium Homodimer Uptake Assay .............................................................. 68 
2.2.4 Annexin-V & Propidium Iodide (PI) Staining .................................................. 68 
2.2.5 C. difficile Adherence Assay ........................................................................... 68 
2.2.6 Confocal Imaging ............................................................................................ 69 
2.2.7 Time-lapse Microscopy .................................................................................. 69 
2.2.8 Gene Expression Analysis ............................................................................... 70 
2.2.9 Enzyme-linked Immunosorbent Assay (ELISA) ............................................... 72 
2.2.10 Occludin Immunofluorescence ...................................................................... 73 
2.2.11 Measurement of Transepithelial Electrical Resistance (TEER)....................... 74 
2.2.12 In vitro Permeability ....................................................................................... 74 
2.2.13 Ussing Vertical Diffusion Chamber System .................................................... 74 
2.2.14 In vitro Organ Culture (IVOC) ......................................................................... 75 
2.2.15 Transfected HEK293 Cells .............................................................................. 75 
2.3 Dendritic Cell Culture ............................................................................................. 77 
2.3.1 Murine Bone-marrow-derived DCs (BMDCs) ................................................. 77 
2.3.2 Human Monocyte-derived DCs ...................................................................... 77 
2.3.3 Dendritic Cell Maturation .............................................................................. 78 
2.3.4 Real-time Polymerase Chain Reaction (PCR) ................................................. 79 
2.3.5 T Cell Proliferation Assay ............................................................................... 81 
2.3.6 Intracellular Cytokine Staining ....................................................................... 83 
2.4 Statistical Analysis .................................................................................................. 83 
Chapter 3 ............................................................................................................................... 84 
3.1 Introduction ........................................................................................................... 85 
3.2 Microbiological Characterisation of C. difficile Strains under Investigation .......... 86 
3.2.1 C. difficile Growth Kinetics ............................................................................. 86 
3.2.2 C. difficile Survival under Aerobic Condition(s) .............................................. 88 
3.2.3 C. difficile Sporulation .................................................................................... 89 
3.3 Characterisation of C. difficile Toxins ..................................................................... 91 
3.3.1 C. difficile Toxin Gene Detection .................................................................... 91 
8 
 
3.3.2 C. difficile Toxin Protein Detection ................................................................. 93 
3.4 C. difficile-mediated Effects on Human Intestinal Epithelial Cells (IECs) ............... 95 
3.4.1 Cytotoxic Effect of C. difficile on Human IEC .................................................. 95 
3.4.2 C. difficile Toxin Cytotoxicity .......................................................................... 98 
3.4.3 C. difficile-induced Apoptosis in Human IEC ................................................ 101 
3.4.4 Effect of C. difficile Adherence on Human IEC ............................................. 105 
3.5 Characterisation of TcdB from Strains CF5 and M68 ........................................... 110 
3.5.1 Mono- glucosylation of Rac by TcdB from Strains CF5 and M68 ................. 110 
3.6 Conclusions .......................................................................................................... 112 
3.6.1 Summary ...................................................................................................... 115 
Chapter 4 ............................................................................................................................. 118 
4.1 Introduction ......................................................................................................... 119 
4.2 C. difficile-mediated Host Innate Immune Response(s)....................................... 120 
4.2.1 Human IEC IL-8 Response to C. difficile Infection ........................................ 120 
4.2.2 C. difficile-mediated IL-6, TNF-α, hBD-2, and IL-1β Responses .................... 127 
4.2.3 C. difficile-mediated Cytokine Expression in HT-29 Cells ............................. 135 
4.3 T84 Cell Cytokine Responses to C. difficile under Aerobic versus Anaerobic                        
Conditions ........................................................................................................................ 139 
4.4 C. difficile-mediated Disruption of Human Intestinal Barrier Function ............... 141 
4.4.1 Occludin Re-distribution during C. difficile Infection ................................... 141 
4.4.2 C. difficile-induced Transepithelial Electrical Resistance (TEER) Loss under 
Aerobic Conditions ....................................................................................................... 143 
4.4.3 Loss of TEER under Anaerobic Environment ................................................ 144 
4.4.4 Increased Paracellular Permeability in Response to C. difficile infection .... 145 
4.5 The Ex Vivo Innate Immunity Response(s) of Human Intestinal Mucosa to C. 
difficile ....................................................................................................................146 
4.6 Conclusions .......................................................................................................... 150 
4.6.1 Summary ...................................................................................................... 153 
Chapter 5 ............................................................................................................................. 154 
5.1 Introduction ......................................................................................................... 155 
5.2 The Role of Toll-Like Receptors in C. difficile Infection ........................................ 156 
5.2.1 IL-8 Response to C. difficile Infection by HEK293 Cells ................................ 156 
5.2.2 Recognition of C. difficile by TLR2/6-transfected HEK293 Cells ................... 158 
5.2.3 IL-8 Response to C. difficile Infection by TLR5-transfected HEK293 Cells .... 160 
9 
 
5.2.4 Role of TLR2-CD14 and TLR4-CD14 HEK293 Transfected Cells in Recognising 
C. difficile Strains .......................................................................................................... 162 
5.2.5 TLR2/1 Heterodimer Activation in Response to C. difficile Stimulation ...... 166 
5.2.6 Role of TLR9-transfected Cells in Recognition of C. difficile ........................ 168 
5.3 Conclusions .......................................................................................................... 170 
5.3.1 Summary ...................................................................................................... 171 
Chapter 6 ............................................................................................................................. 172 
6.1 Introduction ......................................................................................................... 173 
6.2 Murine Bone-marrow-derived Dendritic Cell (BMDC) Immune Response(s) to C. 
difficile Strains .................................................................................................................. 175 
6.2.1 Dendritic Cell Maturation Induced by C. difficile Strains ............................. 175 
6.2.2 C. difficile-mediated Cytokine Gene Expression in BMDC ........................... 179 
6.2.3 C. difficile-induced Cytokine Production by BMDC ...................................... 184 
6.3 The Inflammasome Activation Mediated by C. difficile ....................................... 188 
6.3.1 Caspase-1 Activation in Response to C. difficile Strains ............................... 189 
6.3.2 C. difficile-induced IL-1β Secretion .............................................................. 193 
6.4 Innate Immune Response of Human Dendritic Cells to C. difficile Strains .......... 197 
6.5 Role of C. difficile-stimulated Dendritic Cells on T Cell Activation ....................... 199 
6.5.1 T cell Proliferation in Response to C. difficile-stimulated Dendritic Cells .... 200 
6.5.2 Naive CD4+ T Cell Cytokine Response(s) to C. difficile-stimulated BMDC .... 203 
6.5.3 Splenocytes Cytokine Response(s) to C. difficile-stimulated BMDC ............ 206 
6.6 Conclusions .......................................................................................................... 209 
6.6.1 Summary ...................................................................................................... 212 
Chapter 7 ............................................................................................................................. 213 
7.1 Introduction ......................................................................................................... 214 
7.2 Cytotoxicity of C. difficile Toxin Mutants ............................................................. 215 
7.3 Adherence of C. difficile Toxin Mutants to Human Intestinal Epithelial Cells 
(IECs)......................................................................................................................219 
7.4 Regulation of BMDC Immune Response(s) by C. difficile Toxin Mutant Strains .. 224 
7.4.1 Dendritic Cell Maturation in Response to Infection with C. difficile Toxin 
Mutant Strains ............................................................................................................. 224 
7.4.2 Cytokine Production by Dendritic Cells in Response to C. difficile Toxin 
Mutant Strains ............................................................................................................. 230 
7.4.3 C. difficile Toxin-mediated IL-1β Secretion .................................................. 238 
7.5 Human Dendritic Cell Innate Immune Response(s) to C. difficile Toxin Mutant 
Strains. ............................................................................................................................. 242 
10 
 
7.6 Conclusions .......................................................................................................... 246 
7.6.1 Summary ...................................................................................................... 251 
Chapter 8 ............................................................................................................................. 252 
REFERENCES ......................................................................................................................... 259 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
LIST OF FIGURES  
 
Figure 1.1. C. difficile PaLoc encodes the toxin A and B genes.. ............................................ 25 
Figure 1.2. Phylogenetic comparison of clinical isolates and animal sources of C. difficile 
strains.. ................................................................................................................................... 38 
Figure 1.3. The intestinal mucosal immune system.. ............................................................ 41 
Figure 2.1. Anaerobic infection in vertical diffusion chamber system. ................................. 75 
Figure 3.1. C. difficile strains exhibit differential growth kinetics.. ....................................... 87 
Figure 3.2. C. difficile strains show similar survival trend. ..................................................... 88 
Figure 3.3. C. difficile strains sporulate equally in yeast peptone media. ............................. 90 
Figure 3.4. C. difficile strains sporulate in yeast peptone media. .......................................... 90 
Figure 3.5. Confirmation of tcdA, tcdB, cdtA and cdtB genes in C. difficile strains.. ............. 92 
Figure 3.6. Varying expression of TcdA and TcdB in C. difficile strains. ................................ 94 
Figure 3.7. Lactate dehyrogenase (LDH) release by Caco-2 and HT-29 cell-lines exposed to C. 
difficile. ................................................................................................................................... 97 
Figure 3.8. Strain R20291 exerts potent and early cytotoxic effect on HT-29 cells. ............. 99 
Figure 3.9. Strains R20291, 630 and M68 cause similar cell rounding in Vero cells. .......... 100 
Figure 3.10. C. difficile-induced cell death in infected Caco-2 cells. .................................... 102 
Figure 3.11. Increase in cell death caused by C. difficile infection is time dependent. ....... 102 
Figure 3.12. C. difficile causes apoptosis and necrosis in infected Caco-2 cells. ................. 104 
Figure 3.13. C. difficile strains show similar distribution of unlabelled and FITC-labelled 
bacteria. ............................................................................................................................... 106 
Figure 3.14. C. difficile strains adhere significantly to Caco-2 cells. .................................... 107 
Figure 3.15. C. difficile is an extracellular bacterium. .......................................................... 108 
Figure 3.16. Monolayer disruption occurs following bacterial adherence.......................... 109 
Figure 3.17. CF5 and M68 infection leads to differential Rac1 glucosylation in Caco-2 cells.
 ............................................................................................................................................. 111 
Figure 3.18. TcdB released from CF5 and M68 share protein sequences. .......................... 117 
Figure 4.1. IL-8 gene and protein expression in response to C. difficile in Caco-2 cells. ..... 123 
Figure 4.2. IL-8 induction in response to C. difficile in HT-29 cells. ..................................... 126 
Figure 4.3. C. difficile-induced IL-6 mRNA and protein expression in Caco-2 cells. ............ 128 
Figure 4.4. C. difficile-mediated TNF-α expression in Caco-2 cells. ..................................... 130 
Figure 4.5. C. difficile-mediated hBD-2 induction in Caco-2 cells. ....................................... 131 
Figure 4.6. C. difficile-mediated IL-1β mRNA expression in Caco-2 cells. ............................ 133 
12 
 
Figure 4.7. hBD-1 and IL-18 gene expression in response to C. difficile infection. ............. 134 
Figure 4.8. C. difficile-mediated cytokine mRNA expression in HT-29 cells. ....................... 137 
Figure 4.9. C. difficile-mediated effects on cytokine gene expression in HT-29 cells. ......... 138 
Figure 4.10. C. difficile-induced differential cytokine responses under aerobic and anaerobic 
conditions............................................................................................................................. 140 
Figure 4.11. C. difficile-induced disruption of TJs in T84 cells leads to redistribution of 
occludin. ............................................................................................................................... 142 
Figure 4.12. Time-dependent changes in IEC TEER during C. difficile infection.. ................ 143 
Figure 4.13. C. difficile induces a rapid TEER loss in anaerobically infected T84 cells.. ....... 144 
Figure 4.14. Paracellular permeability increases in response to C. difficile infection.. ....... 145 
Figure 4.15. Ex vivo mucosal cytokine responses to C. difficile infection. ........................... 149 
Figure 5.1. IL-8 response of non-transfected HEK293 cells to C. difficile infection and TLR 
ligands. ................................................................................................................................. 157 
Figure 5.2. C. difficile-mediated IL-8 response in TLR2/6-transfected HEK293 cells. .......... 159 
Figure 5.3. IL-8 secretion in response to TLR5 activation by C. difficile. ............................. 161 
Figure 5.4. C. difficile-induced IL-8 secretion by CD14-transfected HEK293 cells. .............. 162 
Figure 5.5. IL-8 secretion by TLR2-CD14 complex in response to C. difficile stimulation.. .. 164 
Figure 5.6. C. difficile-induced IL-8 secretion by TLR4-CD14 complex. ................................ 165 
Figure 5.7. C. difficile-induced IL-8 response by TLR2/1-transfected HEK293 cells. ............ 167 
Figure 5.8. IL-8 secretion in response to C. difficile stimulation by TLR9. ........................... 169 
Figure 6.1. C. difficile induces maturation of BMDCs by modulating cell surface markers. 178 
Figure 6.2. Cytokine mRNA expression in response to C. difficile infection in BMDCs. ...... 183 
Figure 6.3. Cytokine induction by BMDCs in response to C. difficile infection.. .................. 187 
Figure 6.4. C. difficile triggers caspase-1 activation and IL-1β secretion. ............................ 192 
Figure 6.5. C. difficile toxins trigger IL-1β release by activating an ASC-containing 
inflammasome. .................................................................................................................... 196 
Figure 6.6. Effect of C. difficile strains on IL-12, IL-10, and IL-1β production by human DC.
 ............................................................................................................................................. 198 
Figure 6.7. In vitro proliferation of splenocytes in response to C. difficile-stimulated BMDCs.  
 ............................................................................................................................................. 201 
Figure 6.8. Naive CD4+ T cell proliferation in response to C. difficile-stimulated BMDCs. .. 202 
Figure 6.9. Intracellular IFN-γ and IL-17 staining in CD4+ naive T cells stimulated with C. 
difficile infected BMDC.. ...................................................................................................... 205 
Figure 6.10. Cytokine response of splenocytes stimulated with C. difficile infected BMDC.
 ............................................................................................................................................. 208 
13 
 
Figure 7.1. C. difficile secreted toxins exert varying cytotoxic potential on HT-29 cells. .... 216 
Figure 7.2. C. difficile secreted toxins exert varying cytotoxic potential on Vero cells. ...... 218 
Figure 7.3. C. difficile R20291 toxin mutant strains show similar distribution of unlabelled 
and FITC-labelled bacteria. .................................................................................................. 220 
Figure 7.4. C. difficile toxins do not contribute to C. difficile adherence to Caco-2 cells. ... 221 
Figure 7.5. C. difficile 630 toxin mutant strains show similar distribution of unlabelled and 
FITC-labelled bacteria.. ........................................................................................................ 222 
Figure 7.6. Strain 630 TcdA and TcdB do not affect bacterial adherence levels to Caco-2 
cells. ..................................................................................................................................... 223 
Figure 7.7. C. difficile up-regulates DC surface marker CD80. ............................................. 226 
Figure 7.8. C. difficile induces maturation of DCs by modulating CD86. ............................. 227 
Figure 7.9. C. difficile up-regulates co-stimulatory molecule MHCII. .................................. 228 
Figure 7.10. C. difficile up-regulates CD40 a DC surface marker. ........................................ 229 
Figure 7.11. BMDCs IL-12 induction in response to C. difficile infection. ............................ 232 
Figure 7.12. IL-23 release in response to C. difficile infection by BMDCs. .......................... 233 
Figure 7.13. IL-27 secretion by BMDCs in response to C. difficile infection. ....................... 234 
Figure 7.14. IL-10 release in response to C. difficile infection by murine DCs.. .................. 235 
Figure 7.15. TNF-α production in response to C. difficile infection.. ................................... 236 
Figure 7.16. IL-1β release in response to C. difficile infection.. ........................................... 237 
Figure 7.17. C. difficile toxins trigger IL-1β release by activating an ASC-containing 
inflammasome. .................................................................................................................... 241 
Figure 7.18. Effect of C. difficile toxins on IL-12 production by human DC. ........................ 243 
Figure 7.19. Effect of C. difficile toxins on IL-10 synthesis by human DC. ........................... 244 
Figure 7.20. Effect of C. difficile toxins on human DC IL-1β secretion. ................................ 245 
 
 
 
 
 
 
 
 
14 
 
LIST OF TABLES 
 
Table 2.1. List of C. difficile strains employed in this study.. ................................................. 58 
Table 2.2. Thermal cycle programme to release the total DNA. ........................................... 60 
Table 2.3. List of primers to amplify regions of tcdA, tcdB and binary toxin genes. ............. 61 
Table 2.4. Composition of 2x Laemmli buffer. ...................................................................... 62 
Table 2.5. Composition of 6% Tris SDS gels. .......................................................................... 62 
Table 2.6. List of buffers used for SDS-PAGE and western blotting. ..................................... 63 
Table 2.7. Composition of lysis and stripping buffers. .......................................................... 65 
Table 2.8. Antibodies used to detect Rac1, caspase-1 and IL-1β. ......................................... 66 
Table 2.9. List of primers used for RT-PCR.. .......................................................................... 72 
Table 2.10. Human TLRs agonist used in this study. .............................................................. 76 
Table 2.11. Antibodies used for detecting maturation markers. .......................................... 79 
Table 2.12. List of cDNA master mix components. ................................................................ 79 
Table 2.13. Master mix components for real-time PCR. ....................................................... 80 
Table 2.14. List of primers used in SYBR Green-based real-time PCR. .................................. 80 
Table 2.15. TaqMan probe-based PCR reaction mix component. ......................................... 81 
Table 3.1. C. difficile strains undergo slow growth. ............................................................... 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
PUBLICATIONS & ABSTRACTS 
 
Abstracts: Poster Presentations 
Human intestinal epithelial cell response(s) to Clostridium difficile.  
Nazila V Jafari*1, Elaine Allan2, Lindsey A Edwards1, Mona Bajaj-Elliott1. 1Institute of Child 
Health, 2 Eastman Dental Institute. University College London, UK.  
14th International Congress of Mucosal Immunology (ICMI 2009). July 5-9, 2009, Boston, 
USA.  
 
Effect of Clostridium difficile on human intestine.  
Nazila V Jafari*1, Elaine Allan2, Lindsey A Edwards1, Kathleen A Dunlop1, Mona Bajaj-Elliott1. 
1Institute of Child Health, University College London, UK, 2Eastman Dental Institute, 
University College London UK.  
6th ClosPath International Conference. 19-23 October, 2009, Rome, Italy.  
 
Clostridium difficile Mediated Effects on Intestinal Epithelia.  
Jafari, N.V.1, Allan, E.2, Vernay, B.3, Stabler, R.A.4, Wren, B.W.4, Bajaj-Elliott, M.1, 1,3Institute 
of Child Health,  University College London, London, UK., 2Eastman Dental Institute, 
University College London, London, UK., 4London School of Hygiene and Tropical Medicine, 
London, UK.  
15th International Congress of Mucosal Immunology (ICMI 2011). July 5-9, 2011, Paris, 
France.  
 
 
 
 
 
16 
 
Abstracts: Oral Presentations 
Understanding Clostridium difficile mediated disease pathogenesis.  
Jafari, N.1, Edwards, L.A.1, Allan, E.2, Bajaj-Elliott, M.1, 1Infectious Diseases and Microbiology 
Unit, Institute of Child Health, University College London, London, UK, 2Division of Microbial 
Diseases, Eastman Dental Institute, University College London, London, UK.  
2nd UEGF Teaching Activity on Basic Science. 16-18 July, 2010, Cambridge, UK.  
 
 
Publications  
Nazila V. Jafari, Elaine Allan, Mona Bajaj-Elliott, 2010.  
Human Intestinal Epithelial Response(s) to Clostridium difficile. Clostridium difficile Methods 
and Protocols, Chapter 9.  
P.Mullany, A.P. Roberts (eds.), London, Humana Press, pp. 135-146.  
 
Jafari, N.V., Kuehne, S.A., Elawad, M., Bryant, C.E., Wren, B.W., Minton, N.P., Allan, E., Bajaj-
Elliott, M.  
Clostridium difficile modulates host innate immunity via toxin-dependent and independent 
mechanism(s). Manuscript in preparation.  
 
Jafari, N.V., Dawson, L.F., Stabler, R.A., Wren, B.W., Allan, E., Bajaj-Elliott, M.  
Differential host immunity response(s) to historic and recent C. difficile ribotype 017 strains. 
Manuscript in preparation.  
 
Jafari, N.V., Wren, B.W., Allan, E., Bajaj-Elliott, M.  
Anaerobic conditions enhance C. difficile mediated effects on human intestinal epithelial 
cells. Manuscript in preparation.  
 
17 
 
ABBREVIATIONS 
 
Ab                            Antibody 
AID                          Activation-induced cytidine deaminase  
AIM2                      Absent in melanoma 2 
AJ                             Adherens Junction 
ANOVA                   Analysis of variance 
APC                          Antigen Presenting Cell 
APRIL                       A proliferation-inducing ligand  
APS                          Ammonium persulfate 
ASC                         Apoptosis-associated speck-like protein containing a CARD domain  
BAFF                       B cell-activating factor of the TNF family 
BCR                         B Cell Receptor 
BHI                          Brain Heart Infusion 
BMDC                     Bone-marrow-derived Dendritic Cell 
bp                            base pair 
BSA                          Bovine Serum Albumin 
CAR                         Coxsackievirus and adenovirus receptor 
CARD                      Caspase activating and recruitment domains 
CD40L                     CD40 Ligand 
CDI                          C. difficile Infection 
CDT                         C. difficile Transferase 
CFU                         Colony Forming Unit 
CFSE                        Carboxyfluorescein Diacetate Succinimidyl Ester 
CPE                          Cytopathic Effect 
CSR                          Class-switch DNA recombination  
DAPI                        4',6-Diamidino-2-Phenylindole  
DC                            Dendritic Cell 
DMSO                     Dimethylsulphoxide  
18 
 
EBI3                         Epstein-Barr virus induced gene 3 
ECL                          Enhanced chemiluminescence 
EDTA                       Ethylenediaminetetraacetic acid 
ELISA                       Enzyme Linked Immunosorbent Assay  
ER                            Endoplasmic Reticulum 
F-actin                    Filamentous actin 
FACS                       Fluorescence Activated Cell Sorter  
FAE                          Follicle-associated Epithelium 
FCS                          Foetal Calf Serum 
FITC                         Fluorescein Isothiocyanate 
Foxp3                      Forkhead box P3 
g                               Gram 
g                               Gravity 
GALT                       Gut-associated lymphoid tissue 
GAPDH                   Glyceraldehyde-3-Phosphate Dehydrogenase  
GATA3                    GATA-binding protein 3 
GI                             Gastrointestinal tract 
GM-CSF                  Granulocyte Macrophage Colony Stimulating Factor 
Hprt                        Hypoxanthine guanine phosphoribosyl transferase  
HY                            Hypervirulent 
IECs                         Intestinal Epithelial Cells 
IFN                          Interferon 
Ig                             Immunoglobulin 
IL                             Interleukin 
IRF3                         Interferon regulatory factor 3 
IVOC                       In vitro organ culture  
JAM-A                    Junctional Adhesion Molecule-A 
Knockout                KO 
LDH                         Lactate dehydrogenase 
LF                             Lethal factor 
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LP                            Lamina propria 
LPS                          Lipopolysaccharide 
LRR                         Leucine-rich receptors 
mA                          Milliamp 
Mal                          MyD88 adaptor like 
MALT                      Mucosal-associated lymphoid tissue 
MAMP                    Microbe-associated molecular pattern 
MAPK                     Mitogen-activated protein kinase 
M cell                      Microfold cell 
MD-2                       Myeloid differentiation protein 2 
MFI                          Median Fluorescence Intensity 
MHC                        Major Histocompatibility Complex 
MLN                       Mesentric lymph node 
MOI                         Multiplicity of infection 
MW                         Molecular weight 
MyD88                    Myeloid differentiation antigen 88 
N                              Normal 
nFcR                        Neonatal Fc receptor 
NF-κB                      Nuclear factor kappa B  
NLR                         Nod-like receptor 
Nod                         Nucleotide oligomerisation domain 
OD                           Optical density 
p                              Probability 
PaLoc                      Pathogenicity Locus 
PAMP                      Pathogen-associated molecular pattern 
PBS                          Phosphate-buffered saline 
PCR                          Polymerase Chain Reaction 
PE                            Phycoerythrin 
PeCy5                      Phycoerythrin-cyanine 5 
PG                           Peptidoglycan 
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PerCP                      Peridinin Chlorophyll Protein 
PFA                          Paraformaldehyde 
PFGE                       Pulsed field gel electrophoresis  
PI                             Propidium Iodide 
pIgR                         Polymeric Ig receptor 
PMA                        Phorbol 12-myristate 13-acetate  
PMC                        Pseudomembranous Colitis 
PP                            Peyer’s patche 
PRR                         Pattern recognition receptor 
PS                            Phosphatidylserine  
REA                          Restriction endonuclease analysis  
RFLP                        Restriction fragment length polymorphism 
RIG-1                       Retinoic acid inducible gene 1 
RLR                         RIG-1-like receptor 
RORγt                     Retinoic acid receptor related orphan receptor-γt 
PVDF                      Polyvinylidene fluoride  
rpm                         revolutions per minute 
RT                            Room temperature 
RT-PCR                    Reverse Transcription-Polymerase Chain Reaction 
SDS-PAGE               Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SED                          Sub-epithelial dome 
sIgA                         Secretory IgA 
SLP                          Surface Layer Protein 
sPLA2                      Secretory Phospholipase A2 
STAT                        Signal Transducer and Activator of Transcription 
TACI                         Transmembrane activator and calcium modulating cyclophilin- 
                                 ligand interactor 
TAE                          Tris-Acetate-EDTA  
T-bet                       T-box expressed in T cell 
TBS                          Tris-buffered saline  
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TcdA                        Toxin A 
TcdB                        Toxin B 
TEER                        Transepithelial Electrical Resistance 
TEMED                   N,N,N′,N′-Tetramethylethylenediamine 
TGF-β                      Transforming Growth Factor beta 
Th                            T helper 
Th1                          T helper type 1 cell 
Th2                          T helper type 2 cell 
Th17                        T helper type 17 cell 
TICAM 1                 Toll/IL-1 receptor domain containing adaptor molecule 1 
TIR                           Toll/IL-1 receptor 
TIRAP                      TIR domain containing protein 
TJ                             Tight junction 
TLR                         Toll-like receptor 
TNF-α                      Tumour Necrosis Factor alpha 
TRAM                      TRIF related adaptor molecule  
Treg                         T regulatory cell 
TRIF                         TIR domain containing adaptor protein inducing IFN-β 
TSLP                        Thymic stormal lymphopoietin  
V                               Volt 
WT                           Wild type 
YPM                         Yeast peptone media 
ZO                            Zonula occludin 
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1.1 Clostridium difficile 
 
1.1.1 Introduction 
 
The genus Clostridium is comprised of Gram-positive, spore-forming anaerobic rods. 
Clostridium difficile, originally named Bacillus difficilis, causes gastrointestinal (GI) infection 
and is a key cause of nosocomial illness worldwide. The bacterium was first identified in 
1935 from the stools of healthy newborns (Bongaerts & Lyerly, 1994). The designated name 
related to the difficulties involved in its isolation and study. However, it was not until 1978 
that it was identified as the primary cause of antibiotic-associated diarrhoea and 
pseudomembranous colitis (PMC) (Dodson & Borriello, 1996; Voth & Ballard, 2005).    
C. difficile produces two large heat-labile exotoxins: toxin A (TcdA), an enterotoxin and 
toxin B (TcdB), a cytotoxin. TcdA and TcdB are among the largest bacterial toxins known to 
date and are joined by Clostridium sordellii lethal toxin (TcsL), haemorrhagic toxin (TcsH), 
and Clostridium novyi alpha toxin (Tcnα) to make up the large clostridial cytotoxins (LCTs) 
family (Just & Gerhard, 2004; Voth & Ballard, 2005 ). Toxin-producing clostridial species are 
associated with a range of diseases, including botulism (C. botulinum), tetanus (C. tetani), 
gas gangrene, food poisoning (C. perfringens), diarrhoea, and PMC (C. difficile) 
(Bruggemann, 2005).  
In addition to TcdA and TcdB, two major virulence factors of C. difficile, a number of other 
putative virulence factors have been described including: a binary toxin (CDT) (Rupnik et al., 
2003a), endospores (Sebaihia et al., 2006; Burns & Minton, 2011), surface layer proteins 
(SLP) (Calabi et al., 2002; Wright et al., 2005), fimbriae (Borriello et al., 1990; Sebaihia et al., 
2006), and capsule (Borriello et al., 1990; Davies & Borriello, 1990).  
C. difficile infection (CDI) may result in a spectrum of disease, which can range from mild 
diarrhoea to life-threatening colitis (Dallal et al., 2002; Johal et al., 2004a). CDI often occurs 
following treatment with broad-spectrum antibiotics. In addition to morbidity and 
mortality, CDI is a burden on healthcare due to extended hospitalisation and increased cost 
(Ghantoji et al., 2010). Once regarded as relatively rare occurrence, CDI has become a 
common noscomial infection, but it is not confined to the hospital environment only and 
community-acquired infection is on the rise (Dial et al., 2005; Cartman et al., 2010; 
Freeman et al., 2010) and C. difficile is now also being recognised as an important cause of 
enteric disease in animals (Songer & Anderson, 2006; Rupnik, 2007). CDI continues to 
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increase in most developed countries especially with the emergence of more highly virulent 
strains causing increased disease severity, a rise in fatalities placing a large financial burden 
on healthcare systems worldwide (Goorhuis et al., 2008; Kuehne et al., 2011). The ease of 
spread of C. difficile, the fact that it is often resistant to antibiotics and often causes 
recurrent infections makes management and treatment of CDI problematic in healthcare 
facilities and signifies a need for an improved understanding of C. difficile pathogenesis.  
 
1.1.2 C. difficile Virulence Factors 
 
C. difficile produces a number of factors that contribute to its virulence. Some directly 
contribute to the pathology of the infection, while others enable C. difficile to colonise and 
initiate the pathology (Borriello, 1998). Not all strains are virulent and studies have been 
carried out to determine what accounts for the differing virulence between strains.  
 
1.1.2.1 C. difficile Toxins 
 
The major virulence factors of C. difficile are toxin A (TcdA; 308 kDa) and toxin B (TcdB; 270 
kDa), two highly related UDP-glucosylating toxins. These two toxins share more than 60% 
amino acid sequence homology (Miura et al., 2011). TcdA and TcdB consist of single, large 
polypeptide chain stabilised by disulfide bonds. Amino-termini in both toxins are highly 
conserved, are catalytic and function in the target cell cytoplasm by the same mechanism. 
The carboxy-terminus; however, includes a receptor binding domain, which differs between 
the two toxins (Keel & Songer, 2006).  
C. difficile Pathogenicity Locus (PaLoc) 
The two toxin-encoding genes, tcdA and tcdB, respectively, are situated on the C. difficile 
chromosome in a 19.6 kb pathogenicity locus (PaLoc), along with three accessory genes 
tcdR, tcdC and tcdE (Kuehne et al., 2010) (Figure 1.1). The two toxin genes, tcdA and tcdB, 
are transcribed in the same direction. The tcdR gene encodes an alternative sigma factor 
(TcdR), found upstream of tcdB, and is a positive regulator of tcdA and tcdB expression 
(Deneve et al., 2009). It is responsive to environmental conditions and is increased during 
stationary phase of growth (Voth & Ballard, 2005). tcdC is found downstream of tcdA and it 
encodes an anti-sigma factor (TcdC) which represses toxin production by directly 
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interacting with TcdR and destabilising TcdR holoenzyme (Matamouros et al., 2007). The 
third gene, tcdE encodes the TcdE protein, which has similarities to phage holing proteins 
(Tan et al., 2001). It has been suggested that TcdE may be involved in toxin secretion 
(Dupuy et al., 2008). tcdC is expressed during the exponential phase of growth while all the 
other genes are expressed during the late logarithmic and stationary phases (Matamouros 
et al., 2007; Rupnik et al., 2009). In addition to TcdR and TcdC, CodY a factor encoded 
outside the PaLoc, also participates in the regulation of toxin synthesis by monitoring the 
nutrient sufficiency of the environment. CodY proteins have the ability to repress genes 
(which are not needed in a nutrient sufficient environment) and to release the suppression 
under nutrient-limited conditions (Dineen et al., 2007).  
 
 
 
 
 
Figure 1.1. C. difficile PaLoc encodes the toxin A and B genes. Toxin genes tcdA are tcdB 
are situated on the C. difficile chromosome in a 19.6 kb pathogenicity locus (PaLoc), along 
with three accessory genes tcdR, tcdE and tcdC. Adapted from Voth & Ballard, 2005; Egerer 
et al., 2007; and Albesa-Jove et al., 2010.  
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Functional Domains of TcdA and TcdB 
TcdA and TcdB are multidomain secreted proteins that contain specialised functional 
properties. The N-terminus of each protein has glucosyltransferase activity (the first 543 
amino acids) and represents the biologically active part of the toxin. The middle part of the 
toxins is involved in translocation of the toxins into the host cell cytosol (Albesa-Jove et al., 
2010). The C-terminal domain has short combined repetitive oligopeptides (CROPs) 
required for receptor binding (Carroll & Barrtlett, 2010) (Figure 1.1). In animal models, the 
trisaccharide Gal1 (α1–3) Gal (β1–4) GlcNac is part of the host receptor for TcdA (Rupnik et 
al., 2009). This carbohydrate is not present in humans; however, Na et al. identified 
glycoprotein 96 (gp96), which is expressed on human colonocyte apical membranes as well 
as in the cytoplasm as the main colonocyte receptor for TcdA (Na et al., 2008). The function 
of the C-terminal part of TcdB is probably similar to that of TcdA; however, the receptor for 
C. difficile TcdB has not yet been identified (Jank & Aktories, 2008).  
The C-terminal repetitive region of the secreted toxins binds to host cell receptors. The 
toxin-receptor complex is endocytosed and the toxin translocates to the early endosomes. 
The low pH in this compartment triggers conformational changes, which leads to toxin 
insertion into vesicle membranes via pore formation (Reineke et al., 2007; Albesa-Jove et 
al., 2010). As TcdA forms pores in artificial membrane at low pH, it was hypothesised that 
acidic endosome in living cells may also cause similar changes, a process that is 
accompanied by pore formation (Reineke et al., 2007). In the case of TcdB it has been 
shown that the toxin is cleaved between leucine 543/glycine 544 at neutral pH generating a 
fragment of 63 kDa (catalytic domain), which reaches the cytosol, while a 207 kDa (ligand-
translocation domain) fragment remains in the membrane fraction (Rupnik et al., 2005). A 
later study proposed that other large clostridial cytotoxins share this autocatalytic process, 
which is dependent upon host cytosolic inositolphosphate cofactors. Host cell 
inositolhexaphosphate (InsP6) induces aspartate protease-dependent autocatalytic 
cleavage, resulting in biologically active toxin (Reineke et al., 2007). In contrast, Egerer et al. 
showed that autocleavage is essential for toxin activity, and that leucine 543 is the relevant 
cleavage site and a cysteine protease catalytic triad (cysteine 698, histidine 653, and 
aspartate 587) is involved in toxin processing (Egerer et al., 2007).  
 
 
27 
 
Mechanism of Action 
Following translocation into the cytosol, the toxins target the Ras superfamily of small 
GTPases (Rho, Rac, and Cdc42), modifying them through monoglucosylation of threonine 
35/37 (Genth et al., 2008). These small proteins are important in regulating several distinct 
signalling pathways including cytoskeletal rearrangements and cell growth. Glucosylation 
prevents the structural changes required for active conformation of Rho GTPases, thus 
significantly altering their function resulting in inhibition of cell division and membrane 
trafficking. On cultured intestinal epithelial cells (IECs), the cytotoxic effect is characterised 
by a reduction in transepithelial resistance (TEER), indicating a loss of IEC barrier function. 
Rho glucosylation results in the disappearance of polymerised filamentous actin (F-actin) 
causing cell rounding, termed cytopathic effect (CPE). The toxins also provoke 
mitochondrial damage that eventually proceeds to apoptosis (Just et al., 1994 &1995; 
Genth et al., 2006; Gerhard et al., 2008; Miura et al., 2011).  
The apoptotic properties of C. difficile TcdA and TcdB are well known. These toxins induce 
apoptosis in IECs, neurons, endothelial cells and monocytes. The executioner caspase-3 is 
involved in TcdA-induced apoptosis; however, activation of another executioner, caspase-6 
has also been described. Caspase-3 and 6 are activated by two initiator caspases, caspase-8 
and caspase-9. Caspase-8 is the major driver of the extrinsic apoptotic pathway, which is 
activated via transmembrane death receptors such as the Fas receptor. Caspase-9, 
represents the intrinsic pathway, and is activated by an apoptosome, which is triggered by 
the release of cytochrome c from damaged mitochondria. Ultimately, procaspase-3 is 
cleaved by both caspases-8 and 9 mediated pathways causing apoptosis (Nottrott et al., 
2007; Gerhard et al., 2008).  
C. difficile Hypervirulent Strains 
In the last decade, the global incidence of CDI has increased dramatically in North America, 
Canada and Europe due to the emergence and spread of epidemic strains that 
predominantly belong to PCR ribotype 027 (based on comparison of PCR products patterns 
of the 16S-23S rRNA intergenic spacer region; Rupnik et al., 2001). These strains are also 
characterised as toxinotype III [based on PCR restriction fragment length polymorphism 
(RFLP) analysis of C. difficile PaLoc; Rupnik et al., 2001], North American pulsed field gel 
electrophoresis (PFGE) type 1 (NAP1) and restriction endonuclease analysis (REA) group BI 
(BI/NAP1/027) (Cartman et al., 2010). Ribotype 027 strains are associated with more severe 
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disease, increased mortality, higher relapse rates and increased resistance to 
fluoroquinolone antibiotics (Stabler et al., 2009).   
C. difficile ribotype 027 strains produce 16 and 23 times more TcdA and TcdB respectively 
when compared to historic strains (Warny et al., 2005). Ribotype 027 strains also produce a 
binary toxin (or C. difficile Transferase, CDT), which is proposed to enhance colonisation of 
C. difficile by triggering the formation of microtubule protrusion on cells of the GI 
epithelium (Schwan et al., 2009). These strains also encode a variant tcdC repressor gene. 
Moreover, ribotype 027 strains harbour various deletions at the 3’ end of the tcdC gene, 
resulting in truncated TcdC proteins. An 18 bp deletion in tcdC was initially suggested to be 
the cause of increased toxin production by the epidemic strains (Warny et al., 2005), 
however, Spigaglia et al. detected 39- and 18- bp deletions in tcdC and showed that 
nonsense mutations in tcdC reduced TcdC protein (Spigaglia & Mastrantonio, 2002). 
Matamouros et al. demonstrated that a tcdC gene containing only the 18 bp in-frame 
deletion encodes a TcdC protein that is active both in vivo and in vitro (Matamouros et al., 
2007; Dupuy et al., 2008).  Additional mutations in tcdC have subsequently been described 
in toxin hyperproducing strains. In particular, a single base pair deletion at position 117 
with the previously described 18 bp deletion causes a frameshift mutation and consequent 
truncation of tcdC (Curry et al., 2007).  
Toxin Variant Strains 
The majority of C. difficile strains are A+B+ but a number of isolates have deletions in tcdA, 
resulting in a truncated form of the toxin, and produce only a functional toxin B (A-B+) (Voth 
& Ballard, 2005). Despite the known role of TcdA in disease pathogenesis, strains lacking 
TcdA have been recovered from patients with clinical disease and from outbreaks (Johnson 
et al., 2003). These isolates are a rare cause of disease in the United States (0.2%) but 
constitute anywhere from 3% of all isolates in UK and France to as high as 39% in Japan, 
56% in Israel to replacing completely A+B+ strains in Argentina (97.9%) (Drudy et al., 2007). 
These variant C. difficile strains differ from the reference strain VPI 10463 in the length and 
restriction sites in toxin genes, as well as other regions of the PaLoc (Rupnik et al., 2003b). 
Earlier studies suggested that administration of pure TcdA alone to hamsters was sufficient 
to cause disease, whereas TcdB alone was not (Lyerly et al., 1988). Interestingly, intragastric 
challenge of hamsters with TcdB can cause disease symptoms if prior damage to the 
mucosa has occurred through co-administrations of TcdA. Moreover, co-administration 
results in more severe disease symptoms leading to the notion that both toxins act 
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synergistically (Lyerly et al., 1985). The isolation of variant strains which apparently produce 
no TcdA (A-B+ strains) presents a challenge to the established dogma that both toxins are 
required for disease.  
The first A-B+ strain to be characterised was strain 8864 (toxinotype X) containing a 5.9 kb 
deletion in the 3’ end of tcdA and tcdC preventing production of TcdA, as well as a 1.1 kb 
insertion in between tcdA and tcdE (Soehn et al., 1998). It causes pathology in animal 
models however its virulence in humans remains undefined (Torres, 1991; Borriello et al., 
1992). Serogroup F strains (type strain 1470, toxinotype VIII also known as PCR ribotype 
017) were the second A-B+ strain type that was identified with a 1.8 kb deletion in tcdA, and 
a mutation that introduces a stop codon at amino acid position 47 (von Eichel-Streiber et 
al., 1999). These strains are frequently isolated from asymptomatic infants and lack 
pathogenicity in animals however, they have also been isolated from symptomatic and PMC 
patients and outbreaks (Delmee & Avesani, 1990; Depitre et al., 1993; Rupnik et al., 2003b). 
Toxinotype VIII appears to be the most clinically significant variant strain type causing four 
documented outbreaks, sporadic cases of diarrhoea and PMC (Drudy et al., 2007). Analysis 
of TcdB-8864 and 1470 showed that these toxins are a hybrid between TcdB from reference 
strain VPI 10463 (A+B+) and C. sordellii lethal toxin (Chaves-Olarte et al., 1999), while their 
receptor binding domain is 100% homologous with strain 10463, the enzymatic domain 
shares only 79% homology (Drudy et al., 2007). 
 
1.1.2.2 Other Virulence Factors 
 
Although TcdA and TcdB are the major virulence factors in C. difficile associated disease, 
other factors undoubtedly contribute to virulence, particularly the initial colonisation 
process. 
I. Binary Toxin 
In addition to producing TcdA and TcdB, approximately 6% of C. difficile strains including 
ribotype 027 epidemic strains, produce a third toxin, known as C. difficile binary toxin (CDT). 
Whilst not absolutely required for virulence, CDT may enhance virulence (Cartman et al., 
2010; Carrol & Bartlett, 2010). CDT is a member of the clostridial binary toxins that include 
C2 toxin from C. botulinum types C and D, iota toxin from C. perfringens type E and C. 
spiroforme iota-like toxin. This toxin is an actin-specific ADP-ribosyltransferase consisting of 
two subunits; an enzymatic component CDTa (48 kDa) and a binding component CDTb (99 
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kDa) (Stubbs et al., 2000; Rupnik et al., 2003a). CDT is encoded by two genes, cdtA and 
cdtB, which are transcriptionally linked and are located on the C. difficile chromosome at a 
locus separate from the PaLoc named the  CDT locus (CdtLoc), together with the regulatory 
gene, cdtR (Rupnik et al., 2009). CDT production is tightly regulated by CdtR (Carter et al., 
2007). 
CDT binds to target cells via CDTb and transports the enzymatic CDTa into the cytosol. CDTa 
ADP-ribosylates G-actin at arginine 177 thereby blocking actin polymerisation (Aktories et 
al., 1986; Vandekerckhove et al., 1987). ADP-ribosylated actin acts as a capping protein at 
barbed ends of actin filaments thus inhibiting elongation leading to depolymerisation of F-
actin (Wegner & Aktories, 1988; Aktories & Wegner, 1992). Although the role of CDT in 
pathogenesis is unclear, new findings by Schwan et al. revealed that the actin ADP-
ribosylating toxins, C. difficile CDT, C. perfringens iota toxin and C. botulinum C2 toxin can 
induce the formation of novel thin, dynamic, microtubules on the surface of IECs, leading to 
increased adherence of clostridia both in in vitro and in vivo. These protrusions increase the 
adherence of clostridia to IECs by ~5-fold in vitro and 4-fold in the mouse large intestine 
(Schwan et al., 2009).  
II. Endospores 
Sporulation is initiated under conditions of nutrient limitation. Endospores, which are 
metabolically dormant cells, are formed following asymmetrical cell division. The internal 
cytoplasm is protected by thick concentric external layers, the spore coat and the cortex 
(Lawley et al., 2009), they consequently are highly resistant to a variety of chemical agents, 
desiccation and extreme temperature conditions. These properties allow C. difficile to 
persist on surfaces causing contamination in healthcare settings. Ingestion of spores leads 
to infection or re-infection of co-habiting individuals (Rupnik et al., 2009; Burns & Minton, 
2011).  
Upon reaching the GI tract’s anaerobic environment, the ingested spores germinate to 
toxin-producing vegetative cells and, in susceptible individuals, cause diarrhoeal disease. 
Bile salts and glycine can act as co-germinants for C. difficile spores.  In bile, glycine is 
conjugated to cholate. When glycocholate passes into the lower bowel, the glycyl group is 
deconjugated from cholate by the normal microbial flora. The products of deconjugation, 
cholate and glycine are sufficient to stimulate germination and outgrowth of C. difficile 
spores (Sorg & Sonenshein, 2008).  
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III. Surface Layer Proteins (SLPs) 
C. difficile is surrounded by a paracrystalline array of protein(s) which lie external to the cell 
wall. This surface (S)-layer is composed of two proteins, derived from a single gene, slpA 
(Calabi et al., 2001; Karjalainen et al., 2001). The translated gene product undergoes two 
rounds of post-translational cleavage, firstly to remove the signal sequence following 
secretion, and then internal cleavage at position 355 releases the two mature SLPs; a high 
molecular weight SLP (HMW-SLP, 45 kDa) which is a cell wall binding protein attached to 
the underlying peptidoglycan moiety. The low molecular weight SLP (LMW-SLP, 36 kDa) 
localises to the external surface of the bacterium (Cerquetti et al., 2000; Wright et al., 2005; 
Fagan et al., 2009). Recombinant HMW-SLP is able to adhere to human and mouse 
intestinal tissue whilst antibodies against it are able to block adherence of C. difficile to 
cultured cells (Calabi et al., 2002).  
Several other C. difficile proteins are implicated in attachment to IECs; these include the S-
layer P36 and P47 adhesins proteins (Deneve et al., 2009), a 66 kDa cell wall protein Cwp66 
(Waligora et al., 2001), Fbp68 a 68 kDa fibronectin binding protein (Hennequin et al., 2003), 
the GroEL heat shock protein (Hennequin et al., 2001), and Cwp84, a cysteine protease, 
which is involved in degradation of several extracellular matrix proteins (fibronectin, 
laminin and vitronectin) and may degrade host tissue to enhance the spread of infection 
(Janoir et al., 2007).   
IV. Flagellin 
C. difficile is known to express peritrichous flagella. C. difficile flagella components, FliC 
(flagellin) and FliD (flagellar cap protein) may aid attachment to intestinal mucus. 
Flagellated strains adhere 10-fold greater than nonflagellated strains when tested in the 
mouse cecum (Tasteyre et al., 2001). Glycosylation of the flagellin protein is required for its 
appropriate assembly and consequent motility; however, genomic microarray studies 
indicate that motility may not be required for virulence due to divergence in the flagellar 
sequences noted amongst the varying strains (Twine et al., 2009).  
V. Antibiotic Resistance 
Antibiotic resistance is an important virulence factor of C. difficile, as the bacterium is 
resistant to most antibiotics. The development of resistance amongst isolates can be traced 
over time, particularly for widely used antibiotics such as cephalosporins and clindamycin 
(Delaney et al., 2007). Antibiotic resistance genes in C. difficile is mostly transposon 
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mediated, with erythromycin resistance (ermB) carried on Tn5398 (Hussain et al., 2005; 
Sebaihia et al., 2006), chloramphenicol resistance on Tn4453 (Lyras et al., 2004) and 
tetracycline resistance on Tn5397 (Hussain et al., 2005). The more recent isolates are 
sharing increased resistance to fluoroquinolones encompassing a large range of ribotypes 
and are spreading at an alarming rate (Spigaglia et al., 2008).  
Treatment with broad spectrum antibiotics leads to the disruption of the normal gut flora, 
which enable C. difficile to proliferate. Interestingly, re-colonisation of gut normal flora is 
prevented by C. difficile. This is due to production of para-cresol by the bacterium (Dawson 
et al., 2008). Para-cresol is a phenolic compound, with bacteriostatic properties, produced 
via aminotransfer of tyrosine to para- hydroxyphenylacetic acid, which is then 
decarboxylated to para-cresol. Only C. difficile and Lactobacillus strains are able to produce 
para-cresol from tyrosine. Importantly, C. difficile itself is able to tolerate high 
concentrations of this compound, suggesting that this may provide a competitive 
advantage for C. difficile over other intestinal microflora, consequently contributing to the 
progression of CDI (Sebaihia et al., 2006; Dawson et al., 2009).  
 
1.1.3 C. difficile Pathogenesis 
 
C. difficile is spread via the faecal-oral route. The organism is ingested in vegetative or spore 
form. Spores survive the acidic environment of the stomach and germinate into the 
vegetative form, which can multiply and colonise the colon.  Disturbance of the normal 
intestinal flora increases susceptibility to infection and pathology. The gut microbiota acts 
as a colonisation barrier, which protects against C. difficile. Antibiotic therapy alters the 
normal flora compromising the barrier (Bartlett, 2006). After colonisation, C. difficile 
releases TcdA and TcdB.  Carbohydrate receptors for TcdA have been identified on the 
brush border of IECs. TcdA acts primarily on IECs causing inflammation, fluid and mucus 
secretion and tissue damage (Voth & Ballard, 2005) whereas TcdB shows broad cell tropism 
(Heinlen & Ballard, 2010). TcdA is responsible for the activation and recruitment of 
inflammatory mediators such as IL-6, IL-8 by IECs, and IL-1, IL-6, IL-8, TNF-α by human 
monocytes (Kachrimanidou & Malisiovas, 2011).  
C. difficile glucosylating toxins catalyse the glucosylation of Rho- and or Ras-GTPases from 
UDP-glucose. TcdA and TcdB glucosylate Rho at threonine site 37, Rac and Cdc42 at 
threonine-35. By inactivating Rho proteins, glucosylating toxins induce cell rounding, 
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accompanied by a loss of actin stress fibres, re-organisation of the cortical actin, disruption 
of the intercellular junctions and subsequently an increase in cell barrier permeability 
(termed as CPE). In contrast, cytotoxic effect results in toxin-induced cell death. 
Concomitant with barrier function alteration and increased permeability, TcdA and TcdB 
disrupt apical and basal actin filaments with a subsequent disorganisation of tight junction 
proteins such as ZO-1, ZO-2, occludin, and claudin (Popoff & Geny, 2011) and eventually 
resulting in cell death. TcdA and TcdB are able to induce either type I programmed cell 
death (apoptosis) or type III programmed cell death (necrosis) (Genth et al., 2008).  
C. difficile does not invade the colonic mucosa and does not cause disease if no toxin is 
produced. Even in the presence of toxin, some people become carriers or develop mild self-
limited diarrhoea while others develop severe colitis and may present several relapses of 
the disease. Clinical manifestation depends on the rapidity of the serum antibody response 
to the toxin (Fordtran, 2006). Up to 60% of healthy adults have detectable IgG and IgA 
against TcdA and TcdB and almost 70% of healthy newborns and infants aged up to 12 to 18 
months become colonised with C. difficile while normal colonic flora is being established. 
Large amounts of toxins can be detected in their stools, although children rarely develop 
colitis. Most patients with acute infection do not exhibit an IgM response, but rather a 
secondary IgG response. It has been shown that the development of asymptomatic carriage 
is associated with the development of high titers of anti-TcdA antibodies, whereas low 
titers are correlated with the subsequent development of CDI and more severe disease, 
indicating the probable importance of humoral immunity in preventing disease (Heinlen & 
Ballard, 2010).  
 
1.1.4 Risk Factors 
 
Antibiotic exposure, advanced age and hospitalisation are three major risk factors for C. 
difficile infection. Prior exposure to antimicrobial agents is the most widely recognised and 
modifiable risk factor for CDI, despite infrequent cases of community-onset CDI without 
prior antibiotic treatment. Patients with CDI in a hospital setting are generally exposed to 
an antibiotic prior to acquiring the infection (Rupnik et al., 2009). A recent study showed 
that 85% of CDI patients had received antibiotic therapy within 28 days prior to the onset of 
symptoms (Kachrimanidou & Malisiovas, 2011). Any antimicrobial agent with an 
antibacterial spectrum can cause CDI, but some carry a higher risk than others, e.g. 
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clindamycin followed by ampicillin or amoxicillin played a prominent role in the 1970s but 
were largely supplanted by cephalosporins in the 1980s, and more recently by 
fluoroquinolones (Bartlett, 2006; Rupnik et al., 2009). Other major risk factors for CDI are 
advanced age (>65 years) and hospitalisation. Elderly patients with severe underlying 
illnesses and prolonged hospitalisation are particularly susceptible (Monaghan et al., 2008; 
Kachrimanidou & Malisiovas, 2011). 
Patients receiving immunosuppressive agents such as chemotherapeutic or 
immunosuppressant drugs are also vulnerable for developing CDI, in particular those who 
are not able to mount an effective IgG antibody response against C. difficile toxins. Other 
risk factors associated with CDI include treatment with proton-pump inhibitors, H2 blockers, 
gastric acid suppression agents, and finally the presence of GI diseases such as 
inflammatory bowel disease (IBD) (Monaghan et al., 2008; Rupnik et al., 2009; 
Kachrimanidou & Malisiovas, 2011). 
 
1.1.5 Treatment  
 
Recommendations for CDI therapy vary, as they are based on the extent of disease severity 
and whether it is an initial or recurrent infection. Given the recognised role of antibiotic 
therapy in causing CDI, mild disease may be treated by withdrawing the inciting antibiotic. 
C. difficile has long been considered as a multiple antibiotic resistant organism (resistant to 
erythromycin, clindamycin, lincomycin, tetracycline, and chloramphenicol), mainly due to 
the large number of mobile genetic elements in the genome which harbour antibiotic 
resistant genes (Cartman et al., 2010; Heinlen & Ballard, 2010; Kyne, 2010). 
Currently only metronidazole and vancomycin provide an effective treatment. Whilst 
vancomycin has fewer side effects and is more effective, metronidazole has until now been 
preferred due to its lower price. Further, concerns over the increasing problem of 
vancomycin resistance in other bacteria have made vancomycin the last resort antibiotic. 
Metronidazole is becoming increasingly ineffective and there are reports of metronidazole 
resistant C. difficile strains. This is extremely worrying, as there are increasing reports of 
gene transfer examples between Enterococcus spp. and Clostridium spp. Enterococcus 
faecicum is the major source of vancomycin resistance gene vanA, and as this organism 
lives in the same niche as C. difficile, vanA transfer to C. difficile would appear to be just a 
matter of time, and if so there may be an emergence of metronidazole resistant strains 
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carrying vanA, the consequences would be fatal (Stoddart & Wilcox, 2002; Cartman et al., 
2010). Although metronidazole and vancomycin are effective at inhibiting C. difficile and 
treating symptoms, the use of these antibiotics does not allow for the re-establishment of 
gut normal flora. As a result up to 30% of patients will have recurrent CDI usually within 14 
days of treatment termination and 50% of this group may have multiple recurrences. 
Between 20 and 50% of these recurrences are caused by new C. difficile strains, indicating 
re-infection rather than a relapse of the original infection (Kyne & Kelly, 2001; Rupnik et al., 
2009; Heinlen & Ballard, 2010; Kyne, 2010).  
Other approaches are being investigated in the treatment of CDI, including the use of 
alternative antimicrobial agents, combination of antibiotics, toxin binding agents (a high 
molecular weight toxin binding polymer, GT160-246), probiotics, immunotherapy, phage-
based approaches, and less acceptable but probably effective faecal transplantation; 
however, none of these approaches have yet achieved wide acceptance (Stoddart & 
Wilcox, 2002; Cartman et al., 2010; Kyne, 2010).   
 
1.1.6 Epidemiology  
 
It is not clear whether CDI is due to existing C. difficile in the gut or exposure to an external 
source at the time of susceptibility, although in the vast majority of cases evidently the 
latter is responsible for the infection (Dodson & Borriello, 1996). Spread of the organism in 
health care settings is thought to be the result of ingestion of spores. Patients with CDI can 
be the main source of infection for others as a 20-40% rate of colonisation in hospitalised 
adults is seen compared with 2-3% in healthy adults (Heinlen & Ballard, 2010) although 
asymptomatic carriage may also play a role (Dodson & Borriello, 1996). C. difficile is 
uncommon among healthy adults in the general population; however, up to 50% of infants 
and approximately 20% of hospital patients who are culture positive for C. difficile, are 
asymptomatic carriers (Keel & Songer, 2006).  
Vernacchio et al. (2006) detected C. difficile in the stool of healthy children at a similar rate 
to healthy adults (3.5%) and children with acute diarrhoea (Wilson, 2006). Kim et al. (2008) 
later demonstrated an increase in CDI incidence in hospitalised young children with the 
median age of 4 years. Importantly, the incidence in hospitalised children <1 year of age is 
also on the increase, indicating that C. difficile might be pathogenic in this group as well 
(Zilberberg et al., 2008). More recent studies suggest that CDI in children may also be 
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acquired in the community (Baker et al., 2010). Community-acquired CDI in adults has been 
reported sporadically for a number of years and is linked to the use of gastric acid-
suppressing agents. It has been estimated that approximately 28% of all CDI cases are 
community-acquired (Heinlen & Ballard, 2010).  
In 2002, an increase in severe CDI was reported by the University of Pittsburgh Medical 
Centre in the United States, which signalled the beginning of a continuous rise of CDI rate in 
Canada, US and Europe (Rupnik et al., 2009). Hospitals in Canada began experiencing an 
epidemic of C. difficile associated disease, reporting about 14,000 nosocomial cases 
between 2003 and 2004. In 2005, disease rates increased at least five times greater than 
the historical average. The incidence of CDI in individuals over 65 years of age in just one 
hospital in Quebec increased from 102 in 1991-92 to 210 in 2002 and to 866 in 2003 per 
100,000 people (Warny et al., 2005). Strain typing revealed that ~82% of tested isolates 
were of ribotype 027, previously a minor ribotype in isolate collection (Cloud & Kelly, 2007).  
Hospitals throughout the Unites States also reported increased numbers of severe cases of 
CDI due to ribotype 027 from 2001 to 2003, which continued through 2006 (O’Connor et 
al., 2009). In 2006, CDI rates in US hospitals exceeded 300,000 cases per year and it is 
currently estimated that there are ~500,000 cases per year with 15,000 to 20,000 fatal 
cases (Rupnik et al., 2009). In Europe only a few countries have the necessary systems to 
measure the CDI incidence and the associated death rates, and in some cases testing for C. 
difficile is not optimal. In 2002, the incidence of CDI in Germany increased from 1.7 to 3.8 
cases per 100,000 to 14.8 in 2006 (Burckhardt et al., 2008). In Spain, the incidence of 
diagnosed CDI in patients aged >65 years increased 3-fold between 1997 and 2005 (Soler et 
al., 2008).  
In 2003 the first outbreak due to C. difficile ribotype 027 was reported in the UK, followed 
by another outbreak in 2005 (HC, 2006). A total of 498 CDI cases with 172 deaths were 
caused by these two outbreaks (HC, 2006). Since the first outbreak, several outbreaks due 
to ribotype 027 strains have been documented in almost all UK health board regions 
(Buckley et al., 2011). In UK, the voluntary reporting of positive stool samples (Health 
Protection Agency data) showed that CDI has been an increasing problem since the early 
1990s. Whilst part of the increase is due to improved reporting, it is widely accepted that 
there has also been an increase in the number of cases (Monaghan et al., 2008). In England, 
all the cases of CDI must be reported, and data made publicly available for each healthcare 
facility. In 2008 a national mandatory target was set to reduce the incidence of CDI by 30% 
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by 2010-11 (Duerden, 2011). Death involving CDI was decreased by 31% between 2009 and 
2010 from 3,933 to 2,704. During 2006 to 2010, CDI rates were highest in men and women 
aged >85 at 2,186 and 2,194 per million respectively and C. difficile was involved in 1.1% of 
all deaths in England and Wales and less than 2% of all hospital deaths 
(www.statistics.gov.uk ).  
The increased rates of CDI have primarily been attributed to ribotype 027 strains but are 
not limited to this ribotype only. In different countries other ribotypes such as 001, 053 and 
106 are associated with outbreaks and severe disease. PCR ribotype 078 (toxinotype V) has 
increased from 3% to 13% in several European countries (Rupnik et al., 2009). In the 
Netherlands, patients infected with ribotype 078 are younger than those infected with 
ribotype 027 and more frequently have community associated disease. Ribotype 078 strains 
share features with ribotype 027 strains which include; genes encoding toxins A and B, 
binary toxin, and a variant tcdC. Significantly, the ribotype 078 strains isolated from humans 
are genetically related to isolates from pigs (Goorhuis et al., 2008). It should be noted that 
in many countries, a different ribotype can predominate and present an equivalent threat 
in terms of disease severity, but be extremely rare elsewhere.  
 
1.1.7 The Evolution of C. difficile 
 
Although C. difficile was recognised as a pathogen only three decades ago, a number of PCR 
ribotypes have emerged causing outbreaks worldwide (Bartlett, 2006), with different 
ribotypes dominating a certain time and geographical region (Cheknis et al., 2009). Four 
major clades of C. difficile isolates were revealed in a genomic comparison of 75 well-
characterised C. difficile isolates to that of the genome-sequenced strain 630 (Stabler et al., 
2006). A hypervirulent (HY), a toxin A-B+ and two other clades with intermixed human and 
animal isolates (HA1 and HA2) were identified (Figure 1.2). The HY clade consisted of 20 
PCR ribotype 027 strains, which formed a tight and distinct clade. A later study investigating 
the evolution of this highly virulent clone showed that one modern epidemic 027 strain 
(R20291, the strain responsible for an outbreak at Stoke Mandeville Hospital in 2006) has 
gained five genetic regions over the past two decades compared to the historic and non-
epidemic ribotype 027 strain (CD196). Also 027 strains show considerable genetic 
differences compared to strain 630 and these changes correlate with observed phenotypic 
differences in motility, survival, antibiotic resistance and toxicity (Stabler et al., 2009).  
38 
 
 
 
Figure 1.2. Phylogenetic comparison of clinical isolates and animal sources of C. difficile 
strains. Genomic comparisons of 75 C. difficile strains from diverse geographical locations  
comprising 21 hypervirulent, 13 A+B+, 14 A-B+, and 7 A-B- human isolates (black) and 7 
bovine (green), 6 swine (red), 4 equine (light blue), and 3 murine isolates (blue) showed 
four major clades containing HY, A-B+, HA1, and HA2 (Stabler et al., 2006). 
 
 
The A-B+ clade formed a tight subclade of A-B+ strains; part of a larger clade including a 
subclade of A-B- strains and four animal isolates (Figure 1.2). As the hypervirulent and A-B+ 
isolates were clustered into two independent clades, Stabler et al. suggested a low genetic 
diversity and the wide geographical spread of these phylogenetic lineages. The HA1 and 
HA2 clades were distinct from the hypervirulent and toxin A-B+ strains. HA1 had mainly 
human isolates, while HA2 showed predominantly animal isolates; nevertheless, the 
comparative phylogenomic analysis in this study failed to distinguish any host specificity of 
the strains leading to the possibility of animals as a source of human infection (Stabler et 
al., 2006). 
C. difficile, as a genetically diverse species has evolved within the last 1.1 to 85 million years 
based on two independent dating methods (He et al., 2010). Disease-associated isolates 
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(017s, 027s, and 078s) have emerged from multiple lineages, in addition to genetic 
modifications other elements may have contributed to the emergence of C. difficile as a 
major pathogen indicating independent evolution of virulence in these lineages. 
Interestingly, the population of the hypervirulent clade was identified to have expanded 
around the start of the century, a time corresponding to the first report of ribotype 027 
hospital outbreaks (He et al., 2010).  
 
1.1.8 The Animal Models of C. difficile Infection 
 
Many animal species have been investigated to identify an appropriate model of human 
CDI. Hamster (Price et al., 1979), guinea pig (Knoop, 1979), rabbit (Alcantara et al., 2001), 
pig (Steele et al., 2010), rats and mice (Castagliuolo et al., 1998; Chen et al., 2008) have all 
been considered.  
The hamster models is the most widely used model as CDI can be initiated by 
administration of a range of antibiotics followed by C. difficile exposure (Borriello et al., 
1988). They are particularly sensitive to C. difficile and die within 2-3 days of infection 
following rapid development of CDI (Lyerly et al., 1985). The hamster model develops a 
fulminant colitis but does not demonstrate the spectrum of CDI seen in humans.  
Animals such as mice and rats are not as readily susceptible to CDI as hamsters, however, 
their gnotobiotic counterparts can be colonised by C. difficile and consequently exhibit 
intestinal pathology. The disease in germ-free animals involves the colon, as observed in 
humans, while in hamsters C. difficile affects primarily the cecum and some parts of the 
ileum (Chen et al., 2008).  
Recently, the piglet model was established representing a reproducible model of acute or 
chronic CDI with characteristic PMC. CDI is common in swine, and in piglets causes enteritis 
during the first week of their life showing similar disease to humans (Steele et al., 2010).  
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1.2 Host Immune Response 
 
1.2.1 Innate GI Mucosal Response(s) 
 
The GI tract is the site where the divergent needs of nutrient absorption and host defence 
collide. Nutrient absorption requires a thin large surface area, this however has the 
potential to compromise host defence. Many infectious diseases involve the gut and the 
gut protects itself by harbouring a large number of immune cells (MacDonald & 
Monteleone, 2005).  
The GI mucosal immune system is the largest and most complex part of the immune 
system. It encounters more antigen than any other part of the body, yet it must be able to 
readily discriminate between invasive pathogens and the resident flora as well as harmless 
antigens, such as food proteins (Hecht, 1999). As most human pathogens enter the body 
through a mucosal surface, such as the GI tract, requirement of a prompt immune response 
is necessary to protect and prevent further spread of the encountered infection(s). By 
contrast, hypersensitivity responses against food antigens or commensal bacteria can lead 
to inflammatory disorders like celiac disease and Crohn’s disease, respectively. Therefore, 
immunological tolerance of the GI mucosal immune system is vital for providing protection 
against external pathogens without reacting against itself (Weiner, 1994; Mowat, 2003).  
The gut-associated lymphoid tissue (GALT) is the largest immune organ in the body and can 
be divided into effector sites and organised tissues. Effector site(s) consist of inductive 
lymphocytes that are scattered throughout the epithelium and the lamina propria (LP) of 
the mucosa. The organised tissues, responsible for the induction phase of the immune 
response are the Peyer’s patches (PPs) and mesenteric lymph nodes (MLNs), as well as 
smaller and isolated lymphoid follicles. The lymphoid areas are separated from the 
intestinal lumen by a single layer of columnar epithelial cells, known as the follicle-
associated epithelium (FAE), and a more diffuse area immediately beneath the epithelium, 
known as the sub-epithelial dome (SED) (Mowat, 2003; Spencer et al., 2009; Weiner et al., 
2011). The FAE differs from the epithelium that covers the villus mucosa and the most 
notable feature of the FAE is the presence of microfold (M) cells. The FAE has lower levels 
of digestive enzymes, less pronounced brush border and is infiltrated by the large numbers 
of B cells, T cells, macrophages and dendritic cells (DCs) (Mowat, 2003) (Figure 1.3).   
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Figure 1.3. The intestinal mucosal immune system. A single layer of IEC provides a physical 
barrier that separates the intestinal lumen from the underlying LP. IECs are derived from 
stem cells and can differentiate into villous or colonic absorptive enterocytes, mucin 
producing goblet cells, enteroendocrine cells which secrete hormones, and Paneth cells at 
the base of the small intestine crypts. Beneath the IECs, the LP contains macrophages, DCs, 
B cells (especially IgA-producing plasma cells), and T cells. M cells are located in the 
specialised regions of the small intestine epithelium termed FAE overlying the PPs (Abreu, 
2010).  
 
 
M cells are specialised enterocytes that can be distinguished from the neighbouring IEC. 
Compared with absorptive enterocytes, M cells have less extensive apical brush border, a 
reduced glycocalyx and diminished expression of enzymes involved in absorption. 
Importantly, they have the capacity to rapidly transcytose antigens relatively intact and 
deliver them to antigen presenting cells (APCs) in the PPs and lymphoid cells consequently 
priming naive T and B cells to memory or effector cells. These cells migrate from the 
different lymph vessels of the GALT to the MLN and then through peripheral blood to other 
mucosal effector sites such as the LP. The FAE express Toll-like receptors (TLRs) and 
chemokines to attract antigen presenting sub-epithelial DC into the apical area of the PPs 
(Hershberg, 2002; Niedergang & Kweon, 2005; Wells et al., 2011).  
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The GI tract is unique as it is the largest area of the body in constant contact with 
microorganisms. Virtually all entero-pathogens enter through the oral intake. In the oral 
cavity streptococci predominate in the resident flora. The majority of oral or food-borne 
bacteria are washed with saliva into the stomach, although the secreted gastric acid aims to 
promote sterility; however, Helicobacter pylori are resident in the gastric mucosa of many 
individuals. Digestion and absorption of nutrients continues in the small intestine 
(duodenum, jejunum, proximal ileum) which is relatively sterile. The last section of the GI 
tract is the large intestine (cecum, colon, rectum) harbouring an extensive number of 
resident bacterial flora consisting of different species of anaerobic and aerobic bacteria 
(Cunliffe & Mahida, 2004). 
 
1.2.1.1 Intestinal Epithelium 
 
The intestinal surface covers an area of approximately 250 m2 and is lined by a single layer 
of columnar IEC that forms a barrier between the intestinal lumen and host connective 
tissue. IECs are in continuous contact with the gut microflora, consisting of 1014 
microorganisms exceeding by 10-fold the total ensemble of human cells, belonging to >500 
different bacterial species. The gut has been identified as one of the most densely 
populated habitats known in biology (Guarner & Malagelada, 2003; Sears, 2005; Pastorelli 
et al., 2008).  
 
1.2.1.2 Intestinal Epithelium Barrier Structure and Function 
 
The formidable task of differentiating between pathogens and commensal microflora and 
eliciting the appropriate action is the responsibility of IECs and the underlying mucosal 
immune system. IECs form a monolayer that acts as an impermeable barrier to microbes; 
hence its regulation is critical in restricting access and preventing hyperactivity of the 
intestine (Mumy & McCormick, 2005).  
The epithelium of the small intestine forms an adjacent two-dimensional sheet composed 
of four main epithelial cell types: absorptive enterocytes, mucin secreting goblet cells, 
hormones secreting enteroendocrine cells and antimicrobial peptide secreting Paneth cells, 
which are derived from stem cells (Figure 1.3). Following their origin from stem cells 
located near the crypt base, the epithelial cells (apart from Paneth cells) differentiate as 
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they migrate up the villus tip in 4-7 days. They are subsequently shed by apoptosis upon 
reaching the villus tip. In contrast to the other epithelial cell types, Paneth cells are long-
lived, residing at the crypt base for approximately 20 days. There are also M cells that play a 
central role in sampling antigenic molecules and microorganisms and their delivery to the 
underlying mucosal-associated lymphoid tissue (MALT) (Cunliffe & Mahida, 2004; Colbere-
Garapin et al., 2007). The surface epithelium of the colon lacks villi, and Paneth cells are 
absent, therefore the stem cells reside directly at the crypt base occupying the bottom two-
third of colonic crypts, whereas differentiated cells constitute the top third and the surface 
epithelium (Raedtke & Clevers, 2005). 
Two main lineages of differentiated cell types are recognised within the intestinal 
epithelium: the enterocyte of the absorptive lineage and the secretory lineage, which 
encompasses goblet cells, the enteroendocrine cell, and the Paneth cells. Absorptive cells 
are more abundant in the small intestine and are responsible for secreting hydrolases and 
absorbing nutrients. Number of mucous secreting goblet cells increases from proximal 
(small intestine) to distal (colon and rectum). Enteroendocrine lineage cells represent a 
small proportion (<1%) of the IEC compartment and can be subdivided further on the basis 
of variety of hormones they secret including serotonin, substance P and secretin. Paneth 
cells exist only in the small intestine and reside at the crypt base. They secret antimicrobial 
peptides such as cryptidins (termed defensins in humans) and lysozyme to control the 
microbial content of the intestine (Raedtke & Clevers, 2005; Barker et al., 2008). The 
intestinal epithelium in addition to forming a physical barrier composed of cell membranes 
and interspersed tight junctions, achieves further reinforcement of its barrier function 
through a chemical antimicrobial shield. 
I. Physical Barrier 
 
a) Tight junctions 
The primary responsibility of the IEC is to act as a barrier and prevent the passage of 
harmful intraluminal entities and at the same time function as a selective filter, allowing the 
translocation of essential dietary nutrients, electrolytes, and water from the intestinal 
lumen. The IEC mediates selective permeability through two major routes; transcellular 
(transepithelial) and paracellular pathways. Transcellular permeability is associated with 
solute transport through the IEC and is regulated by selective transporters for amino acids, 
electrolytes, sugars, and short chain fatty acids. Paracellular permeability is defined as 
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transport in the space between IEC and is regulated via a series of intercellular junctions, 
known collectively as the epithelial junctional complex (Groschwitz & Hogan, 2009).  
The epithelial junctional complex is subdivided into tight junctions (TJs), adherens junctions 
(AJs), and desmosomes. TJs are typically located at the apical end of the basolateral 
membrane forming an apical ring, whereas AJs and desmosomes are located more within 
the basolateral membrane and thought to be more important in the mechanical linkage of 
adjacent cells. The TJs, on the other hand, are responsible for sealing the intracellular space 
and regulating selective paracellular ionic solute transport. Both TJ and AJ are linked 
intracellularly to the actin cytoskeleton often seen co-localised with junctions to form a 
belt-like ring of filaments encircling the cell border, referred to as perijunctional actin, 
contrarily desmosomes are linked to intermediate filaments. TJ and AJ are also important in 
the regulation of cellular proliferation, polarisation, and differentiation (Groschwitz & 
Hogan, 2009; Terry et al., 2010). 
AJs also known as zonula adherens are formed by interactions between transmembrane 
proteins, intracellular adaptor proteins and the cytoskeleton. The majority of AJs are 
structured by cadherin-catenin interactions. E-cadherin, a calcium-dependent adhesion 
molecule, is a type I transmembrane protein composed of an intracellular C-terminus and 
an extracellular N-terminus. The extracellular domain interacts with the E-cadherin of the 
neighbouring cell promoting cell-cell adhesion. The intracellular domain contains a catenin-
binding domain that interacts directly with p120 catenin and β-catenin. In turn, β-catenin 
binds to α-catenin 1, which regulates local actin assembly and contributes to development 
of the perijunctional actinomyosin ring. AJs are required for assembly of TJs, which seals 
the paracellular space (Groschwitz & Hogan, 2009; Turner, 2009). 
The TJ complex is composed of transmembrane proteins linked to a network of adaptor 
proteins that form a cytoplasmic plaque, and regulatory molecules that include kinases. The 
transmembrane proteins mediate cell-cell adhesion and form the paracellular barrier. The 
adaptor proteins (such as; zonula occludens 1 (ZO-1), ZO-2, ZO-3) link transmembrane 
proteins to the cytoskeleton acting as scaffolds for recruitment of various signalling 
proteins. TJs contain two main types of transmembrane components; tetra-span and single-
span transmembrane proteins. The tetra-span proteins include occludin, tricellulin, and the 
claudins. The single-span proteins associated with TJs are the junctional adhesion molecules 
(JAMs) and its related proteins coxsackievirus and adenovirus receptors (CAR) (Balda & 
Matter, 2008; Guttman & Finlay, 2009; Turner, 2009; Terry et al., 2010). Expression of AJ 
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and TJ proteins are regulated by phosphorylation, which can either promote TJ formation 
and barrier function or alternatively cause TJ protein re-distribution and complex de-
stabilisation (Groschwitz & Hogan, 2009). 
Interaction between C. difficile TcdA and TcdB leads to disruption of IEC barrier function 
due to enhanced paracellular permeability (Riegler et al., 1995; Sutton et al., 2008). Toxins 
cause disorganisation of apical and basal F-actin resulting in dissociation of occludin and 
ZO-1 from TJ. C. difficile toxins inactivate Rho protein family members, therefore toxin-
mediated TJ dysfunction and cytoskeletal rearrangement may result from inactivation of 
Rho, which is an essential regulator of filamentous actin (Hecht et al., 1988; Nusrat et al., 
2001; Chen et al., 2002).  
II. Chemical Barrier 
 
a) Mucins  
The IEC physical barrier is reinforced by a membrane-anchored glycoprotein network called 
glycocalyx which is formed by the secretion and apical attachment of a heavily glycosylated 
mucin-rich layer (Artis, 2008). Mucins are highly complex glycoproteins that range from 200 
to 2,000 kDa. The GI mucosal surface coated by a hydrated mucus gel creates a physical-
chemical barrier that prevents large particles including microbes from directly contacting 
the IEC (Hecht, 1999; Turner, 2009).   
b) IgA 
Secretory immunoglobulin A (sIgA) is triggered by presentation of commensal antigens to B 
cells in GALT by intestinal DCs. In the gut lumen, IgA is continuously produced in large 
amounts (>5 g per day), binding predominantly to commensal bacteria and to dietary 
antigens (Kraehenbuhl & Corbett, 2004). IgA production will be discussed further in section 
1.2.2.2. 
c) Antimicrobial peptides (AMPs) 
Defensins are small (2-6 kDa), arginine-rich, cationic peptides with broad spectrum 
antimicrobial activity. Defensins contain six conserved cysteine residues, which form three 
intramolecular disulfide bonds and a β-sheet structure. Cationic charge and the 
hydrophobic structure allow them to interact with the anionic elements (e.g. LPS) of the 
prokaryotic membrane, thereby entering and creating pores, causing cell lysis. On the basis 
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of the arrangement and spacing of the disulfide bonds, defensins are divided into two 
major groups; α- and β-defensins. In humans and mice, both groups are encoded by a 
cluster of genes on chromosome 8. They are synthesised as pre-propeptides and are post-
translationally processed into mature and active peptides (Cunliffe & Mahida, 2004; 
Eckman, 2005). 
α-Defensins 
Six α-defensins have been identified in humans; these comprise four neutrophil defensisns 
(HNP1, -2, -3, -4) and two Paneth cell defensins (HD-5, -6). In addition to the α-defensin 
family in humans and mice (termed cryptdins), Paneth cells also express antimicrobial 
proteins such as lysozyme and secretory phospholipase A2 (sPLA2). Paneth cells play a role 
in maintaining the relative sterility of the lumen and/or protecting stem cells (Hecht, 1999; 
Cunliffe & Mahida, 2004; Cederlund et al., 2011). 
HNP-1-3 are potential inhibitors of bacterial toxins. HNP-1 inhibits the protease activity of 
lethal factor (LF) from Bacillus anthracis, and HNP-1-3 protects mice from intoxication (Kim 
et al., 2005). HNP-1 has a neutralising effect on the mono-ADP-ribosyltransferase activity of 
diphtheria toxin and Pseudomonas exotoxin A (Kim et al., 2006a). Recently, Giesemann et 
al. showed that HNP-1, HNP-3, and HD-5 can inhibit C. difficile TcdB by blocking its catalytic 
activity. The specificity of α-defensins in inhibiting TcdB activity was shown as hBD-1 (β-
defensin) and cathelicidin LL-37 have no effect on glucosyltransferase activity of TcdB. 
Additionally, the inhibitory effect of α-defensins is TcdB specific, as under the same 
experimental conditions, TcdA activity is not affected (Giesemann et al., 2008).  
β-Defensins 
Compared with α-defensins, members of the β-defensin subfamily (hBD-1 and hBD-2) are 
more widely expressed throughout the GI tract. In contrast to hBD-1, hBD-2 is not 
expressed constitutively by IEC, but is strongly induced in inflamed or infected tissue, 
particularly in patients with Ulcerative colitis. Two other members of β-defensins, hBD-3 
and hBD-4 are found in colonic epithelium with higher expression in crypt compared with 
surface cells, however, like hBD-2, show strong inducibility by microbial and inflammatory 
stimuli (Hecht, 1999; Eckman, 2005). 
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Cathelicidins 
The cathelicidin family of AMPs is not as widespread in nature as the defensin family, 
suggesting a more recent ancestry. Cathelicidins are cationic in which cathelin, a highly 
conserved N-terminal domain is linked to a C-terminal peptide with antimicrobial activity. 
Humans have one cathelicidin gene that encodes the pre-proprotein LL-37/human cationic 
protein 18 kDa (hCAP18). LL-37/hCAP18 is expressed in neutrophils, mast cells, and 
epithelial cells. This protein is produced in GI tract constitutively in differentiated surface 
and upper crypt IEC in the colon, but not in the deeper regions of the colonic crypt or IEC of 
the small intestine (Eckman, 2005; Cederlund et al., 2011). 
 
1.2.1.3 Pattern Recognition Receptors (PRRs) 
 
The gut epithelium itself is able to sense commensal bacteria and pathogens directly; 
however, integral to this are the pattern recognition receptors (PRRs), which recognise 
conserved molecular structures known as pathogen-associated molecular patterns (PAMPs) 
and activate pro-inflammatory pathways alerting the host to microbial presence 
(MacDonald & Monteleone, 2005). As conserved structures are also present on non-
pathogenic microorganisms (commensals), the term microbe-associated molecular patterns 
(MAMPs) is increasingly being used (Wells et al., 2011). DCs are also known to efficiently 
acquire antigens by extending their dendrites into the gut lumen and directly sample and 
detect the luminal micro-environment by PRRs (Artis, 2008). Three major classes of PRRs 
studied to date are; Toll-like receptors (TLRs), Retinoic acid inducible gene I (RIG-I)-like 
receptors (RLRs), and nucleotide oligomerisation domain (NOD) -like receptors (NLRs) 
(Kawai & Akira, 2010; Wells et al., 2011). 
The ubiquitously expressed RLRs (RIG-I, Mda5 and LGP2) are cytoplasmic proteins that 
recognise viral RNAs and signal through the adaptor molecule IPS-1, inducing innate 
antiviral responses, including the activation of type I interferon (IFN) (Kawai & Akira, 2010). 
NLRs represent a large family of PRRs that recognise microbial molecules in the host 
cytosol. Most NLRs have three domains structure consisting of a variable amino-terminal 
domain, a centrally located Nod domain, and carboxy-terminal leucine-rich repeats (LRRs) 
domain that detect PAMPs. Nod1 and Nod2 were the first NLRs to be identified. Both have 
been identified as intracellular peptidoglycan (PG) receptors, which recognise different 
moieties of PG. Nod2 detects muramyl dipeptide (MDP) found in nearly all Gram-positive 
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and Gram-negative bacteria, whereas Nod1 recognises peptidoglycan fragments containing 
γ-D-glutamyl-mesodiaminopimelic acid (DAP), from most Gram-negative and certain Gram-
positive bacteria. Nod1 and Nod2 both possess a caspase activating and recruitment 
domain (CARD) at their amino-termini, a single CARD domain in Nod1 and two tandem 
CARD domains in Nod2, followed by a nucleotide binding domain and a series of LRRs (Kelly 
& Conway, 2005). Several NLRs, including NLRC4 (or IPAF), NLRP1 and NLRP3 (or NALP3) are 
involved in responding to various stimuli to form the inflammasome complex, which 
promote the release of IL-1β and IL-18 via caspase-1 (Franchi et al., 2009). NLR proteins 
trigger a number of signalling transduction cascades including the pro-inflammatory and 
anti-apoptotic NF-κB (via Nod1 and Nod2), caspase-1 inflammasome (via NLRC4, NLRP3, 
and NLRP1) and apoptotic/pyroptotic cell death (via NLRP1 and NLRP3) (Bergsbaken et al., 
2009; Philpott & Girardin, 2010). Nod1 deficient mice are more susceptible to C. difficile 
infection than Nod2 deficient mice (Hasegawa et al., 2011). Nod1-/- mice show impaired 
neutrophil recruitment and clearance of the bacteria consequently triggering pro-
inflammatory responses and in particular IL-1β, suggesting a protective role of Nod1 against 
C. difficile infection. This data is intriguing as why PG of C. difficile, a Gram-positive 
bacterium is not being recognised by Nod2 remains to be answered.  
TLRs are type I transmembrane receptors that share a high homology to the Toll receptors 
originally identified in Drosophila melanogaster. TLRs are structurally characterised by 
extracellular LRRs at the N-terminal domain, followed by a single transmembrane domain 
and an intracellular Toll/IL-1 receptor (TIR) signalling domain at the C-terminus (Mumy & 
McCormick, 2005). The TIR domain has no role in molecular recognition; however, it is 
required for interactions with TIR containing adaptor proteins, via direct TIR-TIR 
association. TLRs are activated following direct recognition of a wide range of MAMPs. 
Following ligand recognition by the LRR domain, the TIR domains transactivate leading to 
recruitment of the adaptor proteins and cell activation. Hence, TLRs expressed at the apical 
membrane of gut IECs have the ability to detect MAMPs present in the gut lumen and 
initiate intracellular responses (Kelly & Conway, 2005). TLRs recognise multiple MAMPs, 
including lipopolysaccharide (LPS) detected by TLR4, bacterial lipoproteins, lipoteichoic 
acids and PG by TLR2, flagellin by TLR5, unmethylated microbial CpG DNA and viruses by 
TLR9, double-stranded RNA by TLR3 and single-stranded viral RNA recognised by TLR7 
(Iwasaki & Medzhitov, 2004). Depending on their cellular localisation, TLRs are largely 
divided into two subgroups. One group is composed of TLR1, TLR2,TLR4, TLR5, TLR6 and 
TLR11, which are expressed on cell surfaces and the second group (TLR3, TLR7, TLR8 and 
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TLR9) are expressed exclusively in intracellular vesicles such as early and late endosomes 
where they detect incoming nucleic acids (Kawai & Akira, 2010).  TLRs can form complexes 
with various members to confer a further degree of specificity. TLR2 generally forms 
heterodimers with TLR1 or TLR6. TLR2-TLR1 heterodimer recognises triacylated 
lipopeptides from Gram-negative bacteria, whereas the TLR2-TLR6 heterodimer recognises 
diacylated lipopetides from Gram-positive bacteria and Mycoplasma spp. TLR4 forms a 
complex with MD-2 (myeloid differentiation protein 2), additional proteins such as CD14 
and LPS-binding protein complex are also involved in forming the LPS binding (Netea et al., 
2004; Kawai & Akira, 2010).  
Following receptor ligation, TLRs recruit cytoplasmic adaptor proteins to its TIR domain.  
One of the main mechanism(s) of differential downstream signalling is the selective 
recruitment of different adaptor proteins. All adaptors possess a conserved TIR domain 
which ligates via TIR-TIR interactions. Myeloid differentiation antigen 88 (MyD88) is a 
central adaptor required by all TLRs except TLR3, and activates NF-κB and mitogen-
activated protein kinases (MAPKs) to induce host innate immune responses. MyD88 is 
directly recruited by most TLRs however TLR2 and TLR4 can also recruit an adaptor called 
MyD88 adaptor like (Mal) or TIR domain containing protein (TIRAP). Another TIR domain 
containing adaptor protein inducing IFN-β (TRIF), also known as Toll/IL-1 receptor domain 
containing adaptor molecule 1 (TICAM1), acts as an additional adaptor for TLR3 and TLR4 
signalling (Netea et al., 2004; Blasius & Beutler, 2010; Li et al., 2010).  TLR4 recruits TIRAP at 
the plasma membrane and subsequently facilitates the recruitment of MyD88 to trigger the 
initial activation of NF-κB and/or MAPK. TLR4 displays MyD88-independent signalling by 
recruiting TRIF and forming a signalling complex with TRIF related adaptor molecule 
(TRAM), also known as TICAM2, which serves as a bridging adaptor to initiate the TRIF-
dependent pathway that leads to IRF3 (Interferon regulatory factor 3) activation as well as 
the late-phase activation of NF-κB and MAPK and consequently induction of type I 
interferon and inflammatory cytokines (Kawai & Akira, 2010; Kelly & Conway, 2005; Li et al., 
2010).  
Taken all together, the host innate immune system has evolved to detect microbial 
presence via signature motif recognising receptors that lead to an array of signalling events 
which culminate in early host defence and simultaneously activate the adaptive immune 
system for future encounters.  
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1.2.2 Acquired Mucosal Immune Response 
 
The GI mucosal immune system consists of multiple cell types. The IECs are the first layer of 
defence lining the luminal surface of the GI tract, while DCs interlinked among the intestinal 
cells, are capable of sampling the luminal contents and presenting antigens to T cells in the 
lamina propria and lymphoid follicles. In the small intestine, specialised M cells residing in 
the FAE above the PPs transport antigens via transcytosis to the PPs, where APCs process 
and present them to naive lymphocytes (Abreu et al., 2005). DCs are the most effective APC 
involved in this process, bridging the innate and acquired immunity. TLRs expressed on the 
surface of different DC subsets in PPs leads to differential responses, subsequently initiating 
an appropriate T and B cell-mediated immunity (Iwasaki & Medzhitov, 2004; Netea et al., 
2004).  
DCs are continuously produced from haematopoietic stem cells within the bone marrow 
and can be divided into subsets according to surface marker expression, specialised 
function(s) and tissue distribution. Human and mouse DCs are different both in their 
ontogeny and function. In humans, two types of DC have been described; myeloid and 
plasmacytoid. While all murine DCs express CD11c integrin, they can be subdivided into 
three classes according to their surface markers and location including; CD8α, CD4 and 
B220/Gr1 (Rescigno, 2002; Ardavin, 2003). Immature DCs are found in all peripheral tissues 
where they efficiently capture foreign and self antigens, whereas mature DCs are primarily 
found in lymphoid tissues (Banchereau & Steinman, 1998). Immature DCs exposed to 
microbial products, mature and migrate to the T cell area of secondary lymphoid organs 
such as MLNs, where they activate naive T cells. Activation and maturation of DCs occurs 
upon recognition of phylogenetically conserved MAMPs, by expression of PRRs such as 
TLRs, C-type lectins, and mannose receptors. DCs also express the NLR receptor family 
which include nucleotide-binding oligomerisation domain proteins NOD1 and NOD2 (Niess 
& Reinecker, 2006). Immature DCs begin a maturation program in response to antigen 
which induces their migration to lymphoid organs. Ultimately, mature DCs present the 
antigenic peptides in the context of the major histocompatibility complex (MHC) molecules 
and express the co-stimulatory molecules, leading to secretion of cytokines that will aid 
activation of antigen-specific T cells (Niedergang & kweon, 2005). 
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1.2.2.1 T cells 
 
CD4+ T cells are central to host adaptive immune responses. Naive CD4+ T cells differentiate 
into a range of T helper (Th) cells, which are classified on the basis of their cytokine profile 
and related to the function of the specific T cell subset. Th1 cells produce interferon-γ (IFN-
γ) and interleukin-2 (IL-2) and their development is controlled by transcriptional factor T-
bet (T-box expressed in T cells). Th1 cells also provide help to CD8+ T cells and macrophages 
to kill cells infected with viruses and intracellular pathogens (Szabo et al., 2000; Malefyt, 
2009). Th2 cells function via; IL-4, IL-5, IL-10, IL-13 and IL-25. The key regulator of Th2 
commitment is the transcription factor GATA3 (GATA-binding protein 3). Th2 cells provide 
help to B cells leading to their activation and differentiation into secretory immunoglobulin 
producing cells. Th2 cells eliminate extracellular bacteria and regulate B cell class switching 
to IgE through IL-4 (Paul & Zhu, 2010). IL-5 and IL-13 play a pivotal role in recruiting 
eosinophils, a cell type crucial for parasite elimination.  
In recent years additional T cell subsets including Regulatory T cells (Treg), Th17, and Th9 
cells have been identified. Several types of Treg cells have been described on the basis of 
their origin, generation, and mechanism of action. Two main subsets are: naturally arising 
CD25+CD4+ Tregs, which express the transcription factor forkhead box p3 (Foxp3) and 
inducible Tregs, which develop in the periphery from CD4+ T cells exposed to various signal 
such as regulatory cytokines or APCs conditioned by bacterial products. Inducible Tregs 
include populations of T regulatory 1 (Tr1), which secrete IL-10; transforming growth factor 
(TGF)-β producing cells; and inducible Foxp3+ Tregs. Both Tregs (natural or inducible) have 
the capacity to control the intensity of effector responses (Belkaid & Tarbell, 2009; 
Campbell & Koch, 2011). T cell subsets that produce IL-17A, IL-17F, IL-22, and CCL20 are 
designated Th17. Combination of IL-6 and TGF-β acts in concert to differentiate naive CD4+ 
T cells to Th17, interestingly in the absence of IL-6, Tregs can be generated in vitro, 
proposing an intriguing link between Th17 and Tregs. The orphan nuclear receptor RORγt 
(retinoic acid receptor related orphan receptor-γt) is the key lineage defining transcription 
factor for Th17 cells, downstream signalling for Th17 differentiation depends on Stat3 
(signal transducers and activators 3) activation. IL-17 is important in the host defence 
against extracellular bacteria such as Klebsiella pneumoniae, Bacteroides fragilis and against 
fungi like Candida albicans; however, pathogens such as Borrelia burgdorferi, which 
stimulates IL-17 expression causes development of autoimmunity (Stockinger & Veldhoen, 
2007, Stockinger et al., 2007). Combination of TGF-β and IL-4 induce the differentiation of 
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naive murine CD4+ T cells into a unique IL-9 producing Th9 subset. Both human and murine 
Th9 cells do not co-express cytokines that are characteristics of other Th subsets; however, 
in contrast to murine, IL-10 is not expressed by human Th9 cells. Although the exact 
function of this subset of effector Th cells has yet to be defined, it has been proposed that 
Th9 cells may provide additional help for mast cells through the production of IL-9 (Malefyt, 
2009; Ma et al., 2010).   
In the presence of appropriate signals, naive T cells can differentiate into any of the distinct 
T cell subsets. IL-12, a heterodimeric cytokine composed of p35 and p40 subunits, is a key 
inducer and growth factor for polarised Th1 responses and moreover promotes survival, 
differentiation, and gene expression of Th1 cells. An IL-12 family member, IL-23 shares the 
p40 subunit of IL-12. IL-23 is a heterodimer composed of p40 and a unique subunit p19, this 
cytokine plays an important role in maintaining Th17 effector function whilst another IL-12 
family member IL-27 composed of; p35-related protein p28 and a p40-related protein EBI3 
(Epstein-Barr virus induced gene 3), is involved in early initiation of Th1 responses 
antagonising development of Th17 cells (Brombacher et al., 2003; Reiner, 2007; Stockinger 
& Veldoen, 2007; Malefyt, 2009). All three IL-12 family members are produced by DCs in 
response to stimuli. This family is central to the nature of the downstream T cell immune 
outcome and several novel therapies for autoimmune diseases including rheumatoid 
arthritis (RA) and inflammatory bowel disease (IBD) are targeting the IL-12 family.  
Several studies have shown that C. difficile toxins can interact with T cells directly or 
indirectly via monocytes. T cell apoptosis following exposure to TcdA suggests a direct 
interaction between T cells and the toxin, which is concomitant with reduced T cell 
proliferation and suppressed mucosal immune response (Mahida et al., 1998). On the other 
hand, toxins are found to markedly reduce the capacity of toxin treated-monocytes to 
stimulate T cell proliferation implying that C. difficile toxins interact only with monocytes 
(Daubener et al., 1988). Additionally, T and B cells are shown to be relatively more resistant 
to C. difficile toxins compared to the innate immune cells (monocytes/macrophages and 
IECs), suggesting that antibody-mediated protection by the adaptive immune system may 
be of major importance during exposure of the host to high concentrations of C. difficile 
toxins (Solomon et al., 2005).   
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1.2.2.2 B cells 
 
B lineage cells are the central mediators of humoral immunity and critical component(s) of 
the adaptive responses. B cell activation is initiated following antigen recognition via the B 
cell receptor (BCR), resulting in B cell proliferation and differentiation. Activated B cells 
differentiate to form either plasma cells, which are capable of secreting antibody or 
memory cells that provide long-lasting protection against secondary infection (Harwood & 
Batista, 2010). Antibodies released by effector B cells and plasma cells provide the first line 
of protection at mucosal surfaces. In the GI tract the vast majority of mucosal cells secrete 
IgA and to a lesser extent IgM but no IgG, whereas the respiratory and urogenital tracts 
contain equal amounts of IgA and IgG and some IgM. In humans, the respiratory tract also 
contains IgD. Both IgA and IgM interact with the polymeric Ig receptor (pIgR), an antibody 
transporter expressed on the basolateral surface of IEC. After binding to pIgR, IgA and IgM 
dimers translocate to the IEC surface, thus generating secretory IgA (sIgA) and sIgM. IgG 
antibody gains access to respiratory and urogenital secretions through two mechanisms; 
specifically via an antibody transporter known as nFcR (neonatal Fc receptor), and a 
nonspecific mechanism. IgD enters respiratory secretions through an unknown mechanism 
(Cerutti et al., 2011a).  
In the GI tract, sIgA plays multiple protective roles include: entrapping dietary antigens and 
microorganisms in mucus, down-modulating the expression of pro-inflammatory bacterial 
epitopes on commensal bacteria, blocking microbial components attachment to the 
epithelia and facilitating intra-epithelial neutralisation of incoming pathogens and microbial 
inflammatory products. Furthermore, IgA dimers secreted locally by plasma cells remove 
microorganisms that have breached the epithelial barrier either by transporting them back 
to the lumen or by promoting their clearance via an IgA receptor expressed by DCs, 
neutrophils, and other phagocytes (Cerutti & Rescigno, 2008). B cells express IgA antibody 
responses via two different pathways: low affinity IgA production from extra-follicular B 
cells (peritoneal B-1 cells and splenic marginal zone B cells) in a T cells-independent (TI) 
fashion, and high affinity IgA production from follicular B cells (also called B-2 cells) in a T 
cell-dependent manner (TD). Antigens that trigger TI pathway do not require CD4+ Th cells 
to activate B cells, and include microbial TLR ligands (type-1) and microbial polysaccharides 
with repetitive structure (type-2) (Cerutti et al., 2011b). Most antigens initiate mucosal IgA 
responses through a TD reaction that occur in mucosal lymphoid follicles such as, intestinal 
PP and MLN via the expression of a B cell specific enzyme [activation-induced cytidine 
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deaminase (AID)] that is required for diversification of Ig genes through class-switch DNA 
recombination (CSR). Also PPs are rich in TGF-β, a potent IgA-inducing factor. TGF-β 
associates with CD40 ligand (CD40L), a tumor necrosis factor (TNF) family member 
expressed by CD4+ T cell and triggers IgA CSR to generate antigen-specific IgA+ B cells. PPs 
also contain IL-4, IL-6 and IL-10 facilitating the expansion of IgA-expressing B cells. In T cell-
rich regions of the PP, a migrated antigen-loaded DC can initiate a polarised Th2 response. 
Requirement of this response is ‘’conditioning’’ of DCs by IEC through thymic stormal 
lymphopoietin (TSLP). TSLP, an IL-7 like cytokine, stimulates IL-10 production from DCs, an 
IgA-inducing cytokine and inhibits the generation of proinflammatory Th1 cells releasing 
IFN-γ by blocking DC production of IL-12, which is essential to initiate Th1 responses 
(Cerutti & Rescigno, 2008; Cerutti et al., 2011a). As the conventional TD pathway requires a 
longer time (5-7 days) to initiate protective antibody responses, the intestinal mucosa has 
developed a faster TI pathway that generates IgA response to TLR activation. DC and IEC 
recognise microbial components and respond by releasing B cell-activating factor of the 
TNF family (BAFF) and a proliferation-inducing ligand (APRIL). BAFF and APRIL, B cell-
stimulating factors are structurally and functionally related to CD40L and deliver CD40-
independent IgA CSR-inducing signals via transmembrane activator and calcium modulating 
cyclophilin-ligand interactor (TACI). An important property of this receptor is establishing a 
close cooperation with B cell-intrinsic signals from TLRs (Cerutti & Rescigno, 2008; Cerutti et 
al., 2011a; Cerutti et al., 2011b).  
Studies have demonstrated that colonic biopsies from patients with CDI have significantly 
fewer mucosal macrophages and B plasma cells, which was mainly due to reduction in IgA 
producing cells. It has been hypothesised that individuals with low numbers of IgA 
producing cells show severe mucosal inflammation following acquired initial infection. 
Patients with a single episode have significantly higher serum IgG and faecal IgA antitoxin A 
antibody titre than patients with recurrent CDI (Warny et al., 1994; Johal et al., 2004b). 
High serum IgG antibody levels against TcdA correlates strongly with asymptomatic carriage 
of C. difficile, while colonised patients with low IgG antibody levels have increased risk of C. 
difficile diarrhoea. Additionally, patients with a single episode of C. difficile diarrhoea have 
significantly higher concentration of serum IgM and IgG anti-TcdA, by day 3 and day 12 of 
disease onset, when compared to patients with relapsing CDI (Kyne et al., 2000; Kyne et al., 
2001). High IgM antibody response to C. difficile SLPs markedly reduces the risk of recurrent 
CDI (Drudy et al., 2004).  
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AIMS & HYPOTHESIS 
 
In this thesis it was hypothesised that both bacterial virulence and host factors contribute 
to Clostridium difficile mediated pathogenesis. This study addressed the following aims: 
 
 Microbial characterisation of C. difficile strains and their cytotoxic effects on human 
IECs (Chapter 3). 
 In vitro and ex vivo innate immunity response(s) of human intestinal epithelia to C. 
difficile infection (Chapter 4). 
 The role of TLRs in C. difficile recognition (Chapter 5). 
 C. difficile-mediated murine and human DC activation and C. difficile-stimulated 
BMDC effects on T cell proliferation (Chapter 6). 
 Effect of C. difficile toxins on murine and human DC activation (Chapter 7). 
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Chapter 2  
Materials and Methods 
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2.1 Bacterial Culture 
 
2.1.1 Bacterial Strains and Growth Conditions 
 
C. difficile strains were cultured on Brain Heart Infusion (BHI) Agar (Oxoid, Basingstoke, UK) 
or pre-equilibrated BHI broth (Oxoid) containing C. difficile selective supplement (Oxoid) 
and 0.05% cysteine (Sigma-Aldrich, Poole, UK). BHI agar was supplemented with 5% 
difibrinated horse blood (Oxoid). All bacterial cultures were grown in an anaerobic chamber 
(Don Whitley Scientific, Shipley, UK) in an atmosphere of 10% CO2, 10% H2, and 80% N2 at 
37 °C. C. difficile strains used throughout this study are described at Table 2.1.  
 
2.1.2 Bacterial Stock Culture Preparation  
 
Bacterial stocks of C. difficile strains were maintained by suspending bacterial cell 
suspension or isolated colonies in either 30% glycerol or microbank (Pro-Lab, Neston, UK) 
and stored at -70 °C. The cultures were resuscitated by removing a loopful of glycerol stock 
or a single bead from microbank to inoculate a BHI agar plate. Plates were incubated in the 
anaerobic atmosphere at 37 °C for 48 h. To prepare bacterial broth culture, 15 ml pre-
equilibrated BHI broth was inoculated with a single colony. Cultures were grown 
anaerobically shaking at 50 rpm until stationary phase was achieved.  
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Bacterial strains Produced 
toxins  
Ribotype Reference/Source 
027 
 
R20291 
 
R20291 tcdA 
R20291 tcdB 
R20291 cdtA 
R20291 cdtB 
 
630 
 
630 Δerm 
 
630 Δerm tcdA 
630 Δerm tcdB 
630 Δerm tcdA tcdB 
 
M68 
CF5 
 
CF2 
CF3 
 
CD586 
CD816 
CD636 
 
CD37 
 
A+B+, CDT+ 
 
A+B+, CDT+ 
 
A-B+, CDT+ 
A+B-, CDT+ 
A+B+, CDTa- 
A+B+, CDTb- 
 
A+B+ 
 
A+B+ 
 
A-B+ 
A+B- 
A-B- 
 
A-B+ 
A-B+ 
 
A-B+ 
A-B+ 
 
A-B+ 
A-B+ 
A-B+ 
 
A-B- 
 
027 
 
027 
 
027 
027 
027 
027 
 
012 
 
012 
 
012 
012 
012 
 
017 
017 
 
017 
017 
 
017 
017 
017 
 
undetermined 
P. Mullany, Eastman Dental Institute, 
UCL 
Stoke Mandeville Hospital, UK , 2006 
 
 
N. Minton, University of Nottingham, 
UK 
 
 
 
Sebaihia et al., 2006 
 
Hussain et al., 2005 
 
 
Kuehne et al., 2010 
 
 
 
Stabler et al., 2006 
 
 
R. Stabler, London School of Hygiene 
and Tropical Medicine, London, UK 
 
Lewisham isolates 
R. Stabler, London School of Hygiene 
and Tropical Medicine, London, UK 
 
P. Mullany, Eastman Dental Institute, 
UCL 
Wust & Hardegger, 1983 
 
 
Table 2.1. List of C. difficile strains employed in this study. Strains were selected from 
three different ribotypes including; 027 (hypervirulent), 012 (epidemic), and 017 (A-B+) 
strains. Strains 027, R20291, 630, 630 Δerm and CD37 were kindly given by Prof. Mullany 
and R20291 and 630 Δerm toxin mutant strains were kindly provided by Prof. Minton. 
Ribotype 017 strains were a kind gift from Dr. Stabler.  
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2.1.3 C. difficile Growth Kinetics  
 
To establish C. difficile strain growth curves, a starter exponential phase culture was 
prepared by inoculating three single colonies into 10 ml pre-warmed BHI broth (shaking at 
50 rpm) in the anaerobic workstation at 37°C. When an optical density at 600 nm (OD600) of 
0.3-0.4 was reached, cultures were diluted 1:10 in 15 ml of pre-equilibrated BHI broth in a 
25 cm2 cell culture flask (Nunc, Roskilde, Denmark) and grown shaking at 50 rpm (Dawson 
et al., 2008). OD600 was measured by spectrophotometer (Pharmacia Biotech, Ultrospec 
2000 UV/visible) at intervals of 1 h to monitor bacterial growth. Colony forming unit (cfu) 
counts were determined at 0.5, 1.00, and 1.5 OD600 by 10-fold serially diluted bacterial 
cultures in Dulbecco's Phosphate-Buffered Saline (PBS) (Invitrogen/Gibco, Paisley, UK). 
Dilutions were plated on blood agar base (Oxoid) supplemented with 7% difibrinated horse 
blood. Plates were incubated in the anaerobic chamber for 48 h. The number of colonies 
were counted and presented as cfu/ml.    
 
2.1.4 C. difficile Survival under Aerobic Conditions 
 
Since majority of the co-culture experiments presented in this thesis were performed in an 
aerobic environment (5% CO2) it was imperative to examine C. difficile tolerance to oxygen. 
Pre-warmed BHI broths were inoculated with a single bacterial colony. Bacterial cultures 
were grown in the anaerobic chamber at 37 °C till stationary phase was achieved. Then 
stationary phase bacterial cultures were exposed to aerobic conditions (5% CO2). Bacterial 
survival was enumerated by cfu counting over time.  
 
2.1.5 C. difficile Sporulation 
 
Sporulation of C. difficile strains were examined by using yeast peptone medium (YPM) and 
BHI media. YPM consisted of; 16.00 g peptone (Sigma-Aldrich), 10.00 g yeast (Sigma-
aldrich), and 5 g NaCl/L of H2O2. Medium was autoclaved at 121 °C for 15 min. Pre-warmed 
YPM and BHI were inoculated with a colony of C. difficile and grown anaerobically at 37 °C 
for 10 days. A portion of bacterial culture was diluted 1:1 with either PBS or ethanol (to kill 
vegetative cells) for 1 h. Total number of bacteria (vegetative and spore) was enumerated 
in PBS-treated cultures and number of spores were determined by cfu counting in ethanol-
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treated cultures. The remaining bacterial cultures were incubated aerobically (5% CO2) at 
37 °C to monitor spore formation. Spores were enumerated at 8 h post-exposure to oxygen.  
The generated spores were stained by the Wirtz-Conklin staining method (Hamouda et al., 
2002; Ochsner et al., 2009). The spore suspension was fixed on a glass slide with a Bunsen 
flame then stained with 5% Malachite Green (Sigma-Aldrich). Slides were heated for 5 min 
ensuring that the dye remained hot (but not boiling) then rinsed with water and 
counterstained with 0.5% Safranin-O (Sigma-Aldrich) for 1 min. After drying, the slides were 
examined for endospores by light microscopy (20x Leica GMBH, QImaging digital camera). 
Spores were stained in bright green/blue and vegetative cells in pink.  
 
2.1.6 C. difficile Toxin Gene Detection 
 
To detect C. difficile toxin genes, three colonies of each bacterial strain (grown on a BHI 
agar plate) were resuspended directly in 15 μl of Lyse-N-Go (Thermo Scientific, 
Northumberland, UK) PCR reagent. Table 2.2 outlines the thermal cycle programme that 
was performed to lyse the cells and release the total DNA.  
 
 
Cycle # Temperature (°C) Time 
1 
2 
3 
4 
5 
6 
7 
8 
9 
65 
8 
65 
97 
8 
65 
97 
65 
80 
30 sec 
30 sec 
90 sec 
180 sec 
60 sec 
180 sec 
60 sec 
60 sec 
hold 
 
Table 2.2. Thermal cycle programme to release the total DNA. 
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Template nucleic acid (5 μl) was added to a PCR mixture [total 50 μl; 5 μl 10x ThermoPol 
Buffer, 2 μl Nucleotide Solution Mix (final concentration of 200 uM each dNTP), 1 μl (5000 
u/ml) Taq DNA Polymerase, 200 pmoles of each primer (Tables 2.3), and H2O up to 50 μl 
(New England Biolabs, Herts, UK)]. Reactions were subjected to 25 cycles of 95 °C for 30 
sec, 54 °C for 90 sec and 72 °C for 2 min. PCR products were separated on a 1% agarose gel 
(Invitrogen/Gibco) in 1x Tris-Acetate-EDTA buffer (TAE) (Sigma-Aldrich). 1kb ladder (New 
England Biolabs) was used as DNA molecular weight (MW) marker.  
Tables 2.3 describe the primers, which used to amplify regions of tcdA and tcdB, and binary 
toxin genes.  
 
 
 Forward  Reverse 
tcdA 
tcdB 
cdtB 
        5’-GAGGATCCGGCGATATAGATAATAAAG-‘3 
        5’- CAGGATCCATCTATGAGTCAAGAC-‘3 
        5’-CTTAATGCAAGTAAATACTGAG-‘3 
          5’-CTGGATCCAAGGTAAGATGAGTATAC-‘3 
          5’- CTAAGCTTGGTATACCTGCTG-‘3  
          5’-AACGGATCTCTTGCT TCAGTC-‘3 
BIN 5/6         5’-AATATTGGGAGGGAGAATAAATG-‘3           5’-TGTATTTTCATTGTTTCTCCTCC-‘3 
BIN 7/8         5’- ATTGTTGATGCAACATTGATACC-‘3           5’-AATATATAT TGTATTGAGGGGAC-‘3 
 
Table 2.3. List of primers to amplify regions of tcdA, tcdB and binary toxin genes. tcdA and 
tcdB primers were in-house design. A specific region of cdtB gene was amplified using cdtB 
primer (forward position, cdtB 368-389; reverse position, cdtB 878-858) (Stubbs et al., 
2000). BIN5/6 and BIN7/8 primers were utilised to amplify the entire cdtA and cdtB genes 
respectively (Spigaglia et al., 2002).  
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2.1.7 C. difficile Toxin Detection by Western Blotting 
 
Bacterial cultures grown to stationary phase were centrifuged at 2500 rpm for 15 min. 
Protein concentration was determined in bacterial pellets and supernatants by performing 
a Bradford assay (Sigma-Aldrich) per manufacture’s instruction. Briefly, 1 part of the 
samples (blank, protein standards, and bacterial proteins) were mixed with 30 parts of the 
Bradford Reagent. Protein standard was prepared by serially diluting 1 mg/ml Bovine Serum 
Albumin (BSA, Sigma-Aldrich) with distilled water. The absorbance was measured at 595 nm 
(FLUOstar OPTIMA, BMG LABTECH GmbH, Germany). Protein concentration was 
determined by comparison of the bacterial proteins to the standard curve created using 
BSA.  
Samples in laemmli buffer (Table 2.4) were boiled at 95-100 °C for 5 min and subjected to 
6% SDS-PAGE (6% resolving and 4% stacking, Table 2.5) in a Mini-Protean® 3 Cell unit 
(BioRad Laboratories, Hemel Hempstead, UK). Table 2.6 describes buffers used in this 
procedure.  
 
 
2x Laemmli Buffer  
0.5M Tris-HCl  (pH 6.8) 
10% SDS 
Glycerol 
0.1% Bromophenol blue   
β-mercaptoethanol 
MilliQ water 
Total volume 
2.5 ml 
4 ml 
2 ml 
0.5 ml 
2.5-5% 
1 ml 
10 ml 
 
Table 2.4. Composition of 2x Laemmli buffer. 
 
 6% Resolving Gel 4% Stacking Gel 
MilliQ water 
Gel buffer 
30% Acrylamide  
APS 
TEMED 
Total volume 
5.3 ml 
2.6 ml 
2 ml 
100 μl 
10 μl 
10 ml 
7.2 ml 
1.35 ml 
1.33 ml 
100 μl 
10 μl 
10 ml 
 
Table 2.5. Composition of 6% Tris SDS gels.  
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Resolving Gel Buffer  Stacking Gel Buffer  
Tris 
10% SDS 
MilliQ water 
pH 
18.2 g 
4 ml 
100 ml 
8.8 
Tris 
10% SDS 
MilliQ water 
pH 
6.6 g 
4 ml 
100 ml 
6.3 
10x Gel Running Buffer  10x Transfer buffer  
Tris 
Glycine 
SDS 
MilliQ water 
pH 
30.3 g 
144.1 g 
10 g 
1 L 
8.3 
Tris 
Glycine 
MilliQ water 
 
30.27 g 
144.1g 
1 L 
 
Table 2.6. List of buffers used for SDS-PAGE and western blotting. 
 
 
5 μl of SeeBlue® Plus2 Pre-Stained Standard (Invitrogen, Paisley, UK) was included to 
determine the MW and as a visual check for transfer efficiency. Gels were electrophoresed 
at 110 V (BioRad PowerPac 3000, BioRad Laboratories) for 5 h at 4 °C. Proteins were 
transferred to a nitrocellulose membrane (Amersham Hybond ECL membrane, GE 
Healthcare, Little Chalfont, England) using a wet transfer system (BioRad Laboratories) at 
400 mA for 90 min at 4 °C. Post-transfer, non-specific binding was blocked by incubating the 
membrane in the blocking buffer [5% dried skimmed milk (Marvel, UK) in 0.1% Tween 20 
(Sigma-Aldrich)-PBS] overnight at 4 °C on a shaker. This was followed by a single wash with 
0.1% Tween 20-PBS for 5 min, the membrane was incubated with primary goat anti-TcdA or 
anti-TcdB antibody (kindly provided by Prof. Brendan Wren, London School of Hygiene and 
Tropical Medicine; 1:1000), in blocking buffer overnight at 4 °C on a shaker.   
Membrane was washed 3x with 0.1% Tween 20-PBS for 5 min each, the blot was incubated 
with secondary antibody (Polyclonal rabbit anti-goat Ig/HRP; Dako, Denmark; 1:2000) 
overnight at 4 °C on a shaker. Blots were washed 3x with 0.1% Tween 20-PBS for 10 min. 
Toxins were detected using an enhanced chemiluminescence (ECL) reaction (Amersham ECL 
Western blotting detection reagent, GE Healthcare) followed by autoradiography film (Film 
CL-Xposure, Thermo Scientific, Loughborough, UK). The membranes were developed with 
an automated X-ray film developer (Autorad).  
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2.1.8 C. difficile Toxin Cytotoxicity Assay 
 
C. difficile strains were grown to stationary phase in BHI broth. Bacterial cultures were 
centrifuged and supernatants filter sterilised (0.22 μm filter; Millipore, UK). Human colonic 
epithelial cell-line HT-29, and African green monkey kidney cells, Vero (see section 2.2.1) 
cells were seeded at a concentration of 1.5x105 and 0.5x106/ml. Semi-confluent HT-29 and 
confluent Vero cells were co-cultured with 2-fold serially diluted bacterial supernatants. 
Morphological changes 8 h post-infection were observed by microscopy. The cytopathic 
effect (CPE) was determined by comparing infected cells to uninfected control cells scoring 
each dilution on a scale from 0 to +4. A Nickon TMS inverted phase contrast microscope 
was used to visualised the cells at 40X magnification. 
 
2.1.9 Analysis of Rac1 Glucosylation and Inflammasome Activation  
 
2.1.9.1 Rac1 Glucosylation 
 
A human ileocecal epithelial cell-line, Caco-2 (see section 2.2) was infected with strains CF5 
and M68 bacterial culture and Caco-2 Rac1 glucosylation was investigated by western 
blotting. Cells were seeded at a concentration of 5x104/ml and grown to form a monolayer. 
Cells were infected with stationary phase bacterial cultures at an MOI of 250 for 8 h.   
 
2.1.9.2 Inflammasome Activation 
 
Pro- and activated caspase-1 and pro- and mature IL-1β were detected in C. difficile 
infected murine bone-marrow-derived dendritic cells (BMDCs) (see section 2.3).  
Cells were washed once with ice-cold PBS then lysed using ice-cold lysis buffer (Table 2.7) 
for 15 min. Cell suspensions were centrifuged (4 °C, 20 min, 12000 rpm). Supernatants were 
aspirated and subjected to 15% SDS-PAGE. 10 μl of ColorPlus PreStained Protein Ladder 
(New England, BioLabs) was used as MW marker. Gels were electrophoresed at 110 V for 
1.5 h. Proteins were transferred to a PVDF transfer membrane (Amersham HybondTM-P, GE 
Healthcare) using a wet transfer system at 400 mA for 45 min. Blots were blocked by 
incubation in blocking buffer overnight at 4 °C on a shaker. This was followed by a single 
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wash with 0.1% Tween 20-PBS for 5 min, the membrane was incubated with primary 
antibody (Table 2.8) in blocking buffer overnight at 4 °C on a shaker.  
Membrane was washed 3x with 0.1% Tween 20-PBS for 5 min and incubated with 
secondary antibody (Polyclonal rabbit anti-mouse Ig/HRP; Dako, Denmark; 1:2000 or 
Polyclonal goat anti-rabbit Ig/HRP; Dako; 1:2000) overnight at 4 °C on a shaker. Blots were 
washed 3x with 0.1% Tween 20-PBS for 10 min/wash prior to ECL detection. Rac1 was 
quantified densitometrically (BioRad ChemiDoc XRS, Bio-Rad Quantity One 1-D Analysis 
software, Hertfordshire, UK).   
To detect β-actin, membranes were stripped using stripping buffer (Table 2.7) heated at 50 
°C for 30 min. Blots were washed with 0.1% Tween 20-PBS and incubated in blocking buffer 
overnight at 4 °C on a shaker. Membranes were washed and incubated with primary rabbit 
β-actin monoclonal antibody (Cell Signaling Technology, Danvers, USA; 1:1000), in blocking 
buffer overnight at 4 °C on a shaker. Blots were incubated with secondary antibody 
(Polyclonal goat anti-rabbit Ig/HRP; Dako; 1:2000) overnight at 4 °C on a shaker 
subsequently membranes were washed and detected for β-actin.  
 
 
Lysis Buffer  Stripping Buffer  
1.5M Tris 
1% Triton X-100 
0.5M NaCl 
pH  
MilliQ water 
 
333 μl 
100 μl 
3 ml 
8.0 
Up to 
10 ml 
0.5M Tris-HCl 
10% SDS 
β- mercaptoethanol 
MilliQ water 
5 ml 
8 ml 
280 μl 
Up to 
40 ml 
 
Table 2.7. Composition of lysis and stripping buffers. Lysis buffer were supplemented with 
a protease inhibitor cocktail tablet (Roche, Burgess Hill, UK).   
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Primary antibody MW Dilution 
Mouse anti-Rac1 (clone 102) 21 kDa 1:1000 
Caspase-1 p10 (M-20): sc-514 
Polyclonal rabbit anti mouse 
prodomain: 10 kDa 
precursor: 45 kDa  
1:500 
IL-1β (H-153): sc-7884 
Polyclonal rabbit anti human 
mature: 17 kDa 
precursor: 31 kDa 
1:500 
 
Table 2.8. Antibodies used to detect Rac1, caspase-1 and IL-1β. Rac1 antibody was from 
BD Biosciences, USA. Both caspase-1 and IL-1 β antibodies were from Santa Cruz 
Biotechnology, inc., USA.  
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2.2 Mammalian Cell Culture 
 
2.2.1 Mammalian Cell-lines 
 
Caco-2 (American Type Culture Collection, HTB-37) and HT-29 (ATCC, HTB-38) human 
intestinal epithelial cell-lines and Vero (ATCC, CCL-81) African green monkey kidney cells 
were grown in Dulbecco’s Modified Eagle Medium with GlutaMAX- I (DMEM) 
(Invitrogen/Gibco). T84 (ATCC, CCL-248) a human colonic carcinoma cell-line was grown in 
Dulbecco’s Modified Eagle’s Medium Nutrient Mixture F-12 HAM (Sigma-Aldrich). All media 
were supplemented with 10% fetal calf serum (FCS, Invitrogen/Gibco), 1% L-glutamine 
(Invitrogen/Gibco), 1% penicillin-streptomycin solution (Invitrogen/Gibco), and 1% non-
essential amino acids (Invitrogen/Gibco). This media is referred as ‘’complete’’ media. 
Cultures were maintained at 37 °C in 5% CO2. Confluent cell-lines were routinely passaged 
by briefly rinsing with PBS (Invitrogen/Gibco) before detaching cells with 3 ml of trypsin-
EDTA (Invitrogen/Gibco) for 2-3 min. This was followed by the addition of 10 ml complete 
DMEM. Cells were centrifuged (2000 g, 5 min) and pellets were resuspended in 10 ml of 
complete media. Subsequently, cells were subcultivated at a ratio of 1:5 to 1:10 as 
required. The T84 cell pellet was resuspended in 10 ml of complete DMEM F-12 Ham then 
subcultivated at a ratio of 1:2 to 1:4. 
 
2.2.2 Lactate Dehydrogenase (LDH) Release Assay 
 
Caco-2 monolayers and semi-confluent HT-29 cells were incubated with stationary phase 
bacterial cultures at an MOI of 10, 100, and 1000 for 8 h and 24 h. Co-culture supernatants 
were analysed for LDH release using Cytoscan-LDH Cytotoxicity assay kit (GBiosciences, St 
Louis, USA) according to manufacturer’s instruction. Briefly, supernatants were centrifuged 
to remove particulates then 50 μl were transferred into 96-well flat bottom plates (Nunc). 
The reconstituted substrate mix was prepared as instructed and 50 μl of solution was 
added to each well. Plates were covered with foil and incubated at 37 °C for 20 min. 50 μl of 
Stop Solution was added to each well and absorbance was recorded at 490 nm (FLUOstar 
Optima). Cytotoxicity percentage was calculated as follows:  
% Cytotoxicity= Experimental (OD490) - Negative control (OD490) / Maximum LDH release 
(OD490) x 100 
68 
 
2.2.3 Ethidium Homodimer Uptake Assay 
 
Human IEC death in response to C. difficile infection was evaluated by the ethidium 
homodimer uptake method using the Live/Dead viability/cytotoxicity kit (Invitrogen).  Caco-
2 cells were grown on Poly-L-lysine (Sigma-Aldrich) coated coverslips then monolayers were 
infected with stationary phase bacteria at an MOI of 250 for 8 h at 37 °C in 5% CO2. 200 μl 
of the combined Live/Dead assay reagents (2 μM calcein-AM, 4 μM EthD-1) was added and 
incubated for 30 min at room temperature (RT). Following incubation, coverslips were 
mounted on the microscope slide and sealed. Labelled cells were observed under the 
fluorescence microscope (100x Leica DMLB).  
 
2.2.4 Annexin-V & Propidium Iodide (PI) Staining 
 
Caco-2 monolayers were infected with bacterial culture at an MOI of 250. At 6 h post-
infection cells were washed with PBS and detached with acutase (PAA Laboratories GmbH, 
Austria). Cells were transferred into a tube and centrifuged at 200 g for 5 min. Cell pellets 
were resuspended in 100 μl of Annexin-V-FLUOS (Roche) labelling solution containing 20 μl 
Annexin-V-Fluos labelling reagent in 1 ml incubation buffer and 20 μl Propidium iodide 
solution. Cell suspension was incubated 10-15 min at RT then analysed by flow cytometry.  
 
2.2.5 C. difficile Adherence Assay 
 
Prior to co-culture, bacteria were labelled with Fluorescein isothiocyanate (FITC; Sigma-
Aldrich). Saturated solution of FITC was prepared in PBS then filter sterlised. Bacterial 
cultures were diluted with FITC solution at ratio of 1:1 and incubated at 37 °C for 10 min. 
Solution mix was centrifuged (12000 rpm, 2 min) and supernatant aspirated. The labelled 
bacterial pellet was washed 3x with PBS. To detect efficiency of the labelling procedure, 
labelled and unlabelled bacteria were washed with PBS and then fixed in 4% 
Paraformaldehyde (4% PFA was dissolved in PBS by heating at 65 °C for 45 min, aliquots 
were stored at -20 °C) for 10-15 min at RT. Bacteria were washed and resuspended in FACS 
wash buffer (PBS, 1% FCS and 0.1% sodium azide) prior to analysis by flow cytometry. 
FITC-labelled bacteria were co-cultured with Caco-2 monolayers at an MOI of 250. At 6 h 
post-infection cells were washed, detached by acutase and centrifuged at 2000 rpm for 5 
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min. Cell pellets were washed twice with PBS then fixed in 4% PFA. Cells were resuspended 
in FACS wash buffer and analysed by flow cytometry and analysed using FlowJo software 
(Tree Star). 
 
2.2.6 Confocal Imaging 
 
To detect degree of C. difficile adhesion/invasion to IEC, confocal imaging was utilised. 
Caco-2 monolayers were infected with FITC-labelled bacteria at an MOI of 250 for 8 h. Co-
cultures were examined by epifluorescence on an inverted LSM710 confocal system 
mounted on an AxioObserver Z1 microscope (Carl Zeiss Ltd, UK). The images were captured 
with a LD LCI Plan-Apochromat 25x NA 0.8 water immersion DIC objective (Carl Zeiss Ltd). 
The FITC and Cell Mask Orange (Invitrogen) dyes were sequentially excited with a 488 nm 
Argon laser and a 561 nm diode. The emitted light detection range was automatically setup 
by the Smart setup module of the ZEN2009 software to avoid bleed-through between 
emission spectra (Carl Zeiss Ltd). The optical section thickness was set to 3.4 µm and z-stack 
images were acquired with 1.7 µm spacing between optical slices. The image files were 
exported into ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009) where the orthogonal slices were 
created. 
 
2.2.7 Time-lapse Microscopy 
 
C. difficile mediated disruption of IEC integrity was investigated by live microscopy. Caco-2 
cells were grown on a 14 mm, 12-well glass bottom culture plate (Mat Tek, Ashland, USA) 
then infected with FITC-labelled C. difficile strains. Co-cultures were monitored by time-
lapse microscopy over 12 h in 15 min intervals.  
Cells were examined by epifluorescence and transmitted light on an inverted Axiovert 135 
microscope (Carl Zeiss Ltd) equipped with a temperature-controlled environmental 
chamber. The images were captured with a x32 LD A-Plan (NA 0.4) phase contrast objective 
(Carl Zeiss Ltd) using a C4742-80 ORCA-ER digital camera (Hamamatsu Photonics Ltd, UK) 
controlled by the Volocity software (Improvision, UK). Fluorescent Images of FITC-labelled 
bacteria and a phase contrast picture of the field of view were taken before the phase 
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contrast time lapse was recorded at a frame rate of 1 frame/15 min. The time-lapse files 
were exported into ImageJ (W. Rasband, NIH) where they were processed.  
Confocal and time-lapse microscopy were performed by Dr B. Vernay, Light Microscopy 
Facility, Institute of Child Health. 
 
2.2.8 Gene Expression Analysis  
 
2.2.8.1 RNA Extraction 
 
Control uninfected and infected cells were washed with PBS. Cells were lysed by adding 1 
ml of TRIzol (Invitrogen). Lysed cells were transferred to a sterile 1.5 ml microcentrifuge 
tube. 200 µl of chloroform (Sigma-Aldrich) was added and the mix vortexed for 15 sec, 
incubated at RT for 3 min then centrifuged at 12000 rpm for 15 min at 4 °C. The top 
aqueous layer was transferred to a fresh sterile tube containing 500 µl isopropanol (Sigma-
Aldrich) and vortexed. The mixture was incubated at RT for 10 min before centrifuging at 
12000 rpm for 10 min at 4 °C. The pellet was washed with 1 ml 75% nuclease free ethanol 
(Sigma-Aldrich) and removed by centrifugation (7500 rpm for 5 min at 4°C). The total RNA 
was measured by NanoDrop® ND 1000 spectrophotometer (NanoDrop Technologies, USA). 
The pellet was resuspended in 50 µl of RNA Storage solution (Ambion, Warrington, UK) and 
stored at -70 °C. 
 
2.2.8.2 cDNA Synthesis 
 
The following components were added to a nuclease free microcentrifuge tube: 
Oligo (dT)12-18 (500 µg/ml) (Invitrogen)            1 µl 
5 µg total RNA (Invitrogen)                                x µl                                                                                           
10 mM dNTP Mix (Invitrogen)                          1 µl                                                                                 
Sterile nuclease free water (Severn Biotech Ltd, Kidderminster, UK),      to 12µl                                                                
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The mixture was heated to 65 °C for 5 min to promote binding between oligo dT and polyA 
tail of mRNA molecules, and rapidly transferred on ice. Subsequently, the following 
reagents were added to the contents of the tube: 
5x First-Strand Buffer (Invitrogen)                     4 µl  
0.1 M DTT (Invitrogen)                                         2 µl 
RNaseOUTTM                                                          1 μl 
 
The contents of the tubes were mixed gently and incubated at 25 °C for 2 min. 1 µl of 
SuperScriptTM II RT (Invitrogen) was added and mixed by pipetting, next incubated at 42 °C 
for 50 min. The reaction was inactivated by heating at 70 °C for 15 min.  
 
2.2.8.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
The obtained cDNA was used as a template for PCR amplification.  
The following reagents were added to a microcentrifuge tube and mixed: 
BIOMIXTM RED (Bioline, London, UK)                                              12.5 µl 
Nuclease free water (Severn Biotech Ltd)                                     9.5-10.5 µl 
10 µM Forward primer (Sigma-Genosys, Pampisford, UK)         1 µl  
10 µM Reverse primer                                                                      1 µl 
cDNA                                                                                                    1-2 µl 
 
The amplification profile consisted of denaturation at 94 °C for 90 sec, annealing at 58 °C 
for 90 sec, and extension at 72 °C for 90 sec for 40 cycles. The sequence-specific primers 
were used, the expected PCR product size are listed in Table 2.9.  
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mRNA product 5’ primer 3’ primer PCR size (bp) 
IL-8 ATGACTTCCAAGCTGGCCGTGGCT TCTCAGCCCTCTTCAAAAACTTCTC                  289 
IL-6               ATGAACTCCTTCTCCACAAGCGC GAAGAGCCCTCAGGCTGGACTG 628 
TNF-α CGGGACGTGGAGCTGGCCGAGGAG CACCAGCTGGTTATCTCTCAGCTC 355 
IL-1α GTCTCTGAATCAGAAATCCTTCTATC CATGTCAAATTTCACTGCTTCATCC 420 
IL-1β   AAACAGATGAAGTGCTCCTTCCAGG TGGAGAACACCACTTGTTGCTCCA 388 
hBD-1 TTGTCTGAGATGGCCTCAGGTAAC   ATACTTCAAAAGCAATTTTCCTTTAT 253 
hBD-2 CCAGCCATCAGCCATGAGGGTCTTG CATGTCGCACGTCTCTGATGAGGGAGG 276 
IL-18 GCTGCTGAACCAGTAGAAGACAATTGC CCTTGATGTTATCAGGAGGATTC 384 
Caspase-1 AACCCAGCTATGCCCACATCCTCA CAGATTTTGTAGCAGCATTGTCATGC      230 
GAPDH CTACTGGCGCTGGCAAGGCTGT GCCATGAGGTCCACCACCCTGCTG 359 
 
Table 2.9. List of primers used for RT-PCR. The oligonucleotide primers and PCR product 
size. [IL-8, IL-6, TNF-α, IL-1α, IL-1β (Jung et al., 1995)] [hBD-1, hBD-2, GAPDH (Zaalouk et al., 
2004)], IL-18 & caspase-1 were in-house design. 
 
 
2.2.8.4 Gel-Electrophoresis  
 
PCR products were separated on a 2% agarose gel (Invitrogen) in 1x Tris-Borate-EDTA buffer 
(Sigma-Aldrich) at 50 V. Band intensities were quantified by densitometry (BioRad 
ChemiDoc XRS, Bio-Rad Quantity One 1-D Analysis software). Gene expression was 
normalised to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).  
 
2.2.9 Enzyme-linked Immunosorbent Assay (ELISA) 
 
Cytokine protein secretion was measured by ELISA according to manufacturer’s instructions 
(eBioscience®, Hatfield, UK). Briefly, 96-well ELISA plates were coated with 100 µl/well of 
capture antibody diluted in coating buffer. Plates were sealed and incubated overnight at 4 
°C then washed 5x with 250 µl/well wash buffer (0.05% Tween 20-PBS) allowing time for 
soaking (~1 min) during each wash step to increase the effectiveness of the washes. 100 μl 
of 1x assay diluent was used to block non-specific binding. Plates were incubated at RT for 1 
h then washed. Using 1x assay diluent, 2-fold serial dilutions of the standard was prepared, 
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50 µl of the standard was added to each well in order to generate a standard curve. 50 µl of 
samples were added and plates were covered and incubated at 4 °C overnight then 
washed. 50 µl of detection antibody (in assay diluent) was added and plates were sealed 
and incubated at RT for 1 h followed by washing. 50 µl of Avidin-HRP (in assay diluent) was 
added and plates were incubated at RT for 30 min. Wells were washed with wash buffer for 
1 to 2 min prior to aspiration. 50 µl of substrate solution (Tetramethylbenzidine Substrate 
Solution) was added at RT for 15 min. Finally 50 µl stop solution (2N H2SO4) was added to 
each well and absorbance was read at 450 nm by Multiskan Ascent ELISA reader (Thermo 
Electron Corporation, UK).  
 
2.2.10 Occludin Immunofluorescence  
 
T84 cells were seeded on glass coverslips at a density of 5x105/ml and were grown to 
confluence. Cells were infected with bacterial cultures at an MOI of 250 for 8 h. To enhance 
occludin staining, cells were pre-extracted in buffer containing 10 mM Hepes (pH 7.1), 0.2% 
Triton X-100, 100 mM KCL, 3 mM MgCl2, 1 mM CaCl2, and 200 mM sucrose for 2 min on ice. 
Following pre-extraction, monolayers were fixed in 4% PFA for 15 min at RT. PFA was 
removed by 3 washes with 1% BSA/PBS. Subsequently, monolayers were permeabilised in 
0.1% TritonX-100 (Sigma-Aldrich) in 1% BSA/PBS at RT for 30 min followed by blocking with 
5% goat serum (Sigma-Aldrich) in 1% BSA/PBS for 1 h. Monolayers were incubated with 4 
μg/ml rabbit anti-Occludin (Zymed, Invitrogen) antibody overnight at 4 °C. Cells were 
washed 3x with 1% BSA/PBS (total 45 min). Cells were incubated with Alexa Flour 488 goat 
anti-rabbit IgG secondary antibody (Invitrogen), diluted 1:500 in 1% BSA/PBS for 1 h in the 
dark at RT, followed by a single wash for 15 min in the dark. Coverslips were mounted on 
slides with Vectashield mounting medium with 4',6-diamidino-2-phenylindole (DAPI) 
(Vector, Peterborough, UK) and visualised using a fluorescence microscope (Leica DMLB, 
CoolSNAP-Procf camera).  
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2.2.11 Measurement of Transepithelial Electrical Resistance (TEER) 
 
Barrier function of T84 monolayers were assessed by measurement of TEER and increased 
permeability to FITC-dextran.  
Prior to bacterial co-culture, 12 mm polyester membrane transwell inserts (Corning, New 
York, USA) were coated with collagen from rat tail (Sigma-Aldrich). Collagen was diluted in 
60% ethanol and membranes were coated at 10 μg/cm2 volume. Collagen-coated 
membranes were equilibrated with culture media DMEM F-12 HAM for 30 min. T84 cells 
were grown on collagen-coated membranes at 37 °C, 5% CO2. When monolayers showed 
TEER of ~1500 Ω x cm2 indicating establishment of epithelial barrier function, infection was 
performed and TEER was measured over 24 h using an epithelial Volt-Ohm meter voltmeter 
(World Precision Instruments Ltd, Stevenage, UK).  
 
2.2.12 In vitro Permeability 
 
Epithelial permeability was measured by applying FITC-conjugated dextran (4 kDa, 0.2 
mg/ml, Sigma-Aldrich) to the apical compartment of transwell inserts. Aliquots from 
basolateral chambers were collected for assessment. FITC associated fluorescence was 
measured by FLUOstar Optima plate-reader after excitation at 488 nm and detection at 520 
nm.  
 
2.2.13 Ussing Vertical Diffusion Chamber System 
 
T84 cells were grown on a 12mm snapwell inserts (tissue culture treated polyester 
membrane) supported by a detachable ring (Corning). The TEER was monitored until 
resistance reached ~1500 Ω x cm2. Snapwell inserts with polarised cells were mounted 
between two half chambers of a vertical diffusion chamber (Harvard Apparatus, Kent, UK). 
Both side chambers were filled with non-supplemented DMEM F-12 HAM and bacteria 
(MOI of 250) was added to the apical side (Figure 2.1). The apical chamber was diffused 
with an anaerobic gas mixture (10% CO2, 10% H2, and 80% N2, BOC, UK) and the basolateral 
compartment with 5% CO2 (BOC). 8 h post-experiment, supernatants were collected and 
concentrated to 1 ml using Amicon Ultra 3K centrifugal filter device (Millipore) for cytokine 
analysis. TEER was measured in a time-dependent manner.  
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Figure 2.1. Anaerobic infection in vertical diffusion chamber system. This figure is adapted 
from Schuller & Phillips, 2010.  
 
 
2.2.14 In vitro Organ Culture (IVOC) 
 
Intestinal biopsies were obtained, with fully informed parental consent, from paediatric 
patients (12-30 individuals, mean age of 10) during routine endoscopy for intestinal 
disorders. Tissues taken from normal area were microscopically examined. Tissue samples 
oriented mucosal surface upward were placed on sterile foam supports in 12-well plates. 
The foams were saturated with IVOC media consisting of complete DMEM media 
supplemented at ratio of 1:1 with NCTC-135 medium (Sigma-Aldrich). Media levels were 
adjusted to just reach tissue level on the foam but not to immerse it (Hicks et al., 1996). The 
explants were inoculated with 5x108 C. difficile bacteria at 37 °C in 5% CO2 humidified 
incubator for 3-6 h.  
 
2.2.15 Transfected HEK293 Cells 
 
HEK293 cells were grown in DMEM supplemented with 10% FCS, 1% penicillin-streptomycin 
solution, and 100 µg/ml Normocin (Source BioScience LifeSciences, Nottingham, UK). 
HEK293 transfected cells with TLR2/1, TLR2/6, TLR5, and TLR9 were grown in DMEM 
supplemented with 10% FCS, 1% penicillin-streptomycin solution, 100 µg/ml Normocin, and 
10 µg/ml Blasticidin S (Source BioScience LifeSciences, Nottingham, UK). Blasticidin S was 
 
 
 
Image unavailable due to copyright 
restrictions 
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replaced with 510 µg/ml Puromycin in ordered to grow TLR2-CD14, TLR4-CD14, and CD14 
cells (TLR-transfected-HEK293 cells were kindly provided by Dr. David Guiliano, Department 
of Immunology and Molecular Pathology, UCL).  
Cells were seeded in duplicates at a density of 3.5X104/ml in a 96-well plate and grown for 
24 h. Prior to infection, media was replaced with fresh DMEM and 20% non-heat-
inactivated FCS without antibiotics. Cells were co-cultured with bacterial cultures at an MOI 
of 10 for 8 h. TNF-α (125 ng/ml) was used as a positive control for all cell-lines in addition to 
specific ligands for each TLR (Table 2.10). Supernatants were collected and IL-8 induction 
(indicator of TLR-mediated NF-κB activation) was measured by ELISA. 
 
 
TLR Ligands Concentration 
TLR2: HKLM 
TLR2/6: FSL-1 
TLR2/1: Pam3CSK4 
TLR4: E. coli K 12 LPS 
TLR5: S. typhimurium Flagellin 
TLR9: ODN2006 (type B) 
1x10
8
 cells/ml 
500 ng/ml 
1 μg/ml 
500 ng/ml 
5 μg/ml 
50 μM 
 
Table 2.10. Human TLRs agonist used in this study. Human TLR1-9 agonist kit was from 
InvivoGen, San Diego, USA.  
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2.3 Dendritic Cell Culture 
 
2.3.1 Murine Bone-marrow-derived DCs (BMDCs) 
 
Femurs and tibias of C57BL/6 wild-type (WT) or Nod2, Ipaf, Nlrp3, and ASC knockout (KO) 
mice (6-12 weeks old, KO mice were kindly provided by Dr. Clare Bryant, Department of 
Veterinary Medicine, University of Cambridge) were separated and the surrounding 
muscles were removed by scissors. Intact bones were washed with PBS, 2% FCS, and 10 
μg/ml gentamycin (Sigma-Aldrich) solution. Both ends were cut and bone-marrow was 
flashed with PBS, FCS, gentamycin solution. Bone-marrow was resuspended gently with 
pipette to break the clusters then centrifuged at 1600 g for 7 min. The cells were depleted 
of red blood cells using 1 ml/pair of legs red blood cell lysing buffer (Sigma-Aldrich) for 5 
min. Cells were washed twice with PBS and centrifuged at 1600 g for 7 min. Cells were 
resuspended in 50 ml/pair of legs Iscove’s Modified Dulbecco’s Medium (IMDM) 
(Invitrogen) containing 50 μl 2-Mercaptoethanol (Invitrogen), 50 μl gentamycin, and 100 μl 
of recombinant mouse Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) 
(Invitrogen). Cells were cultured in 6-well plates and incubated at 37 °C. Cells were fed 
every 2 days. On day 7, cells were harvested by collecting non-adherent cells and detaching 
adherent cells with 2 mM EDTA-PBS (EDTA from Ambion). Cells were washed twice with 
PBS then resuspended in complete RPMI without antibiotics and seeded at a density of 
1x106/ml.  
 
2.3.2 Human Monocyte-derived DCs 
 
Blood samples were obtained from healthy donors, collected in a sterile tube containing 10 
U/ml heparin (CP Pharmaceuticals Ltd, Wrexham, UK). Blood samples were diluted with an 
equal volume of Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen). Subsequently, 
blood-RPMI mix was layered delicately over LymphoprepTM (AXIS-SHIELD, Oslo, Norway) at 
a ratio of 2:1 and centrifuged at 800 g for 20 min. Peripheral blood mononuclear cells 
(PBMC) layer was carefully removed by pipetting, cells were washed with RPMI 
supplemented with 10% FCS, 1% L-glutamine , and 1% penicillin-streptomycin solution.  
CD14+ monocytes were separated by magnetic separation method using MACS column and 
MACS Separator (Mini MACS) per manufacturer’s instructions. Briefly, after centrifugation 
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of PBMC, pellets were resuspended in MACS buffer (PBS, 2 mM EDTA, and 0.1% BSA; filter 
sterilised) then centrifuged at 300 g for 10 min. Supernatants were removed completely 
and pellets resuspended in 80 μl of MACS buffer/107 cells and 20 μl of CD14 MicroBeads 
(Miltenyi Biotec GmbH, Germany) then mixed and incubated at 4 °C for 30 min. Cells were 
washed with MACS buffer and centrifuged at 300 g for 10 min next resuspended in 5 ml 
MACS buffer.  
MACS column was placed in the magnetic field of the Mini MACS Separator and washed 
with 3 ml MACS buffer then 5 ml cell suspension was applied to the column. Unlabelled 
cells that passed through the column were collected and column was washed twice with 3 
ml of MACS buffer. Column was removed from the separator and 5 ml of MACS buffer was 
added to the column. Labelled cells were collected using the plunger to flush out the cells. 
Cells were washed with complete RPMI and centrifuged at 300 g for 10 min. CD14+ 
monocytes were resuspended in complete media supplemented with 50 ng/ml 
recombinant human IL-4  and 100 ng/ml recombinant human GM-CSF (both from R & D 
Systems, Minneapolis, USA). Cells were cultured in a 6-well plate and incubated at 37 °C for 
5-7 days to generate DCs.   
   
2.3.3 Dendritic Cell Maturation  
 
Dendritic cells were seeded at a density of 1x106/ml and infected with bacterial culture at 
an MOI of 10. 8 h post-infection, cells were collected and centrifuged at 1600 rpm, 4 °C for 
7 min. Supernatants were removed and cell pellets washed with 1 ml FACS wash (PBS, 1% 
FCS and 0.1% sodium azide) and centrifuged. Pellets were resuspended in 200 μl of blocking 
buffer (PBS, 10% FCS, 0.02% sodium azide) with rat anti-mouse CD16/CD32 (Mouse BD Fc 
Block™) (1: 1000) (BD Pharmingen™, BD Biosciences, USA). Cells were incubated for 10-15 
min on ice and centrifuged at 2000 rpm for 5 min at 4 °C. Antibodies utilised (Table 2.11) 
were prepared in blocking buffer and 50 μl of antibody solution was added to cell pellet and 
mixed by pipetting. Cells were incubated on ice for 30-45 min then centrifuged. Pellets 
were washed twice with FACS wash buffer and fixed with 4% PFA for 20 min. Cells were 
washed and pellets resuspended in 100 μl PBS and analysed by flow cytometry.  
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Antibody Clone Dilution 
Anti-Mouse CD80 PE-Cy5 
Anti-Mouse CD86 FITC 
Anti-Mouse MHC Class II FITC 
Anti-Mouse CD40 PE 
16-10A1 
GL1 
14-4-4S 
1C10 
1:300 
1:400 
1:400 
1:40 
 
Table 2.11. Antibodies used for detecting maturation markers. All antibodies were from 
eBioscience.  
 
 
2.3.4 Real-time Polymerase Chain Reaction (PCR) 
 
RNA was extracted from co-cultured cells as described in section 2.2.8.1. Extracted RNA was 
DNase treated to remove contaminating DNA using the TURBO DNA-freeTM Kit (Ambion). 
10x TURBO DNase Buffer (0.1 volume) and 1 μl of TURBO DNase was added to the RNA, 
mixed gently and incubated at 37 °C for 20-30 min. DNase Inactivation Reagent was 
resuspended and 0.1 volume was added and incubated at RT for 2 min mixing occasionally. 
The mix was centrifuged at 10000 g for 1.5 min and the RNA transferred into a fresh tube. 
cDNA was prepared by using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, USA). 2x Reverse Transcription master mix was prepared (20 μl of 
reaction/sample) on ice by adding the reaction mix components (Table 2.12) and mixed 
gently. The cDNA reverse transcription reaction was prepared by pipetting 10 μl of 2x 
master mix and 10 μl of RNA sample into a microcentrifuge tube. The tubes were sealed 
and briefly centrifuged then loaded to the thermal cycler and heated at 25 °C for 10 min, 37 
°C for 120 min, 85 °C for 5 min, then cooled to 4 °C. 
cDNA Reaction Mix Volume  
10x Reverse Transcription Buffer 
25x dNTP Mix (100 mM) 
10x Reverse Transcription Random Primers 
MultiScribe
TM
 Reverse Transcriptase 
RNase Inhibitor 
Nuclease-free H2O 
Total per Reaction 
2.0 μl 
0.8 μl 
2.0 μl 
1.0 μl 
1.0 μl 
3.2 μl 
10.0 μl 
 
Table 2.12. List of cDNA master mix components.  
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2.3.4.1 SYBR Green-based Gene Expression Analysis 
 
Real-time PCR master mix was prepared by dispensing reagents (Table 2.13) into a 0.1 ml 
PCR tube (Qiagen, Crawley, UK). 1 μl of 5 μM working solution of each forward and reverse 
primer was also included (Table 2.14). Next, 2 μl of cDNA template was added to the master 
mix making the total reaction volume 20 μl. Tubes were briefly centrifuged then loaded on 
the Real-time Rotary Analyser (Rotor-Gene 6000, Corbett Life Science, Cambridge, England). 
The thermal reaction was: Hold at 95 °C for 10 min; 40 cycles of 95 °C for 15 sec, 58 °C for 
30 sec, and 72 °C for 30 sec; Melt 70 °C to 95 °C, rising 1 °C, wait for 90 sec per melt and 5 
sec for each step.  
 
 
Reagent Volume 
2x JumpStart  
Taq Ready Mix 
Primers  
MilliQ water 
Total Volume 
10 μl 
 
2 μl 
6 μl 
18 μl 
 
Table 2.13. Master mix components for real-time PCR. SYBR® Green JumpStartTM Taq 
ReadyMixTM was from Sigma-Aldrich.  
 
 
 Forward Primer Reverse Primer 
IL-12 p35 
IL-12 p40 
IL-27 p28 
IL-27 EBI3 
IL-10 
IL-6 
IL-1β 
GAPDH 
 
5'-CCTCAGTTTGGCCAGGGTC-3' 
5'-GGAAGCACGGCAGCAGAATA-3' 
5′-TTCCCAATGTTTCCCTGACTTT-3’ 
5′-TGAAACAGCTCTCGTGGCTCTA-3’ 
5’-GGTTGCCAAGCCTTATCGGA-3’ 
5’-GTTCTCTGGGAAATCGTGGA-3’ 
5’-CCAAAAGATGAAGGGCTGCT-3’ 
5’-CCTGGAGAAACCTGCCAAGTATG-3’ 
 
5'-CAGGTTTCGGGACTGGCTAAG-3' 
5'-AACTTGAGGGAGAAGTAGGAAT-3' 
5′-AAGTGTGGTAGCGAGGAAGCA-3’ 
5′-GCCACGGGATACCGAGAA-3’ 
5’-ACCTGCTCCACTGCCTTGCT-3’ 
5’- TGTACTCCAGGTAGCTATGG-3’ 
5’- AGAAGGTGCTCATGTCCTCA-3’ 
5’- AGAGTGGGAGTTGCTGTTGAA-3’ 
 
Table 2.14. List of primers used in SYBR Green-based real-time PCR. Primers were from 
Eurofins MEG Operon, Ebersberg, Germany.  
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2.3.4.2 TaqMan Probe-based Gene Expression Analysis 
 
PCR master mix component (Table 2.15) was pipetted in duplicate for each sample into a 
nuclease-free 0.1 ml PCR tube (Qiagen) 4 μl of cDNA template was added and mixed gently. 
Tubes were briefly centrifuged then loaded on the Real-time Rotary Analyser (Rotor-Gene 
6000) and the following thermal cycle was performed: Hold at 95 °C for 10 min; 45 cycles of 
95 °C for 15 sec and 60 °C for 60 sec. 
 
 
PCR Reaction Mix  Volume  
20x TaqMan® Gene Expression Assay
1 
2x TaqMan® Gene Expression Master Mix 
RNase-free water 
Total Volume
 
1.0 μl 
10.0 μl 
5.0 μl 
20 μl 
 
Table 2.15. TaqMan probe-based PCR reaction mix component. All the reagents were from 
Applied Biosystems. 1Gene expression assay was performed for IL23a, alpha subunit p19 
and Hprt (hypoxanthine guanine phosphoribosyl transferase).  
 
 
2.3.5 T Cell Proliferation Assay 
 
2.3.5.1 T Cell Proliferation of Splenocytes 
 
1x106/ml BMDC from WT mice were stimulated with PFA fixed C. difficile strains at an MOI 
of 50 for 24 h. In these experiments LPS- (Lipopolysaccharides from Escherichia coli 
0111:B4, Sigma-Aldrich) was used as a positive control.  
Splenocytes were harvested from WT mice by mashing a spleen and passing the contents 
through a cell strainer (70 μm, BD Falcon, BD Biosciences). Cells were washed with PBS and 
centrifuged at 1600 g for 7 min. Red blood cells were depleted using 1 ml of red blood cell 
lysing buffer for 5 min. Cells were washed twice with PBS and centrifuged. Pellets were 
resuspended in complete RPMI and incubated at 37 °C for 2-3 h. 
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Harvested splenocytes were washed in PBS and resuspended at 0.5x106/ml in PBS. Cells 
were labelled with CFSE [5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester] 
(eBioscience) to a final concentration of 10 μM and incubated at 37 °C for 8-10 min. Cells 
were washed twice with PBS/FCS and resuspended in complete RPMI containing 50 μl 2-
Mercaptoethanol and 50 μl gentamycin. Dynabeads® Mouse T-Activator CD3/CD28 was 
added to CFSE-labelled splenocytes at a bead-to-cell ratio of 1:5 then co-cultured with C. 
difficile-stimulated BMDCs in a 96-well plate in a DC-to-splenocyte ratio of 1:10. Co-cultures 
were incubated at 37 °C for 72-96 h. Cells were co-stained with anti-mouse CD4 PE-Cy5 
(dilution 1:160) (eBioscience) as described in section 2.3.3 and analysed at 48, 72, and 96 h 
by flow cytometry gated on CD4+ cells.   
 
2.3.5.2 Naive CD4+ T Cell Proliferation  
 
Naive CD4+ T cells were isolated from spleen of OT-II transgenic mice (kindly provided by Dr. 
David Escors, Division of Infection and Immunity, UCL) using MagCellect* Mouse Naïve CD4+ 
T Cell Isolation Kit (R & D Systems, Inc.). 5 ml of 1x MagCellect Buffer/10x107 cells was 
prepared by mixing 0.5 ml of MagCellect 10x Buffer with 4.5 ml PBS and stored on ice. 
Splenocytes were suspended in cold 1x MagCellect Buffer at a cell density of 10x 107/ml. 
Cells were transferred into a 5 ml polystyrene tube and 100 μl of MagCellect Mouse Naïve 
CD4+ T Cell Biotinylated Antibody Cocktail was added, mixture was gently mixed and 
incubated at 4 °C for 15 min. Next, 125 μl of MagCellect Streptavidin Ferrofluid was added 
to the cell-antibody suspension, mixed gently and incubated at 4 °C for 15 min. 1x 
MagCellect Buffer was added to the cell suspension to bring the volume of the reaction to 2 
ml. The tube was placed in the MagCellect Magnet and incubated for 6 min at RT. The 
desired cells in the suspension was recovered by aspirating the reaction supernatant while 
the tube was still in the magnet and transferred into a fresh tube.  
Isolated naive CD4+ T cells were labelled with CFSE and subsequently co-cultured with C. 
difficile-stimulated BMDCs in the presence of OVA323-339 peptide (Abgent, Inc., San Diego, 
USA) at a concentration of 1:1000 containing 10 units/ml recombinant mouse IL-2 
(Invitrogen) and incubated at 37 °C. Cells were co-stained with anti-mouse CD4 PE-Cy5 
(dilution 1:160) (eBioscience) and analysed at 48, 72, and 96 h by flow cytometry gated on 
CD4+ T cells.  
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2.3.6 Intracellular Cytokine Staining 
 
BMDCs stimulated with PFA-fixed C. difficile co-cultured with T cells were analysed for 
cytokine 96 h post-incubation. Cells were pelleted then resuspended in complete RPMI in 
the presence of 50 ng/ml Phorbol 12-myristate 13-acetate (PMA), 500 ng/ml ionomycin, 
and 5 μg/ml brefeldin A (all from Sigma-Aldrich) and incubated at 37 °C for 5 h.  
Cells were harvested by centrifugation at 2000 rpm for 5 min at 4 °C then stained as 
described in section 2.3.3 with anti-mouse CD4 PE antibody (dilution 1:200) (eBioscience). 
Following cells surface staining, PFA fixed cells were washed twice with perm buffer (FACS 
wash buffer containing 0.1% saponin) then resuspended in 50 μl of anti-mouse IFN-γ PerCP-
Cy5.5 (dilution 1:100) and anti-mouse IL-17A FITC (dilution 1:200) (eBioscience) in perm 
wash and incubated on ice for 20 min. cells were washed twice with perm wash then 
resuspended in FACS wash buffer and analysed by flow cytometry.  
 
 
2.4 Statistical Analysis 
 
Data were analysed using GraphPad Prism version 5.00 (San Diego, USA). Non parametric t-
test (Mann-Whitney) was performed to compare groups in non-parametric data. Grouped 
analyses was achieved by two-way ANOVA and Bonferroni post-test to compare replicate 
means by row and compare each column to all the other columns. Data considered 
significant if only probability was p<0.05. 
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Chapter 3  
Clostridium difficile-Intestinal   
Epithelial Cell Interactions (I) 
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3.1 Introduction 
 
In recent years C. difficile infection (CDI) has emerged as the leading cause of healthcare 
diarrhoea in the developed world. CDI continues to rise due to the rapid emergence and 
transcontinental spread of highly virulent C. difficile strains of PCR ribotypes 027 and 078 
(Dawson et al., 2009). Historically most C. difficile strains were clindamycin resistant 
however, the emergence and spread of PCR ribotype 027 strains with acquired resistance 
to fluoroquinolone antibiotics is a new feature that was not present in historic strains of the 
same genotype (Rupnik et al., 2009).  
C. difficile strain 630, an epidemic PCR ribotype 012 was the first to be genome sequenced 
(Sebaihia et al., 2006). This strain was isolated in 1982 from a patient with PMC produces 
both TcdA and TcdB (A+B+). Several C. difficile strains have now been sequenced (Welcome 
Trust Sanger Institute, UK), these include strain R20291 from the hypervirulent clade 
(Stabler et al., 2009). This strain, which was isolated in 2006 during an outbreak at Stoke 
Mandeville Hospital, is a PCR ribotype 027. It releases a third toxin termed binary toxin 
(CDT) as well as TcdA and TcdB (A+B+, CDT+). In addition to strain R20291, the Sanger 
Institute is currently sequencing two other C. difficile strains, CF5 and M68 from the A-B+ 
clade, which are respectively historic and recent representatives of PCR ribotype 017 (He et 
al., 2010). CF5 was isolated in Belgium in 1995 from an asymptomatic patient, while M68 
was isolated in 2006 during an outbreak in Ireland (Stabler et al., 2006).   
Despite advances made in understanding of C. difficile microbial pathogenesis, very little 
information is available on the interaction and contribution of C. difficile itself with the 
human host. Focus of the present study was therefore to improve our current limited 
understanding of C. difficile-mediated disease pathogenesis. 
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3.2 Microbiological Characterisation of C. difficile Strains under 
Investigation 
 
As C. difficile isogenic mutants have only recently become available (Lyras et al., 2009), this 
study initially opted to explore the effect of C. difficile virulence factors on the host by 
employing four different strains which included: R20291, 630, M68 and CF5. It was 
hypothesised that comparing and contrasting host responses to the selected array of 
strains may clarify toxin-specific mechanism(s) involved in host-pathogen interactions. Prior 
to commencing co-culture studies it was pertinent to investigate the microbiological 
features of the strains employed.  
 
3.2.1 C. difficile Growth Kinetics 
 
The in vitro growth kinetics of the bacterial strains was determined. This was necessary to 
ensure that the bacteria were studied in the late exponential/early stationary growth phase 
when the culture is in a vegetative state, and to establish the optimal range of multiplicity 
of infection (MOI) for co-culture experiments.    
Growth curves of C. difficile strains R20291, 630, M68, and CF5 are shown in Figure 3.1. 
Bacterial cultures were grown to exponential phase by inoculating pre-equilibrated BHI 
broth with three single colonies. Secondary pre-equilibrated BHI broths were inoculated 
with primary exponential phase cultures to obtain OD600 nm of 0.01. All strains exhibited a 
short lag phase and there was no significant difference between the strains in the first two 
hours of growth. R20291, M68, and CF5 had similar growth rates reaching mid-logarithmic 
phase at ~3 h and entered stationary phase 4-5 h post-inoculation. In contrast, although 
strain 630 grew at a similar rate to the other strains in the first 2 h, its growth was slower 
thereafter, reaching mid-logarithmic at 4 h and stationary phase at 8 h. Viable counts were 
performed at three time points corresponding to OD600 readings of 0.5, 1.00, and 1.5 (Table 
3.1) to determine the bacterial generation/doubling time and also to determine the MOI at 
OD600 of 1.5 or once bacteria reached to its stationary phase.  
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Figure 3.1. C. difficile strains exhibit differential growth kinetics. C. difficile strains were 
inoculated into BHI broth and growth rates monitored by optical density at 600nm. 
Statistically, there was no significant difference between the growth rates of R20291, M68, 
and CF5 however 630 showed a significantly slower rate of growth compared to the other 
strains between 3-7 h post-inoculation. Data presented as the mean ± SEM, n=3. *p<0.05, 
**p<0.01, ***p<0.001 (ANOVA with Bonferroni post-test) represent significant inter-strain 
difference.  
 
  
 
 
 
 
Table 3.1. C. difficile strains undergo slow growth. Viable counts were performed at OD600 
of 0.5, 1.00, and 1.5 and the generation times were found to be 15-22 min (fastest being 
R20291 and slowest 630). Using the viable counts at OD600= 1.5, the relative MOI required 
in the co-culture studies was determined for each strain. Data represent mean ± SEM of 
three independent experiments.  
 
 
Strains CFU/ml(OD600=0.5) CFU/ml(OD600=1.0)          CFU/ml(OD600=1.5)          
R20291 2.9 x 108 ±5.7x107    5.8 x 108 ±2.3x107    7.0 x 108 ±1.0x108 
630 1.5 x 108 ±6.1x107    5.6 x 108 ±6.2x107    6.1 x 108 ±8.8x106 
M68 2.4 x 108 ±3.4x107       5.7 x 108 ±1.2x108      6.4 x 108 ±1.1x108   
CF5 3.6 x 108 ±3.7x107    5.5 x 108 ±1.4x108    7.3 x 108 ±8.7x107  
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3.2.2 C. difficile Survival under Aerobic Condition(s) 
 
As C. difficile is an obligate anaerobe, exposing the bacteria to aerobic co-culture conditions 
of 5% CO2 is likely to result in bacterial death during the time-course of the experiment. As 
the host responses measured are therefore likely to be in response to both live and dead 
bacteria, it was imperative to investigate any potential variation between the strains in the 
rate of cell death in response to oxygen.  
BHI broth was inoculated with bacterial colonies and grown to stationary phase. Then, the 
stationary phase bacterial cultures were exposed to aerobic conditions and bacterial 
survival was enumerated over time by viable counting (Figure 3.2). C. difficile strains 
showed no significant difference in degree of cell death over the 8 h time-course. 
Furthermore, no significant inter-strain difference in viable counts was observed amongst 
the strains.  
 
 
 
Figure 3.2. C. difficile strains show similar survival trend. Bacterial cultures were grown to 
stationary phase and subsequently they were exposed to aerobic conditions. Strains 
survival was determined in a time-dependent manner by CFU quantification. Data 
represent mean ± SEM (ANOVA with Bonferroni post-test), n=4.  
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3.2.3 C. difficile Sporulation 
 
C. difficile produces endospores as a means to survive in hostile and/or unfavourable 
environments (Paredes et al., 2005) but will germinate in the presence of specific effectors, 
termed germinants (Burns et al., 2010). As exposure to oxygen during co-culture 
experiments can be considered a ‘’stress’’ signal, it was necessary to investigate the rate of 
spore formation by each of the four strains under aerobic conditions. 
Sporulation ability was examined using yeast peptone media (YPM), a medium described by 
Akerlund et al. for inducing C. difficile sporulation (Akerlund et al., 2006 & 2008), and BHI 
medium. Anaerobically grown bacterial cultures were subjected to aerobic conditions and 
spore formation was enumerated by viable counting (Figure 3.3). Spores generated in YPM 
were visualised under a light microscope by the Wirtz-Conklin staining method (5% 
Malachite Green/ 0.5% Safranin) (Hamouda et al., 2002; Ochsner et al., 2009) endospores 
appeared bright green/blue and vegetative cells were pink (Figure 3.4, arrowheads). 
Spore formation was undetectable in cultivated BHI cultures; however, all four strains 
sporulated to a similar degree in inoculated YPM media (Figure 3.3). 
Collectively, Figures 3.1-3.3 indicated that strains R20291, M68, and CF5 exhibited similar 
microbiological properties. In comparison, strain 630 shared comparable sporulation and 
survival under aerobic conditions but showed slower growth kinetics. 
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Figure 3.3. C. difficile strains sporulate equally in yeast peptone media. C. difficile strains 
were grown anaerobically in YPM or BHI media for 10 days, then they were exposed to 
oxygen for 8 h and spore-formation was enumerated after ethanol-killing of vegetative 
cells. Data represent mean ± SEM (ANOVA with Bonferroni post-test), n=3. 
 
 
 
Figure 3.4. C. difficile strains sporulate in yeast peptone media. Generated spore 
suspensions were stained with 5% malachite green and 0.5% safranin O and visualised 
microscopically (20x Leica GMBH, QImaging digital camera). Endospores with no 
germination stained greenish-blue (arrowheads), whilst outgrown bacteria stained in pink.  
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3.3 Characterisation of C. difficile Toxins 
 
C. difficile secretes two well characterised glucosyltransferase toxins, TcdA and TcdB. The 
genes encoding TcdA and TcdB, accompanied with three regulatory genes (tcdC, tcdE, tcdR), 
are located on the 19.6 kb PaLoc (Kuehne et al., 2011). Additionally, ~6% of C. difficile 
isolates (Dawson et al., 2009), and in particular strains of ribotype 027 produce a third toxin 
(CDT). This toxin is encoded on a separate region of the chromosome comprising the two 
components of CDT (cdtA & cdtB) and a regulatory gene (cdtR) (Carter et al., 2007).  
Some C. difficile strains have deletions in the sequences of one or more genes in the PaLoc 
compared with the sequence of the reference strain VPI 10463. The most well known and 
studied representatives of variant C. difficile strains are the A-B+ strains. These strains 
mostly belong to toxinotype VIII and are characterised by a 1.8 kb deletion within repetitive 
regions of tcdA gene, and a mutation which introduces a stop codon at amino acid position 
47, consequently affecting production of TcdA (Rupnik et al., 2003b).  
 
3.3.1 C. difficile Toxin Gene Detection 
 
Although all four strains under investigation have been characterised previously (Stabler et 
al., 2006), it was important to confirm the presence of tcdA, tcdB, cdtA, and cdtB genes 
prior to study. Presence of the various toxin genes was verified by PCR (Figure 3.5). Strain 
CD37 a non-toxigenic strain was used as a negative control in C. difficile toxin gene 
detection.  
TcdA gene (tcdA) was detected in strains R20291 and 630 as well as strains M68 and CF5 as 
a 519 bp fragment (Figure 3.5 a). This data was expected since A-B+ strains from toxinotype 
VIII do possess the tcdA gene even though they have lost the capacity for TcdA protein 
production. An 1121 bp fragment corresponding with tcdB gene was seen in all strains 
(Figure 3.5 b). To detect cdtA and cdtB genes, three different primer sets were used, cdtB 
primer to amplify a specific region of the cdtB gene, and BIN5/6 and BIN7/8 primers to 
amplify the entire cdtA and cdtB genes respectively (Figure 3.5 c). A 489 bp product was 
detected in R20291 corresponding with the cdtB gene, a 1452 bp and a 2413 bp fragment 
was identified in the whole amplified regions of cdtA and cdtB confirming the presence of 
these genes in R20291. As expected no bands were observed in the remaining strains.   
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Figure 3.5. Confirmation of tcdA, tcdB, cdtA and cdtB genes in C. difficile strains. C. difficile 
strains were screened for toxin A, B, and CDT genes. Presence of toxin A (a) and B genes (b) 
was confirmed in the all strains. Using three different sets of primers existence of binary 
toxin genes were investigated and were detected only in strain R20291 (c). CD37 is a non-
toxigenic strain.  
 
 
 
 
 
 
 
 
(b) (a) 
(c) 
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3.3.2 C. difficile Toxin Protein Detection 
 
Subsequent to verification of the toxins genes in all four strains, it was necessary to confirm 
the secretion of the toxins. Expression of CDT could not be studied as no specific antibody 
was available.  
Bacterial cultures were grown to stationary phase and centrifuged.  Bacterial pellet (108 
cells) and supernatant (100 μg total protein) were subjected to 6% SDS-PAGE and toxin 
protein detected by western blotting (Figure 3.6).  
TcdA protein was detected in bacterial cells (Figure 3.6 a) and supernatants (Figure 3.6 b) of 
strains R20291 and 630, confirming the production of TcdA by these strains. Interestingly, 
both strains expressed similar amounts of TcdA. In contrast, no detectable TcdA protein 
was noticed for strains CF5 and M68 in either compartment (Figures 3.6 a & b). 
Presence of TcdB was detected in R20291, 630, and CF5 bacterial pellets (Figure 3.6 c) and 
in the supernatants of strains R20291 and CF5 (Figure 3.6 d). Strain CF5 produced more 
TcdB protein compared to the rest of the strains. Secretion of TcdB was not detected in 
bacterial pellet or supernatant of strain M68 with the employed antibody (Figures 3.6 c & 
d). Consequently, protein concentration was increased 10-fold in order to assist the 
detection of TcdB in strain M68. TcdB secretion was detected in the bacterial pellet (109) of 
all four strains (Figure 3.6 e) confirming that M68 indeed does produce TcdB.  
In summary, tcdA and tcdB were present in all four strains, whilst binary toxin gene was 
identified only in strain R20291 (Figure 3.5). A comparable expression of TcdA was detected 
in strains R20291 and 630, while CF5 and M68 showed no detectable levels. It was also 
observed that C. difficile strains released TcdB protein to varying levels, with strain CF5 
exhibiting significant expression of TcdB followed by R20291, 630, and M68 (Figure 3.6).  
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Figure 3.6. Varying expression of TcdA and TcdB in C. difficile strains. Bacterial pellet (108) 
and supernatant (100 μg total protein) were subjected to 6% SDS-PAGE. TcdA was detected 
in bacterial pellets (a) and supernatants (b). Using toxin B antibody, TcdB protein was 
detected in bacterial pellets of strains R20291, 630, and CF5 (c) and in bacterial 
supernatants of strains R20291 and CF5 (d). Presence of TcdB protein was investigated 
further in a concentration-dependent manner. TcdB expression was observed in bacterial 
pellets (109) of all four strains (e) but only strains R20291 and CF5 showed production of 
TcdB in bacterial supernatants (f).  
 
 
 
 
(a) (b) 
(c) (d) 
(e) (f) 
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3.4 C. difficile-mediated Effects on Human Intestinal Epithelial 
Cells (IECs) 
 
The first host cell that C. difficile interacts with are the IECs of the colon. To determine the 
bacterial mediated effects on human IEC, two well characterised cell-lines; Caco-2, human 
ileocecal epithelial cells and HT-29, human colonic epithelial cells were employed. Host IEC 
responses to C. difficile hypervirulent strain R20291 (A+B+, CDT+), strain 630 (A+B+), and A-B+ 
strains (M68 and CF5) were investigated. In early experiments, cell-lines were infected with 
bacteria at three MOIs (10, 100, and 1000), and cell viability was examined at 8 and 24 h 
post-infection. These experiments were conducted to establish the optimum MOI and time-
course of infection for subsequent studies.   
 
3.4.1 Cytotoxic Effect of C. difficile on Human IEC 
 
The C. difficile-induced effect on IEC membrane integrity was assessed by measurement of 
the extracellular release of the cytosolic enzyme, lactate dehydrogenase (LDH), which is 
released following cell death. 
Caco-2 (Figures 3.7 a & b) and HT-29 (Figures 3.7 c & d) were infected with the four C. 
difficile strains at an MOI 100 (Figures 3.7 a & c) and 1000 (Figures 3.7 b & d) for 8 and 24 h. 
Uninfected control Caco-2 cells showed a basal cell death of  ~10-12%. Infection with MOI 
of 100 resulted in a modest increase in cytotoxicity at 8 h with R20291 causing the most 
(~20%) toxicity. By 24 h however, infection with strains R20291, 630, and M68 resulted in 
80-90% cell death. At this time-point, CF5 mediated ~40% cytotoxicity, which was 
significantly less compared to other strains (p<0.001) (Figure 3.7 a).  
In comparison, when experiments were conducted at an MOI of 1000, R20291, 630, and 
M68 induced significant cell death at 8 h post-infection (≤50%), while CF5 showed the least 
cytotoxicity (<20%). Nonetheless, 24 h post-infection, CF5 at this MOI caused ≥90% cell 
death as seen for the other three strains (Figure 3.7 b). These studies indicated that MOI of 
1000 and 24 h post-infection time-point were not optimal to study host-pathogen 
interactions. Therefore, future experiments were conducted utilising an MOI of 100-500, 
whilst generally terminating higher MOI experiments at earlier time-points.  
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Similar infections were also conducted in HT-29 cells (Figures 3.7 c & d). Interestingly, the 
basal cytotoxicity of uninfected control cells were ~15-25%; higher than that observed for 
Caco-2 cells (Figure 3.7 a & b). This basal rate increased to ~30% at 8 h and 50-65% at 24 h 
upon infection with C. difficile strains at an MOI of 100, with no significant difference noted 
between the tested strains (Figure 3.7 c). Again, an increase in MOI (1000) led to a 
significant cytotoxicity response (Figure 3.7 d). CF5 yielded less cytotoxicity compared to 
the other three strains at 8 h, while at 24 h all the strains caused similar (85-95%) cell 
death.  
Results from above (Figure 3.7), suggested that R20291, 630, and M68 have the ability to 
induce cell death to a similar extent, in contrast CF5 at early time-points of infection 
showed a modest toxic effect on the two IEC lines tested.  
 
 
 
  
 
   
 
(a) 
(b) 
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Figure 3.7. Lactate dehyrogenase (LDH) release by Caco-2 and HT-29 cell-lines exposed to 
C. difficile. Caco-2 monolayers were co-cultured with C. difficile strains at an MOI of 100 (a) 
and 1000 (b) and LDH release was measured at 8 and 24 h post-infection. Similarly, HT-29 
cells were infected with C. difficile strains at an MOI of 100 (c) and 1000 (d) and cytotoxicity 
was measured at 8 and 24 h. Data are means ± SEM for n=5 experiments. *p<0.05, **p<0.01, 
and ***p<0.001 (ANOVA with Bonferroni post-test) represent significant difference from 
uninfected cells.  
 
 
 
 
 
 
(c) 
(d) 
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3.4.2 C. difficile Toxin Cytotoxicity 
  
The functional properties of the toxins were examined by cytotoxicity assays utilising HT-29 
and Vero (African green monkey kidney cell) cell-lines. HT-29 and Vero cells are susceptible 
to both TcdA and TcdB; however, HT-29 cells are known to be more sensitive to TcdA and 
Vero cells more sensitive to TcdB (Torres et al., 1992). In these series of experiments, a non-
toxigenic strain, CD37, was used as a negative control.  
Semi-confluent HT-29 cells were co-cultured with filter-sterilised supernatants of stationary 
phase bacterial culture at an MOI of 500 and structural changes were observed 
microscopically at 8 h post-infection (Figure 3.8 a). No morphological changes compared to 
uninfected control cells were observed in cells infected with strain CD37. 8 h post-infection, 
cell alteration was noticeably visible in R20291 infected cells (Figure 3.8 a, arrowheads); 
while an intermediate cell rounding was initiated in cells infected with strains 630 and M68. 
No morphological change was observed in cells infected with strain CF5 (Figure 3.8 a). The 
cytopathic effect (CPE) of TcdA on HT-29 cells was quantified by infecting cells with 2-fold 
dilutions of filter-sterilised bacterial supernatants (Figure 3.8 b). A minimum cytotoxic 
activity was detected in uninfected control cells and cells infected with non-toxigenic strain 
CD37. R20291 showed the highest cytotoxicity compared to uninfected cells, while strains 
630 and M68 exhibited an intermediate toxicity. The least cell intoxication was caused by 
strain CF5 (Figure 3.8 b).  
Similar co-cultures were conducted using Vero cells to examine TcdB cytotoxicity (Figure 
3.9). Confluent Vero cell monolayers were infected with filter-sterilised supernatants of 
stationary phase bacterial culture at an MOI of 500, and cell rounding observed 8 h post-
infection (Figure 3.9 a). Cell monolayers cultured with the non-toxigenic strain CD37 
showed no morphological changes compared to uninfected control cells. Considerable cell 
rounding was observed in cells infected with R20291 at 2 h. 8 h post-infection, cells 
incubated with strains 630 and M68 were rounded, but no significant change was detected 
in the cells infected with strain CF5 (Figure 3.9 a). The cytopathic effect of TcdB on Vero 
cells was also quantified by co-culturing cells with 2-fold dilutions of filter-sterilised 
bacterial supernatants (Figure 3.9 b). A minimum cytotoxic activity was detected in 
uninfected control cells and cells infected with CD37. Strains R20291, 630, and M68 caused 
similar cytotoxicity and showed very significant cell intoxication compared to uninfected 
control cells. Strain CF5 exhibited the least cell toxicity (Figure 3.9 b).  
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Figure 3.8. Strain R20291 exerts potent and early cytotoxic effect on HT-29 cells. Sub-
confluent HT-29 cells were co-cultured with C. difficile supernatants at an MOI of 500. Cell 
morphological changes were observed microscopically (20x, Leica DFC320) at 8 h post-
infection. Strain R20291 caused a significant cell rounding (arrow), whilst intermediate cell 
changes were observed with strains 630 and M68. Strain CF5 caused no cell morphological 
alteration (a). 2-fold dilutions of bacterial supernatants were used in HT-29 cell cytotoxicity 
assay in which the end-point titre of each dilution series was scored at 8 h post-infection. 
Data is presented as the mean ± SEM, n=3. *p<0.05, **p<0.01 compared to uninfected 
control, and ^p<0.05 represents significant inter-strain difference (b). CD37 is a non-
toxigenic strain. P values were obtained using ANOVA with Bonferroni post-test analysis.  
(b) 
(a) 
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Figure 3.9. Strains R20291, 630 and M68 cause similar cell rounding in Vero cells. 
Confluent Vero cell monolayers were co-cultured with bacterial supernatants at an MOI of 
500. Morphological changes were observed microscopically at 8 h post-infection. R20291 
caused a complete cell rounding (arrow). A significant cell morphological change was 
observed with strains 630 and M68, while CF5 caused the least cell alteration (a). 2-fold 
dilutions of bacterial supernatants were used in Vero cell cytotoxicity assay in which the 
end-point titre of each dilution series was scored at 8 h post-infection. Data is presented as 
the mean ± SEM, n=3. ***p<0.001 compared to uninfected control, and ^p<0.05, ^^p<0.01 
represent significant inter-strain difference (b). CD37 is a non-toxigenic strain. P values 
were obtained using ANOVA with Bonferroni post-test analysis.     
(b) 
(a) 
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3.4.3 C. difficile-induced Apoptosis in Human IEC 
 
It has been documented that C. difficile toxins target and disrupt the function of host Rho 
GTPases family members including Rho, Rac, and Cdc42. Rho GTPases are involved in actin 
cytoskeleton regulation and their inactivation leads to dysregulation of the cytoskeletal 
structure causing disruption of actin-associated apical junctional complex and subsequent 
cell death (Genth et al., 2006; Genth et al., 2008; Popoff & Geny, 2011).  
Several studies have already shown that C. difficile induces apoptosis in human primary IECs 
and in cell-lines. TcdA and TcdB induce apoptosis by a mechanism dependent on 
inactivation of Rho, activation of caspase-3, -8, and -9 and Bid, and mitochondrial damage 
followed by cytochrome c release (Fiorentini et al., 1998; Brito et al., 2002; Matarrese et al., 
2007; Nottrott et al., 2007; Gerhard et al., 2008). In the following experiments, the role of 
C. difficile strains in causing cell death was investigated by utilising two well known 
methods. 
 
3.4.3.1 Ethidium Homodimer Uptake Assay 
 
Dead cells were marked and identified by using ethidium homodimer, a red fluorescence 
since their compromised membranes were permeable to this high affinity nucleic acid stain.  
Caco-2 monolayers were infected with C. difficile strains bacterial culture at an MOI of 250 
and cell death was evaluated at 4 h and 8 h post-infection by quantifying number of cells 
marked by red fluorescence (Figures 3.10 & 3.11).  
Uninfected control cells showed <10% cell death at 4 h and 8 h. Upon infection, the number 
of dead cells at 4 h increased to 20% with strains R20291 and M68 causing similar rates of 
cell death and CF5 showing no significant increase compared to uninfected cells (Figure 
3.11). At 8 h, the number of marked cells increased further. More than 30% of infected cells 
with R20291 were dead, while strains 630 and M68 caused similar rates of cell death (~25-
30%). Strain CF5 showed the lowest rate of cell death ~15% at 8 h, which was not 
significantly higher than the number of dead cells at 4 h infection. On the other hand, cell 
death rate caused by R20291 at 8 h was significantly increased compared to cell death at 4 
h (p<0.001). Similar results were also observed with strains 630 and M68 (p<0.05).   
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Figure 3.10. C. difficile-induced cell death in infected Caco-2 cells. Caco-2 cell monolayers 
were infected with C. difficile bacterial cultures at an MOI of 250 and cell death was 
evaluated by the ethidium homodimer uptake method. Dead cells were marked by red 
fluorescence stain. Data is representative of three individual experiments.  
 
 
 
Figure 3.11. Increase in cell death caused by C. difficile infection is time dependent. Dead 
cells were counted from a minimum of five separate fields at 4 h and 8 h post-infection and 
presented as a percentage of the total number of cells in the corresponding field. Results 
are presented as mean value ± SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 (ANOVA with 
Bonferroni post-test) represent significant difference from uninfected cells. 
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3.4.3.2 Detection of C. difficile-induced Apoptosis by Annexin-V & Propidium 
Iodide 
 
C. difficile-mediated apoptosis in IECs was investigated by employing annexin-V and 
propidium iodide (PI) staining. During the early stages of apoptosis, translocation of 
phosphatidylserine (PS) from the inner side of the plasma membrane to the outer layer 
leads to exposure of PS at the surface of the cell. Annexin-V has a high affinity for PS and 
since necrotic cells also expose PS, PI was utilised as a DNA stain to distinguish necrotic 
cells.  
Caco-2 monolayers were co-cultured with C. difficile cultures at an MOI of 250; at 6 h post-
infection, cells were stained with Annexin-V and PI prior to analysis by flow cytometry 
(Figure 3.12). Apoptotic cells were positive for Annaxin-V only (lower-right quadrant) and 
necrotic or late apoptotic cells were positive for both Annexin-V and PI (upper-right 
quadrant), while the viable cells were negative for both Annexin-V and PI (lower-left 
quadrant) (Figure 3.12 a). Less than 2% of uninfected control cells were apoptotic. Cells 
infected with R20291, 630, and M68 showed a similar number of apoptotic cells, whilst cell 
apoptosis caused by strain CF5 (<5%) was not significantly higher than that in the 
uninfected control (Figure 3.12 b). Cells which were positive for both Annexin-V and PI were 
considered necrotic cells. In uninfected control cells <1.5% of cells were necrotic. A similar 
number of necrotic cells was detected in infected Caco-2 cells with strains R20291, 630, and 
M68 (~5%) and CF5 showed 3% cell necrosis (Figure 3.12 b).  
Overall, strains R20291, 630, and M68 caused significant increase in cell apoptosis and 
necrosis compared to strain CF5; interestingly, the number of apoptotic cells caused by 
each strain was not significantly higher than necrotic cells. The above data showed that 
strains R20291, 630, and M68 caused a significant number of cell death, early apoptosis or 
late apoptosis (necrosis), whilst CF5 infection resulted in significantly less cell death.    
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Figure 3.12. C. difficile causes apoptosis and necrosis in infected Caco-2 cells. Caco-2 
monolayers were co-cultured with C. difficile strains at an MOI of 250. Cells were stained 
using Annexin-V and PI at 6 h post-infection and analysed by flow cytometry. 2 μM 
Ionomycin (an apoptotic inducer) was used as a positive control. Data is representative of 
three independent experiments (a). Number of apoptotic/necrotic cells were quantified 
and presented as a percentage.  **p<0.01 and ***p<0.001 (ANOVA with Bonferroni post-test) 
represent significant difference from uninfected cells (b).  
(a) 
(b) 
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3.4.4 Effect of C. difficile Adherence on Human IEC 
 
Adherence to the IEC is a prerequisite for colonisation by many GI pathogens (Eckmann et 
al., 1995; Kagnoff & Eckmann, 1997). To colonise mucosal surfaces, bacteria commonly 
interact with glycan structures of the host glycocalyx via bacterial adhesins such as fimbriae 
or pili, various outer membrane proteins and cell wall components (Moran et al., 2011).  
Colonisation of the GI tract by C. difficile is essential to its pathogenesis, which requires 
bacterial adherence to the mucosa. Drudy et al. 2001, showed adherence of C. difficile to 
human small and colonic IECs and in cell-lines utilising fluorochrome-labelled C. difficile. 
Several studies have shown binding of C. difficile to cultured cell-lines and GI tissues, and 
data suggests multiple adhesion mechanism(s) involving several bacterial surface layer 
proteins (Eveillard et al., 1993; Calabi et al., 2002; Cerquetti et al., 2002).  
To detect and quantify bacterial adherence to IEC, C. difficile strains were labelled with 
fluorescein isothiocyanate (FITC). Efficiency of the labelling procedure was tested (Figure 
3.13) prior to co-culture with Caco-2 monolayers at an MOI of 250. 6 h post-infection, cells 
were detached and analysed (Figure 3.14 a), adherence was expressed as change in median 
fluorescent intensity (MFI) (Figures 3.14 b).  
A minimum MFI value (~5) was detected in uninfected control cells and similar value was 
also observed in Caco-2 cells infected with unlabelled bacteria (Figures 3.14 b). Compared 
to uninfected control cells, all four strains adhered significantly to Caco-2 cells; however, 
strain R20291 showed increased adherence (MFI ~150) compared to the rest of the strains. 
A similar level of adherence (MFI ~100) was observed in strains 630, M68, and CF5 (Figure 
3.14 b). 
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Figure 3.13. C. difficile strains show similar distribution of unlabelled and FITC-labelled 
bacteria. The FITC-labelling of the bacteria was seen as a shift of the bacteria along the FL1 
axis in the histogram display mode, showing unlabelled (left peak) and FITC-labelled C. 
difficile (right peak). The fluorescence signal of the labelled population showed no overlap 
with unlabelled population indicating that the whole population was labelled. This data is 
representative of three individual experiments. 
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Figure 3.14. C. difficile strains adhere significantly to Caco-2 cells. FITC-labelled bacteria 
were co-incubated with Caco-2 cells at an MOI of 250. Flow cytometric analysis of Caco-2 
cells alone and after incubation with FITC-labelled C. difficile showed bacterial association 
as a shift of adhered bacteria to Caco-2 cells along the FL1 axis in the histogram display. 
This data is representative of three separate experiments (a). Results were quantified and 
presented as change in MFI. Data represent mean ± SEM, n=3. ***p<0.001 represents 
significant difference from uninfected cells, and ^^^p<0.001 represents significant inter-
strain difference (b). P values were obtained using ANOVA with Bonferroni post-test.  
(b) 
(a) 
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Furthermore, invasion of IEC by C. difficile was assessed by acquiring confocal images. In 
figure 3.15, FITC-labelled CF5, the least toxic strain was co-cultured with Caco-2 monolayer 
at an MOI of 250. The optical images, taken at 8 h post-infection were displayed in three 
orthogonal projections [xy top left corner (a), xz down panel (b), yz right panel (c)] to 
distinguish between extracellular and internalised bacteria. Orthogonal views showed 
bacteria in close contact with apical surface of Caco-2 cells, further screening revealed no 
evidence of bacterial invasion.  
 
 
 
 
 
Figure 3.15. C. difficile is an extracellular bacterium. Caco-2 cells (stained with cell mask 
orange) were infected with strain CF5 (FITC-labelled) and examined by confocal microscopy 
at 8 h post-infection. Images were displayed in three xy (a), xz (b), and yz (c) orthogonal 
views. xz and yz projections showed bacteria in apical surface of Caco-2 monolayer. Images 
were taken by Dr. B. Vernay, UCL, ICH.  
 
(a) (c) 
(b) 
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C. difficile association with IEC leads to time-dependent disruption of the epithelial 
monolayer. These cellular events were also followed. FITC-labelled C. difficile strains were 
co-cultured with Caco-2 monolayers and disruption of cell monolayer was monitored by 
time-lapse microscopy up to 12 h in 15 min intervals (Figure 3.16). An intact monolayer was 
observed in uninfected control cells at 12 h post-infection. Significant monolayer integrity 
disturbance was observed in infected cells with strains R20291, 630, and M68. On the other 
hand, cell monolayer infected with strain CF5 remained undamaged (Figure 3.16). 
In summary, C. difficile strains exhibited a significant adherence to Caco-2 cells. However, 
despite similar adherence levels exhibited by strains 630, M68, and CF5, differential 
morphological changes were detected observing the least cell monolayer disruption by 
strain CF5.  
 
 
 
 
Figure 3.16. Monolayer disruption occurs following bacterial adherence. Caco-2 
monolayers were co-cultured with FITC-labelled C. difficile strains at an MOI of 250. 
Morphological changes were visualised by time-lapse microscopy. Caco-2 monolayers 
infected with strains R20291, 630, and M68 showed substantial cell damages at 12 h post-
infection comparing to uninfected control cells. In contrast, cell monolayer infected with 
CF5 maintained its integrity (32x phase contrast objective, Carl Zeiss Ltd). Images were 
taken by Dr. B. Vernay, UCL, ICH.  
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3.5 Characterisation of TcdB from Strains CF5 and M68  
 
Both CF5 and M68 belong to ribotype 017 and carry the A-B+ phenotype. Despite both 
releasing TcdB (Figure 3.6), CF5 displayed a significant reduction in its potential cell 
cytotoxicity when compared to the strain M68 (Figures 3.8 & 3.9).   
It is well-established that C. difficile TcdA and TcdB target the Rho subfamily of small 
GTPases and modify it via glucosylation leading to inactivation of Rho, Rac, and Cdc42 
proteins and causing cytoskeletal changes. Treatment of different mammalian cell-lines 
with TcdB results in decreased levels of cellular Rac1 protein (Chaves-Olarte et al., 2003; 
Genth et al., 2006). Anti-Rac1 antibody (clone 102) interacts specifically with non-
glucosylated Rac1, thus greater glucosylation leads to less binding, an indicator for the 
extent of Rac1 glucosylation. It was hypothesised that TcdB from strains CF5 and M68 cause 
differential Rac1 glucosylation leading to variation in their cytotoxic potential.  
 
3.5.1 Mono- glucosylation of Rac by TcdB from Strains CF5 and M68  
 
To establish whether TcdB from CF5 and M68 differ in its potential to modulate IEC Rac1 
glucosylation, a co-culture study was conducted employing Caco-2 cells. Confluent 
monolayers were infected with bacterial cultures at an MOI of 250, then analysed at 8 h 
post-infection for Rac1 glucosylation (Figure 3.17 a). Rac1 was quantified densitometrically 
(Figure 3.17 b). 
Uninfected control cells showed a spontaneous high expression of Rac1 (Figure 3.17). Both 
CF5 and M68 treated cells showed reduced levels of Rac1 compared to uninfected cells, 
whilst strain M68 caused a very significant decrease of Rac1 (Figure 3.17 a & b). Moreover, 
M68 infected cells exhibited a significant loss of Rac1 when compared with CF5 (p<0.01) 
indicating a considerable Rac1 glucosylation. The same samples were also examined for β-
actin (45 kDa) to confirm equal loading (Figure 3.17 a).  
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Figure 3.17. CF5 and M68 infection leads to differential Rac1 glucosylation in Caco-2 cells. 
Caco-2 cells were infected with CF5 and M68 bacterial cultures at an MOI of 250. At 8 h cell 
lysates were subjected to 15% SDS-PAGE followed by western blotting. Rac1 and β-actin 
levels were analysed with appropriate antibodies (a). Rac1 was quantified by densitometry 
(Bio-Rad ChemiDoc XRS) (b). Data represent the mean ± SEM, n=3. *p<0.05 and ***p<0.001 
compared to uninfected control, and ^^p<0.01 represents an inter-strain comparison. P 
values were obtained using ANOVA with Bonferroni post-test analysis.  
 
 
 
 
(a) 
(b) 
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3.6 Conclusions  
 
Clostridium difficile is an anaerobic, spore-forming bacterium that has been recognised as 
the causative agent of CDI (Bartlett et al., 1978; George et al., 1978). CDI occurs following 
antibiotic-mediated disruption of the normal gut microbiota, which enables C. difficile to 
proliferate and cause symptoms ranging from asymptomatic carriage to severe diarrhoea, 
PMC and death. TcdA and TcdB are major virulence factors of C. difficile but this bacterium 
harbours an array of other virulence factors as well. The majority of studies on C. difficile so 
far have focused on using purified/recombinant toxins and the role of the bacterium itself 
in initiating disease has been overlooked. Therefore, the objective of this study was to 
elucidate early interactions between whole bacteria and the IEC. Understanding of early 
events may help in improving future diagnostics and therapeutics to this life-threatening 
infection.    
In the current study, initial optimisation was conducted employing four different C. difficile 
strains due to lack of isogenic mutants at the commencement of this project. These 
included strain R20291 from the hypervirulent clade, a fully sequenced strain 630 (A+B+), 
and variant C. difficile strains CF5 and M68 (A-B+), which are historic and recent 
representatives of PCR ribotype 017, respectively (Stabler et al., 2006). Prior to co-culture 
studies, C. difficile strains were characterised microbiologically and their capacity of toxin 
production was determined. The cytotoxic effect of C. difficile on human IEC was 
investigated by measuring LDH release, and the rate of infection-induced apoptosis and 
necrosis. Also the degree of bacterial adherence and subsequent effects on IEC monolayer 
disruption were investigated.  
Similar growth kinetics were observed for strains R20291, M68, and CF5 reaching stationary 
phase at 4-5 h, while 630 showed slower growth, achieving stationary phase at 8 h post-
inoculation. Strain 630 slow growth also corresponded with a longer doubling time 
(~22min) compared to the other strains (≥15 min). As C. difficile strains express toxins 
during the late logarithmic and stationary phases of growth (Voth & Ballard, 2005), MOI 
was determined by viable counting once each strain reached its stationary phase (OD 600 of 
1.5). Similar trend of cell death was observed with all four strains up to 8 h. Additionally, 
bacterial exposure to an aerobic environment can trigger spore formation. Sporulation is 
initiated under harsh or adverse environment leading to formation of metabolically 
dormant but highly resistant spores (Sorg & Sonenshein, 2008). It has been shown that C. 
difficile spore germinates in BHI media (Paredes-Sabja et al., 2008) therefore, YPM, a 
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sporulation medium was employed to compare and contrast the spore formation. No 
sporulation was detected in BHI, whilst under the same conditions up to 1x106/ml spores 
were observed in YPM also it was noted that all four strains sporulated to similar levels. 
Taken all together, it was hypothesised that during co-culture studies since C. difficile 
strains were grown in BHI, bacterial exposure to aerobic conditions led to bacterial death 
not sporulation.  
Previous studies have shown that C. difficile can adhere to various cell-lines including Caco-
2 and Vero cells in vitro and to mice caecal mucus in vivo (Karjalainen et al., 1994; Cerquetti 
et al., 2002). C. difficile strains adhered significantly to Caco-2 cells compared to uninfected 
control cells (p<0.001) however, R20291 exhibited greater adherence compared to the rest 
of the strains (p<0.001). To date a number of C. difficile virulence factors involved in 
adherence to IEC have been identified. C. difficile SLPs facilitate adhesion to cultured cell-
lines and ex vivo human GI tissues (Calabi et al., 2002). SLPs consist of two subunits; HMW 
and LMW. Extensive SLP sequence variation has been observed between different C. 
difficile strains, particularly in the LMW which lies external to the HMW on the bacterial cell 
surface (Wright et al., 2005; Fagan et al., 2009; Deneve et al., 2009). This inter-strain 
variability might explain the differential adherence capacity observed between R20291 and 
the other strains. Further on this note, strain R20291 produces binary toxin and CDT can 
increase C. difficile adherence to IEC in vitro and in vivo (Schwan et al., 2009). 
At present, the role of individual toxins to IEC adherence remains undefined. The 
experiments conducted here however do highlight some potential features of C. difficile 
TcdA and TcdB function. Strains R20291 and 630 produced similar amounts of TcdA, in 
contrast the amount of TcdB produced by the various strains showed marked variation, in 
particular strain CF5 showed considerably more TcdB production than that observed with 
the other strains. This data can be interpreted as either a feature of the antibody 
employed, which resulted in better recognition of strain CF5 TcdB or that this strain does 
indeed produce higher level of TcdB. Further investigations utilising other toxin-specific 
antibodies are required to confirm which suggestion may hold.  
Strains R20291, 630, and M68 caused cell toxicity to a similar extent, while CF5 showed a 
modest cytotoxicity at early time-points of infection. This was confirmed with ethidium 
homodimer uptake assay and Annexin-V/PI staining. Furthermore, cytotoxicity assays 
utilising HT-29 and Vero cells, which are known to be respectively more sensitive to TcdA 
and TcdB showed significant toxicity with R20291 infected HT-29 cells, and strains 630 and 
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M68 showed an intermediate level however, the difference was not statistically significant. 
If we hypothesise (based on Figure 3.6) that TcdA and TcdB from strains R20291 and 630 
are equipotent then the trend for greater toxicity by the R20291 could be assigned to the 
presence of CDT. These suggestions at present remain assumptions as the lack of reagents 
impeded us from studying these aspects of host-pathogen crosstalk. An emerging theme 
from the data presented was that strain CF5 was the least toxic strain in all assays tested.   
TcdA between strains R20291 and 630 exhibit 98% identity while enzymatic region of TcdB 
are 96% identical, C-terminal region in contrast shows the highest degree of sequence 
variation exhibiting only 88% identity (Lanis et al., 2010). As strains M68 and CF5 sequences 
have not yet been completed, the comparison between the four strains in order to identify 
the sequence variation was not possible, however sequence differences should allow us to 
further dissect functional differences between the TcdB from the two strains. This is worth 
pursuing as studies have shown that toxins of some C. difficile strains and in particular TcdB 
have inherent variability such as in their glucosylating enzymatic activity (Torres, 1991; Alfa 
et al., 2000; Chaves-Olarte et al., 2003; Stabler et al., 2008), therefore, the inactivation of 
Rac1, which is glucosylated by all clostridial toxins (Genth et al., 2006) was investigated. 
Interestingly, significantly reduced levels of Rac1 were detected in cells infected with strain 
M68 compared to CF5, indicating greater Rac1 glucosylation by M68.  
To improve our current limited understanding of TcdB structure and function, we 
proceeded with large-scale TcdB protein purification from M68 and CF5 bacterial cells. Cells 
from a 72h culture were harvested then separated on 6% SDS PAGE (data not shown, n=1). 
Appropriate band size products were cut and subjected to mass spectrometric analysis (Dr. 
Kevin Mills & Dr. Wendy Haywood; ICH/Biological mass spectrometry Centre). Detected 
protein sequences were identified using www.uniprot.org a protein database by aligning 
against C. difficile TcdB protein sequence (Figure 3.18). The preliminary data recovered 57 
peptides from CF5 (Figure 3.18 a) and 33 peptides were identified in M68 (Figure 3.18 b) 
however, so far no amino acid difference or modification has been found. It needs to be 
noted that these studies are currently under investigation.  
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3.6.1 Summary 
 
Taken all together, the work in this chapter demonstrated that: 
 Strains R20291, M68 and CF5 showed similar microbiological properties, while 630 
shared comparable sporulation kinetics and survival under aerobic conditions. 
 Strain R20291 exhibited a very significant adherence to Caco-2 cells compared to 
other strains.  
 Strains R20291, 630 and M68 exhibited similar cytotoxicity and cell death, whilst 
CF5 showed the least effect. 
 Strain M68 significantly glucosylated Rac1 compared to CF5.  
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Figure 3.18. TcdB released from CF5 and M68 share protein sequences. Crude toxin 
obtained from CF5 (a) and M68 (b) pellets were analysed by proteomics in order to identify 
any protein post-translational modifications.  
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Chapter 4  
Clostridium difficile-Intestinal        
Epithelial Cell Interactions (II) 
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4.1 Introduction 
 
The GI tract is lined by a single layer of IEC which provides a primary barrier separating the 
intestinal lumen from the underlying tissue. The intestinal epithelium not only has a 
physical protective role, which is reinforced by the presence of mucus, but also absorbs 
water, salt and nutrients, secretes hormones and antimicrobial peptides. Another 
important function of the IEC is executing a clear discrimination between pathogens and 
commensals and initiating innate immune responses, whilst it is constantly exposed to 
dietary, microbial antigens and an estimated 1014 commensal bacteria (Mowat, 2003; 
Colbere-Garapin et al., 2007; Artis, 2008). 
C. difficile is an important nosocomial pathogen mediating a spectrum of diseases ranging 
from mild diarrhoea to fatal colitis, most often in the context of current or recent treatment 
with antibiotics. Administration of antibiotics leads to alteration in the gut ecosystem and 
disruption of the normal microbiota. These changes create a niche that allows C. difficile to 
colonise the colon, overgrow, and release two exotoxins; TcdA and TcdB (Beaugerie & Petit, 
2004; Mahida, 2004). Both toxins are pro-inflammatory and enterotoxic, causing 
production of IL-6 and IL-8 in the human intestine (Mahida et al., 1996; Ng et al., 2003; 
Savidge et al., 2003) and IL-1, IL-6, IL-8, and TNF-α by human monocytes (Flegel et al., 1991; 
Linevsky et al., 1997; Jefferson et al., 1999; Warny et al., 2000).  
The effect and the role of C. difficile toxins have been well characterised mainly by utilising 
purified toxins in animal models of infection (Pothoulakis et al., 1994; Rocha et al., 1997; 
Souza et al., 1997; Castagliuolo et al., 1998; Alcantara et al., 2001) and in vitro studies 
(Riegler et al., 1995; Branka et al., 1997; Melo Filho et al., 1997; Mahida et al., 1998; Ishida 
et al., 2004; Meyer et al., 2007; Sutton et al., 2008), or employing recombinant toxins (Sun 
et al., 2009). Surprisingly, very little information is available on the effect of C. difficile itself 
on human IEC. Thus, the aim of this study was to investigate how GI mucosa responds to 
the bacterial cell itself and its secretory products. 
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4.2 C. difficile-mediated Host Innate Immune Response(s) 
 
Intestinal epithelial cells in addition to providing a physical and biochemical barrier, express 
a wide range of PRRs that can recognise bacterial factors and subsequently execute 
regulation of immune responses in the intestinal microenvironment. C. difficile TcdA and 
TcdB have been shown to induce disruption of epithelial barrier function and expression of 
pro-inflammatory cytokines and it has been documented that both toxins can stimulate the 
expression of IL-8 in human IEC (Mahida et al., 1996; Kim et al., 2002; Johal et al., 2004c; 
NA et al., 2005). There is only one study to date that suggests differential host cytokine 
responses to different concentrations of toxin. Johal and colleagues found IL-8 expression in 
response to high concentrations of TcdA (≥ 100 ng/ml), while low concentrations (≤ 10 
ng/ml) induce TGF-β, a protective cytokine (Johal et al., 2004c). One has to take these 
studies with caution as toxin concentration during an on-going CDI is not known. At 
present, IEC innate immune responses to whole bacteria are unknown. 
In this study, C. difficile-induced inflammatory response(s) was examined using human IECs 
including; Caco-2, HT-29, and human colonic cell-line T84. The initial study was conducted 
using C. difficile strains; 027, 630 and its erythromycin-sensitive derivative strain (630 Δerm) 
(A+B+), and CD37 (a non-toxigenic C. difficile strain) at an MOI of 50. Strain 630 Δerm is a 
deletion mutant that has been generated by continuous subculture and has lost its 
phenotypic resistance to erythromycin and clindamycin (Hussain et al., 2005).  
Later in the study, these series of experiments were concluded using R20291 (PCR-ribotype 
027), 630 (A+B+), and M68 and CF5 (A-B+) strains in order to elucidate differential response 
of A+B+ strains versus A-B+ C. difficile strains at various doses of MOIs.  
 
4.2.1 Human IEC IL-8 Response to C. difficile Infection 
 
To study IEC IL-8 response to C. difficile infection, Caco-2 monolayers were infected with 
027, 630, 630 Δerm, and CD37 bacterial cultures at an MOI of 50. IL-8 mRNA expression was 
determined in a time-dependent manner at 2, 4, 6, and 8 h post-infection by semi-
quantitative RT-PCR (Figure 4.1 a). Gene expression was quantified by densitometery and 
normalised to GAPDH. Data is presented as fold induction (Figure 4.1 b).  
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Cells infected with C. difficile strains showed ≥ 3-fold increase in IL-8 mRNA expression at 2 
h and 4 h, followed by a decline to ~1-fold at 6 h and 8 h post-infection. No significant inter-
strain difference was observed at any examined time-points (Figure 4.1 b). 
C. difficile-induced IL-8 mRNA expression was further investigated by infecting Caco-2 
monolayers with bacterial cultures of strains R20291, 630, M68, and CF5 at an MOI of 100. 
Gene expression was determined at 4 h and 8 h post-infection by RT-PCR (Figure 4.1 c). 
Infections with C. difficile strains caused similar increase in IL-8 mRNA expression, showing 
an increase of up to 3-fold at 8 h post-infection (Figure 4.1 d). 
Previous studies have shown the effect of C. difficile toxins on human IEC leading to IL-8 
production; however, it is unknown whether intestinal epithelia respond differentially to 
whole bacteria and its components. In this study, IL-8 release from human IEC in response 
to bacterial culture (whole bacterial cell plus supernatant) was compared with whole 
bacterial cell, filter-sterilised supernatant (containing toxins and secretory products) and 
spore preparations at 8 h post-infection (Figure 4.1 e).  
Basal IL-8 protein levels in uninfected Caco-2 cells were generally <5 pg/ml. Upon infection 
with bacterial cultures and whole bacterial cells, IL-8 secretion increased to 10-40 pg/ml 
and 10-60 pg/ml, respectively. Bacterial supernatants induced intermediate amounts <20 
pg/ml while C. difficile spores increased IL-8 release between 5-30 pg/ml (Figure 4.1 e).  
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Figure 4.1. IL-8 gene and protein expression in response to C. difficile in Caco-2 cells. Caco-
2 monolayers were infected with bacterial cultures at an MOI of 50 and IL-8 mRNA 
expression was quantified at specific time-points. Representative RT-PCR analysis at MOI 50 
(a), data presented as fold change and represent mean ± SEM, n=3 (b). Representative RT-
PCR analysis at MOI 100 (c), data presented as fold change and represent the average of 
two experiments (hence, no error bars given) (d). Induction of IL-8 in response to C. difficile 
bacterial culture, whole bacterial cell, supernatant, and spore (MOI of 500) was measured 
by ELISA at 8 h post-infection. LPS (1 μg/μl) was used as a reference stimulus. Data 
represent mean ± SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 represent significant 
difference from uninfected cells, and ^p<0.05 and ^^^p<0.001 represent significant inter-
strain difference (e). P values were obtained using ANOVA with Bonferroni post-test 
analysis.  
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C. difficile-mediated IL-8 response was further investigated by conducting similar infections 
in HT-29 cells (Figure 4.2). HT-29 infected cells with 027, 630, 630 Δerm, and CD37 bacterial 
cultures showed ≤ 2-fold increase in IL-8 mRNA expression between 2 and 6 h post-
infection. At 8 h, expression showed >2-fold increase. No significant difference in IL-8 
response was detected amongst the strains (Figure 4.2 a & b). HT-29 cells infected with 
strains R20291, 630, M68, and CF5 exhibited >2-fold increase in IL-8 expression at 4 h. 
Similar IL-8 expression levels were also detected at 8 h post-infection, while no significant 
inter-strain difference was observed at either time-points (Figure 4.2 c & d).  
Secretion of IL-8 protein was investigated by co-incubating HT-29 cells with bacterial 
cultures, whole bacterial cells, supernatants, and spores (Figure 4.2 e). Uninfected control 
cells showed <20 pg/ml IL-8, which were higher than that observed for uninfected Caco-2 
cells (Figure 4.1 e). Bacterial cultures and whole bacterial cells caused marked induction of 
IL-8 (200-1500 pg/ml and 600-1400 pg/ml, respectively) interestingly, bacterial 
supernatants and spores resulted in <50 pg/ml IL-8 expression (Figure 4.2 e).  
Collectively, C. difficile strains mediated 2 to 5-fold increase in IL-8 mRNA expression in 
Caco-2 and HT-29 cells, with the highest up-regulation generally detected between 6 and 8 
h post-infection. Furthermore, A-B+ strains initiated similar IL-8 responses to A+B+ strains. 
This data also showed that C. difficile bacterial culture and whole cell bacteria mediated 
higher IL-8 induction compared to bacterial supernatants (containing secreted toxins) and 
spores. Importantly, HT-29 cells were much more responsive to C. difficile as measured by 
marked increase in IL-8 protein levels in comparison Caco-2 cells were significantly less 
responsive. 
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Figure 4.2. IL-8 induction in response to C. difficile in HT-29 cells. HT-29 cells were infected 
with bacterial cultures at an MOI of 50 and IL-8 mRNA expression was quantified at specific 
time-points. Representative RT-PCR analysis of IL-8 mRNA expression (a), data presented as 
fold change and represent the average of two experiments (hence, no error bars given) (b). 
Representative RT-PCR analysis of IL-8 mRNA expression at MOI 100 (c), data presented as 
fold change and represent the average of two experiments (hence, no error bars given) (d). 
Induction of IL-8 protein in response to C. difficile bacterial culture, whole bacterial cell, 
supernatant, and spore (MOI of 500) was measured by ELISA at 8 h post-infection. LPS (1 
μg/μl) was used as a reference stimulus. Data represent mean ± SEM, n=3. *p<0.05 and 
**p<0.01 represent significant difference from uninfected cells, and ^p<0.05 represents 
significant inter-strain difference (e). P values were obtained using ANOVA with Bonferroni 
post-test analysis. 
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4.2.2 C. difficile-mediated IL-6, TNF-α, hBD-2, and IL-1β Responses  
 
To investigate IECs pro-inflammatory response(s) to C. difficile, Caco-2 monolayers were 
infected with 027, 630, 630 Δerm, and CD37 bacterial culture at an MOI of 50 and IL-6, TNF-
α, hBD-2, and IL-1β mRNA expression was quantified as essentially described above for IL-8 
(Figures 4.3-4.6 a).  
Caco-2 infected cells showed 2-3-fold induction in IL-6 gene expression up to 6 h post-
infection, with strain 027 exhibiting a trend for greater IL-6 up-regulation compared to the 
other strains (Figure 4.3 a).  
In a separate series of experiments Caco-2 monolayers were co-cultured with strains 
R20291, 630, M68, and CF5 at an MOI of 100. Gene expression of IL-6 and IL-1β was 
determined at 4 and 8 h (Figures 4.3 & 4.6 b). In this series mRNA expression of TNF-α and 
hBD-2 was not measured. Infected Caco-2 cells showed a moderate IL-6 mRNA expression 
at 4 h post-infection, which increased to >2-fold at 8 h. No significant inter-strain difference 
was detected in modulating IL-6 expression (Figure 4.3 b). The IL-6 level was undetectable 
in uninfected control cells. Upon infection all four strains caused a very modest and similar 
increase to ~15 pg/ml (Figure 4.3 c).   
 
 
 
 
 
(a) 
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Figure 4.3. C. difficile-induced IL-6 mRNA and protein expression in Caco-2 cells. Caco-2 
monolayers were infected with bacterial cultures at an MOI of 50. IL-6 mRNA expression 
was followed by RT-PCR and presented as fold change. Data represent mean ± SEM, n=3 (a). 
IL-6 expression in response to C. difficile strains (MOI 100). Data represent the average of 
two experiments (hence, no error bars given) (b); IL-6 protein expression was measured at 
8 h post-infection. Data represent mean ± SEM, n=3. ***p<0.001 represents significant 
difference from uninfected cells (c). P values were obtained using ANOVA with Bonferroni 
post-test analysis. 
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Similar co-culture experiments were conducted to detect TNF-α gene and protein 
expression (Figure 4.4). Caco-2 cells infected with strains 027, 630, 630 Δerm, and CD37 
showed an increase of ~3-4-fold in mRNA expression at 6 h post-infection with a decline at 
8 h, all four strains exhibited similar TNF-α gene expression profile (~3-fold) (Figure 4.4 a).  
When Caco-2 monolayers were co-cultured with bacterial cultures at an MOI of 100 and 
500, TNF-α protein expression increased in a dose-dependent manner (Figure 4.4 b). TNF-α 
was undetectable in uninfected control cells, a modest response (<10 pg/ml) was detected 
at an MOI of 100, whilst MOI of 500 caused induction of >20-80 pg/ml (Figure 4.4 b). 
Also, hBD-2 mRNA expression was followed during C. difficile infection. 2-4 h post-infection, 
a very modest (1-2-fold) increase was noted, with >2-3-fold increase at 8 h post-infection 
(Figure 4.5 a). hBD-2 protein level was quantified during infection with strains R20291, 630, 
M68, and CF5. hBD-2 remained undetectable in uninfected control cells. Strains R20291 
and 630 caused induction to a similar extent (~100 pg/ml), while M68 elicited a more 
potent response (~150 pg/ml). Strain CF5 in contrast was less potent (80 pg/ml) (Figure 4.5 
b). 
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Figure 4.4. C. difficile-mediated TNF-α expression in Caco-2 cells. Caco-2 monolayers were 
infected with bacterial cultures at an MOI of 50. TNF-α mRNA expression was quantified 
and presented as fold change. Data represent mean ± SEM, n=3 (a). TNF-α protein 
expression was measured at 8 h post-infection (MOI of 100 and 500). Data represent mean 
± SEM, n=3. **p<0.01 and ***p<0.001 represent significant difference from uninfected cells, 
and ^p<0.05, ^^p<0.01 and ^^^p<0.001 represent significant inter-strain difference (b). P 
values were obtained using ANOVA with Bonferroni post-test analysis.  
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Figure 4.5. C. difficile-mediated hBD-2 induction in Caco-2 cells. Caco-2 monolayers were 
infected with bacterial cultures at an MOI of 50. Gene expression of hBD-2 was quantified 
and presented as fold change. Data represent mean ± SEM, n=3 (a). hBD-2 protein levels 
measured at 8 h post-infection (MOI 100). Data represent mean ± SEM, n=3. *p<0.05, 
**p<0.01 and ***p<0.001 represent significant difference from uninfected cells (b). P values 
were obtained using ANOVA with Bonferroni post-test analysis.   
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IL-1β mRNA expression was also measured (Figure 4.6). Caco-2 cells infected with 027, 630, 
630 Δerm, and CD37 bacterial cultures showed ~3-4-fold increase in gene expression at 6 h 
post-infection, followed by a modest increase at 8 h. Strain CD37 caused the least change in 
IL-1β expression (Figure 4.6 a). 
Strains R20291, 630, M68, and CF5 mediated a 2-fold increase in IL-1β mRNA expression at 
4 h post-infection with a marginal increase at 8 h. R20291 infection exerted a potent effect 
on IL-1β, while strain CF5 was the least effective (Figure 4.6 b). IL-1β protein remained 
undetectable in infected Caco-2 cells.  
Taken all together, this data suggested that C. difficile bacterial cultures caused 2 to 4-fold 
increase in gene expression of IL-6, TNF-α, hBD-2, and IL-1β, mainly between 4 and 8 h 
post-infection. C. difficile- induced TNF-α secretion in a dose-dependent manner, further 
significant antimicrobial hBD-2 induction was also noted. The lack of IL-1β protein in 
infected Caco-2 cells despite mRNA induction was an interesting observation.  
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Figure 4.6. C. difficile-mediated IL-1β mRNA expression in Caco-2 cells. Caco-2 monolayers 
were infected with bacterial cultures at an MOI of 50. Gene expression of IL-1β was 
quantified at 2, 4, 6, and 8 h post-infection and presented as fold change. Data represent 
mean ± SEM, n=3 (a). IL-1β mRNA expression was measured at 4 h and 8 h post-infection 
(MOI 100). Data represent the average of two experiments (hence, no error bars given) (b). 
Data was analysed using ANOVA with Bonferroni post-test.  
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hBD-1 and IL-18  expression was also determined at 4 and 8 h post-infection (Figure 4.7). A 
modest <2-fold increase in hBD-1 mRNA expression was noted at 4 h reaching ~2-fold at 8 h 
post-infection (Figure 4.7 a). IL-18 mRNA showed no significant change at 4 h but 
expression elevated up to 2-fold at 8 h (Figure 4.7 b). Protein expression of hBD-1 and IL-18 
were not measured.  
 
 
 
 
 
 
Figure 4.7. hBD-1 and IL-18 gene expression in response to C. difficile infection. Caco-2 
monolayers were infected with bacterial cultures at an MOI of 100 and mRNA expression 
was quantified by RT-PCR. Gene expression of hBD-1 and IL-18 were presented as fold 
change. Data represent the average of two experiments (hence, no error bars given) and 
was analysed using ANOVA with Bonferroni post-test. 
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4.2.3 C. difficile-mediated Cytokine Expression in HT-29 Cells 
 
C. difficile-mediated IEC cytokine response(s) were also studied in HT-29 cells. Experiments 
were essentially conducted as described above for Caco-2 cells.   
C. difficile strains (027, 630, 630 Δerm and CD37) caused similar IL-6 expression, showing 
>2-fold mRNA up-regulation in the first 6 h of infection. At 8 h, expression increased slightly 
reaching ~3-fold (Figure 4.8 a). IL-1α showed no significant increase at 2 h, while exhibiting 
~2-fold increase only at 6 h post-infection (Figure 4.8 b). IL-1β gene expression increased 2-
fold at 6 and 8 h (Figure 4.8 c). hBD-1 increased nearly 1-fold 6 h post-infection, while 
reaching a ~3-fold increase at 8 h (Figure 4.8 d). C. difficile caused minimal enhancement of 
TNF-α expression at 2 and 4 h (Figure 4.8 e).  
HT-29 cells were also infected with strains R20291, 630, M68, and CF5 at an MOI of 100. 
Infected cells showed >2 fold IL-1β gene expression at 4 h with a slight increase detected at  
8 h post-infection (Figure 4.9 a). Approximately 2-fold hBD-1 gene expression was detected 
at 4 h, which remained unchanged at 8 h (Figure 4.9 b). C. difficile strains caused only a 
moderate increase of IL-18 gene expression (>1-2-fold) (Figure 4.9 c).   
In summary, C. difficile strains caused 2 to 4-fold increase in inflammatory cytokine gene 
expression in both Caco-2 and HT-29 cell-lines. Importantly, the magnitude of inflammatory 
responses elicited to the presence of A+B+ and A-B+ strains were not significantly different.  
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Figure 4.8. C. difficile-mediated cytokine mRNA expression in HT-29 cells. HT-29 cells were 
infected with C. difficile bacterial cultures at an MOI of 50. Fold change in IL-6 (a), IL-1α (b), 
IL-1β (c), hBD-1 (d), and TNF-α (e) mRNA expression was quantified by RT-PCR. Data 
represent the average of two experiments (hence, no error bars given) and was analysed 
using ANOVA with Bonferroni post-test. 
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Figure 4.9. C. difficile-mediated effects on cytokine gene expression in HT-29 cells. HT-29 
cells were infected with bacterial cultures at an MOI of 100. IL-1β (a), hBD-1 (b), and IL-18 
(c) gene expression was measured and presented as fold induction. Data represent the 
average of two experiments (hence, no error bars given) and was analysed using ANOVA 
with Bonferroni post-test. 
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4.3 T84 Cell Cytokine Responses to C. difficile under Aerobic 
versus Anaerobic Conditions 
 
Caco-2 and HT-29 cell-lines are routinely employed as model cell-lines to dissect host-
pathogen interactions in the GI tract. The very modest effect of C. difficile on IEC cytokine 
response(s) described in the previous section was unexpected. Further, the aerobic 
conditions employed for the co-culture studies were sub-optimal as C. difficile is an 
anaerobic bacterium. To circumvent the various issues raised, the effect of C. difficile 
infection was investigated using well-characterised T84 cells. T84, a human colonic IEC 
grows to confluence as a monolayer and exhibits tight junctions (TJ). T84 cell is also the cell-
line of choice to investigate IEC TJ biology plus the strongly-bonded cell layer allows IEC to 
polarise when grown on transwells/snapwell filter leading to spatial compartmentalisation, 
creating an apical and basolateral compartment. This experimental method when placed in 
an Ussing vertical chamber system allows the generation of an apical anaerobic and a 
basolateral aerobic environment, a more appropriate reflection of the colonic environment 
and therefore, a better model to study host-pathogen interactions. 
T84 cells grown on transwell or snapwell were co-incubated with bacterial cultures at an 
MOI of 250 upon forming a monolayer. Supernatants were collected at 8 h post-infection to 
measure cytokine induction by ELISA (Figure 4.10).  
A basal level of <20 pg/ml IL-8 was measured in uninfected control T84 cells. In aerobic co-
culture (5% CO2) C. difficile strains induced IL-8 protein (25-100 pg/ml), these levels 
increased further (60-250 pg/ml) when the same experiment was performed providing an 
anaerobic environment for bacteria (Figure 4.10 a). TNF-α levels were low in uninfected 
control cells (<10 pg/ml), upon infection under aerobic conditions, 25-80 pg/ml TNF-α was 
secreted by infected cells, while in an anaerobic co-culture induction increased to 
significantly higher amounts (90-450 pg/ml) (Figure 4.10 b). hBD-2 was undetectable in 
control cells, infection had minimal effect under aerobic conditions (<10 pg/ml) although 
the amounts were increased under an anaerobic environment (10-30 pg/ml) (Figure 4.10 c).  
In summary, C. difficile strains mediated significantly greater inflammatory cytokine 
response(s) when host-pathogen crosstalk was allowed to occur under apically provided 
anaerobic conditions, environment optimal for the bacterium.   
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Figure 4.10. C. difficile-induced differential cytokine responses under aerobic and 
anaerobic conditions. T84 cells were co-cultured with bacterial culture (MOI 250) under 
aerobic or anaerobic conditions. IL-8 (a), TNF-α (b), and hBD-2 (c) proteins were quantified 
8 h post-infection. Data represent mean ± SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 
represent significant difference from uninfected cells, and ^p<0.05, ^^p<0.01 and ^^^p<0.001 
represent significant difference in cytokine production under an aerobic versus anaerobic 
environment. P values were obtained using ANOVA with Bonferroni post-test analysis. 
(a) 
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4.4 C. difficile-mediated Disruption of Human Intestinal Barrier 
Function 
 
In the presence of intact cell layer, the epithelial barrier seal is established and maintained 
by the IEC (Turner, 2009). The epithelium permeability is regulated mainly by the presence 
of TJ complexes. TJs are composed of integral proteins including; occludin, claudins, and 
junctional adhesion molecule-A (JAM-A), which are located between individual composing 
cells (Pastorelli et al., 2008). Occludin is a functional component of the paracellular barrier 
permeability and has a role in cellular defence. Occludin is expressed predominately at TJs 
in epithelial and endothelial cells. The C-terminus of occludin interacts with zonula 
occludens-1 protein (ZO-1) linking occludin to the actin cytoskeleton (Groschwitz et al., 
2009; Du et al., 2010). Pathogens attack the intestinal barrier with various virulence factors 
directly by disruption and causing a decrease in transepithelial resistance or indirectly by 
phosphorylation/dephosphorylation of TJ proteins (Baumgart et al., 2002). In addition to 
cell disruption, loss of adherens junctions results in ineffective epithelial cell polarisation 
and differentiation causing premature cell apoptosis (Turner, 2009).  
Several studies have already shown C. difficile toxins-mediated effects on intestinal 
epithelial barrier function using purified toxins or bacterial supernatants (Riegler et al., 
1995; Alfa et al., 2000; Nusrat et al., 2001; Savidge et al., 2003; Sutton et al., 2008), 
however, it is yet to be defined whether whole cells of C. difficile play an additional role in 
disruption of TJs.  
 
4.4.1 Occludin Re-distribution during C. difficile Infection 
 
C. difficile-induced effect on IEC barrier function was investigated by following occludin 
expression during bacterial infection. As C. difficile leads to extensive actin cytoskeletal 
changes and cell rounding (Chapter 3), it was hypothesised that infection may mediate 
occludin redistribution during these cellular processes.  
T84 monolayers were co-cultured with C. difficile bacterial cultures at an MOI of 250. Cells 
were immunostained for occludin and observed by fluorescence microscopy in a time-
dependent manner (Figure 4.11). Occludin remained primarily confined to the membrane 
in uninfected control cells throughout the course of the experiment, on the other hand 8 h 
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post-infection, occludin had predominantly redistributed to an intracellular area with a 
corresponding decrease at the edge of epithelial cells. Extensive disruption of occludin was 
observed following infection with strains R20291, 630, and M68 (arrowheads in Figure 
4.11). In contrast, minimal occludin redistribution was detected with CF5-infected 
monolayers compared to uninfected cells (Figure 4.11).  
In parallel, cells infected with R20291, 630, and M68 showed significant barrier function 
disruption, whilst strain CF5 caused the least impact.  
 
 
 
 
 
Figure 4.11. C. difficile-induced disruption of TJs in T84 cells leads to redistribution of 
occludin. T84 monolayers were infected with C. difficile bacterial cultures at an MOI of 250. 
At 8 h post-infection cells were stained for occludin and redistribution was observed by 
fluorescence microscopy (100x Leica DMLB). Data is representative of three independent 
experiments.   
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4.4.2 C. difficile-induced Transepithelial Electrical Resistance (TEER) Loss 
under Aerobic Conditions 
 
C. difficile strains promote removal of occludin from TJs allowing its redistribution inside the 
IEC cytoplasm. Occludin redistribution induces destabilisation of the TJ complexes, leading 
to alteration of intestinal paracellular permeability. The effect of C. difficile on IEC 
permeability was assessed by measurement of transepithelial electrical resistance (TEER) 
and permeability to FITC-dextran.  
T84 cells were grown on a permeable membrane prior to co-incubation with C. difficile 
cultures at an MOI of 250 under aerobic conditions. TEER changes were monitored over 24 
h (Figure 4.12). Uninfected control cells exhibited a moderate decrease in TEER 
measurement during the experimental time. 2 h post-infection, cells infected with strains 
R20291, 630, and M68 showed a ~15% loss in TEER measurements. In contrast, strain CF5 
caused decline in TEER at a slower rate showing a similar loss only after 4 h. Loss in TEER 
measurement continued at a steady rate. At 24 h, strains R20291, 630, and M68 infected 
cells showed a dramatic (~90%) loss in TEER compared to uninfected control cells, while 
strain CF5 showed ~60% TEER loss. 
  
 
 
Figure 4.12. Time-dependent changes in IEC TEER during C. difficile infection. T84 
monolayers were infected with bacterial cultures at an MOI of 250 in an aerobic 
environment. Change in TEER was monitored up to 24 h. Data represent mean ± SEM, n=3. 
*p<0.05, **p<0.01 and ***p<0.001 (ANOVA with Bonferroni post-test) represent significant 
difference of uninfected cells with infected cells.  
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4.4.3 Loss of TEER under Anaerobic Environment 
 
Effect of C. difficile strains on epithelial barrier function under anaerobic conditions was 
examined by employing the Ussing vertical diffusion chamber system providing an 
anaerobic environment for the bacteria while supporting 5% CO2 basolateral conditions. 
The experiment was conducted by measuring baseline TEER prior to co-incubation with 
bacteria in the apical compartment, the change in resistance was measured subsequently 
at 8 h post-infection (Figure 4.13).   
Uninfected control cells not only maintained but improved the ‘’intactness’’ of the 
monolayer during the experimental time-course, as an increase in TEER measurement was 
observed. At 8 h, 75-90% TEER loss was detected in cells infected with strains R20291, 630, 
and M68. In contrast, CF5 caused <50% decrease in TEER but it was not statistically 
significant.  
Taken all together, Figures 4.12 and 4.13 showed that strains R20291, 630, and M68 caused 
greater TEER loss in infected T84 cells; on the contrary strain CF5 exhibited the least effect.  
It was also noted that anaerobic conditions enhanced epithelial barrier disruption by all 
four strains.   
 
 
 
Figure 4.13. C. difficile induces a rapid TEER loss in anaerobically infected T84 cells.T84 
monolayers were infected with bacterial cultures at an MOI of 250 under an anaerobic 
environment. Change in resistance was compared at 8 h post-infection to corresponding 
pre-infected wells. Data represent mean ± SEM, n=3. ***p<0.001 (ANOVA with Bonferroni 
post-test) represents significant difference between uninfected and infected cells.  
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4.4.4 Increased Paracellular Permeability in Response to C. difficile 
infection  
 
Loss of TEER in infected T84 cells was concomitant with increased paracellular permeability, 
which was measured by apical to basolateral flux of a FITC labelled marker across the cell 
monolayer.  
T84 monolyaers were infected apically with C. difficile strains at an MOI of 250, plus FITC-
dextran (a paracellular marker) was added to the apical chamber (Figure 4.14). Uninfected 
control cells showed <10% basal level of FITC-dextran influx although this increased over 
time. Upon infection, an increase in paracellular permeability was observed as early as 2 h 
post-infection in response to all four strains (~10%). FITC-dextran flux progressively 
increased reaching 30% at 8 h and >70% at 24 h post-infection.  
Collectively, A-B+ C. difficile strains caused similar effect as A+B+ strains on IEC barrier 
function leading to TJ disruption and increase in paracellular permeability. CF5 infection led 
to less occludin redistribution and TEER loss but interestingly showed comparable results 
with other strains in mediating paracellular permeability.  
 
 
 
Figure 4.14. Paracellular permeability increases in response to C. difficile infection. T84 
monolayers were co-cultured with C. difficile cultures at an MOI of 250 and FITC-dextran 
flux from apical to basolateral compartment was measured up to 24 h post-infection. Data 
represent mean ± SEM, n=3. ***p<0.001 (ANOVA with Bonferroni post-test) represents 
significant difference between uninfected and infected cells.   
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4.5 The Ex Vivo Innate Immunity Response(s) of Human 
Intestinal Mucosa to C. difficile 
 
In vitro models of infection using epithelial cell-lines have been used broadly to study host-
pathogen interactions; however, cultured cell-lines only indicate how IEC may respond. In 
vitro organ culture (IVOC) is a better alternative that permits studies of host-pathogen 
interactions under physiologically relevant conditions, where tissues retain their natural 
architecture and epithelial lining as the host response includes contribution from the 
underlying lamina propria and the cells it contains rather than just the IEC lining. Thus far, 
the conventional IVOC method has been used extensively to study E. coli, Salmonella, and 
Campylobacter pathogenesis (Haque et al., 2004; Schuller et al., 2009; Edwards et al., 
2010).  
To investigate C. difficile interactions with human intestinal mucosa, human paediatric 
pinch biopsies from healthy area of transverse colon were utilised. Ethical approval to study 
host-pathogen interactions was obtained (06/Q0508/26). No patient data was collected, 
therefore tissue usage was anonymous. The explant was co-cultured with 5 x 108 bacteria 
and mucosal cytokine responses were measured 3-6 h post-infection (Figure 4.15 a-f).  
IL-8 was measurable in supernatants from uninfected colonic tissue, however C. difficile 
infection enhanced IL-8 secretion by 3 to 4-fold with strain CF5 exhibiting a trend for less 
response (Figure 4.15 a). IL-6 was detected in uninfected tissues but levels were low 
compared to IL-8 (median 60 versus ~200 pg/ml) infection increased IL-6 responses to a 
median ~200 pg/ml (Figure 4.15 b). Although no significant difference was observed 
between the various strains in mediating IL-6 production, the trend for R20291 being the 
most potent and CF5 the least effective continued. Infection had a dramatic effect on IL-1β 
induction when compared to uninfected controls (80 versus 800 pg/ml) (Figure 4.15 c). 
Strains R20291 and M68 infection led to marked IL-1β release, with significantly less effect 
of CF5.  
The GI mucosal host defence response to C. difficile infection was also determined. IFN-γ, 
IL-17A and IL-22 are the cytokine implicated in this response. Minimal IFN-γ was observed 
in uninfected biopsies, infection caused marked induction 400-900 pg/ml (Figure 4.15 d) 
significant difference between R20291 and CF5 response was noted. IL-17A was detected at 
low levels in uninfected tissue, the induction upon C. difficile infection was <60 pg/ml 
147 
 
(Figure 4.15 e), these levels were the lowest amongst the cytokines tested. IL-22 was 
detectable in uninfected biopsies, this cytokine was significantly induced in response to 
infection (~300 pg/ml) (Figure 4.15 f). 
In summary, C. difficile infection led to a significant increase in mucosal inflammatory 
responses in paediatric colonic biopsies compared to uninfected tissues. No inter-strain 
difference was observed in IL-8, IL-6, and IL-22 secretions although CF5 induced significantly 
less IL-1β, IFN-γ, and IL-17A when compared to levels detected with strains R20291, 630, 
and M68.  
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Figure 4.15. Ex vivo mucosal cytokine responses to C. difficile infection. Macroscopically 
normal and matched colonic biopsies from paediatric patients (12-30 individuals with mean 
age of 10.4 ± SD of 4.7) were infected with each C. difficile strains (5 x 108). Bars represent 
median levels. Inductions of various cytokines were measured at 3-6 h post-infection. 
*p<0.05, **p<0.01 and ***p<0.001 represent significant difference from uninfected controls, 
and ^p<0.05 and ^^^p<0.001 represent significant inter-strain difference. Data was analysed 
using a Mann–Whitney U test.                      
 
 
 
 
 
 
(e) 
(f) 
150 
 
4.6 Conclusions  
 
Cells that line the mucosal surface of the intestine form a critical barrier that divides the 
host’s internal milieu from the external environment and act as a selectively permeable 
barrier to luminal contents preventing unwanted solutes, microorganisms and antigens 
from entering the body. In addition to the continuous exposure to dietary and 
environmental antigens, the intestinal microenvironment forms one of the most densely 
populated microbial habitats, harbouring an estimated 1014 commensal bacteria. Thus, the 
IECs, which once considered a simple physical barrier not only can directly sense 
commensal bacteria and pathogens but also play an integral role in discriminating between 
commensal and pathogenic bacteria, subsequently mounting an appropriate host 
response(s) (Jung et al., 1995; Hershberg, 2002; Radtke et al., 2005; MacDonald et al., 2005; 
Artis, 2008; Groschwitz et al., 2009).    
In this study IEC cytokine response(s) to C. difficile was investigated. For this purpose, 
various IEC cell-lines including Caco-2, HT-29 and T84 cells were employed. Also cytokine 
expression in response to C. difficile infection was compared under aerobic versus 
anaerobic co-culture environments. Additionally, mucosal cytokine responses to C. difficile 
were examined in an ex vivo model of infection by utilising paediatric colonic biopsies.  
Following bacterial adherence, IEC interaction with bacteria, provides early signals for the 
initiation and maintenance of the mucosal inflammatory response. Several studies have 
already demonstrated the epithelial response to C. difficile toxins and more specifically 
TcdA contribution to accumulation and activation of inflammatory cells, including 
neutrophils and monocytes, at the site of infection by establishing a chemotactic gradients 
such as IL-8 within the underlying mucosa (Mahida et al., 1996; Kim et al., 2002; Johal et al., 
2004c; NA et al., 2005; Canny et al., 2006; Kim et al., 2006b; Lee et al., 2007). However, 
how the C. difficile adherence contributes to the up-regulation of pro-inflammatory gene 
expression in epithelia is uncertain; nonetheless, it may not be an exclusive requirement as 
epithelial monolayers do respond to bacterial supernatant and toxins (Mahida et al., 1996; 
Kim et al., 2002; Johal et al., 2004c; Canny et al., 2006; Kim et al., 2006b; Lee et al., 2007). 
It was observed that C. difficile infection caused an overall 3 to 4-fold increase in mRNA 
expression of several pro-inflammatory cytokines, the induction that maximum 8 h post-
infection. Cytokine mRNA expression was not affected by increasing the MOI from 50 to 
100. C. difficile strains induced 3 to 4-fold IL-8 gene expression in infected Caco-2 and HT-29 
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cells; importantly majority of the induction was mediated by bacterial cells, as both 
supernatant and spores were less potent. To the best of our knowledge the present study is 
the first to report these responses. Despite similar magnitude of IL-8 mRNA by HT-29 cells, 
these cells induced 10-15 times more IL-8 protein in response to bacterial cultures and 
whole cells than that secreted by infected Caco-2 cells. Studies are now forthcoming that 
suggest Caco-2 cells irrespective of stimuli received remain poor IL-8 producers. This clearly 
highlights need for caution while interpreting data. Nonetheless, HT-29 cells responded to 
bacterial supernatants and spores similar to Caco-2 cells. 
Gene and/or protein expression of IL-6, TNF-α, beta defensins hBD-1 and hBD-2 was 
investigated during C. difficile infection. Both Caco-2 and HT-29 showed increase in cytokine 
and antimicrobial responses, indicating activation of multiple host signalling pathways 
leading to enhancing IEC innate immunity to C. difficile. Although C. difficile induced IL-1β 
mRNA expression, no protein was detected by ELISA.  
Analysis of GI mucosal responses revealed that C. difficile strains caused a robust 
inflammatory cytokine response in colonic tissues as early as 3h post-infection. It was noted 
that C. difficile infection caused a strong induction of IL-8 and comparatively weak IL-17A, 
suggesting that IL-8 may play a more crucial role in mediating early neutrophil recruitment 
necessary for containment of the infection. Interestingly, C. difficile infection caused robust 
induction of IL-22 compared to IL-17A. The role of IL-17A in IEC is both pro-inflammatory 
and antimicrobial. In contrast, IL-22 has a more regenerative and protective role on IEC. C. 
difficile infection also caused strong pro-inflammatory IL-1β and IFN-γ responses. 
As C. difficile is an anaerobe, induction of IL-8, TNF-α, and hBD-2 proteins by T84 cells in 
aerobic co-cultures were compared with cells infected with anaerobically-grown bacteria. 
Anaerobic conditions induced significant increase in cytokine secretion and more rapid 
TEER loss. These observations need to be investigated further to clarify whether increased 
cytokine response was due to optimal conditions for bacterial growth and/or subsequent 
enhancement of bacterial adherence.  
Studies have shown that C. difficile toxins alter the barrier function of polarised IEC such as 
Caco-2 and T84 cells by increasing paracellular permeability (Hecht et al., 1988, 1992; Johal 
et al., 2004c; Sutton et al., 2008). Johal and co-workers (2004c) demonstrated that TEER 
loss in T84 cells in response to TcdA is dose dependent and exposure to >10 ng/ml TcdA 
leads to complete and irreversible loss of TEER. Concomitant with the permeability 
increase, toxins disrupt apical and basal actin filaments leading to disorganisation of 
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junctional complexes and redistribution of ZO-1, ZO-2, occludin, and claudin within TJs. 
TcdB decreases actin-ZO-1 association and disperse ZO-1 and occludin from membrane, 
without occludin phosphorylation (Nusrat et al., 2001; Chen et al., 2002). Since Rho plays an 
important role in TJ assembly, it was presumed that the effects of TcdA and TcdB on TJs 
result from Rho glucosylation (Jou et al., 1998; Popoff and Geny, 2009). Furthermore, 
disruption of the actin cytoskeleton has been shown to be involved in IL-8 secretion in HT-
29 and Caco-2 cells (Nemeth et al., 2004). In the current study, strains R20291, 630, and 
M68 caused an extensive occludin disruption at 8 h, increased TEER loss and enhanced 
FITC-dextran flux at 24 h in aerobically infected T84 cells, indicating disruption of epithelial 
barrier function and increased permeability. Although CF5 also caused disruption of the 
epithelium and increased permeability it did so to a lesser degree compared to other 
strains.   
Taken all together, IEC cell-lines and human colonic biopsy tissue bear the capacity to 
distinguish the various C. difficile strains as irrespective of the biological parameter 
measured, strain R20291 was consistently more potent than strain 630 suggesting the 
presence of CDT maybe partly responsible for the observed greater potency. Also amongst 
the two A-B+ strains M68 and CF5, the latter was consistently less potent compared to M68 
suggesting virulence differences between the two strains which at present uncharacterised. 
Marked induction of GI mucosal responses within 3 h of bacterial infection highlighted 
players that are most likely involved not only in early immunity but in a susceptible person 
the same players may also play a role in initiating disease pathogenesis.   
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4.6.1 Summary  
 
This chapter showed that: 
 C. difficile whole bacterial cells induced a significant IL-8 secretion compared to 
supernatants and spores. 
 The magnitude of inflammatory cytokine gene expression in response to A+B+ 
strains versus A-B+ strains was not significantly different.   
 Strain R20291 was detected to cause greater inflammatory cytokine protein 
expression in both intestinal epithelial cell-lines and human colonic tissues when 
compared with 630 and M68, whilst CF5 induced the least response.  
 Under an anaerobic condition C. difficile strains mediated significantly more 
inflammatory cytokine response(s) and TEER loss.  
 Strains R20291, 630 and M68 caused significant epithelial barrier function 
disruption and enhanced paracellular permeability. 
 Although epithelial disruption was detected in response to CF5 infection but it was 
to a lesser extent compared to other strains.  
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Chapter 5  
Potential Crosstalk between Clostridium 
difficile and Host Toll-Like Receptors 
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5.1 Introduction  
 
In the GI tract tissue homeostasis is maintained by a harmonious relationship between the 
mucosal immune system and the environment. This coexistence occurs in the presence of a 
diverse range of bacterial species. There is no doubt that multiple mechanism(s) are likely 
to be involved in maintaining homeostasis however at present our understanding of these 
are limited. In the last decade the role of host Toll-like receptors (TLRs) in GI health and in 
disease has begun to emerge (Mumy & McCormick, 2005; Tapping, 2009). TLRs are the 
most studied group of host pattern recognition molecules. Their expression is ubiquitous as 
they are found on non-immune (epithelial, fibroblast) innate and adaptive (T, B and Treg) 
cell types. TLRs recognise conserved structural components (MAMPs) of microbes triggering 
signals leading to protective, tolerant responses or inflammation (Vora et al., 2004; Li et al., 
2010).   
There is currently limited information regarding the recognition of C. difficile by the 
immune system. Two studies have reported a potential role of TLRs in C. difficile infection. 
Jarchum et al. demonstrated that flagellin-mediated TLR5 stimulation protected mice from 
death during C. difficile colitis by delaying C. difficile growth and toxin production. TLR5 
stimulation improved pathological changes in the cecum and colon of infected mice and 
reduced epithelial cell loss and apoptosis, thereby protecting the integrity of the intestinal 
barrier during the infection (Jarchum et al., 2011). In another study, Ryan et al. suggested a 
role for TLR4 in recognition of SLPs and subsequent initiation of the immune response 
necessary for clearance of C. difficile (Ryan et al., 2011). Although these studies implicate 
TLR5 in protection during C. difficile infection and TLR4 in recognising SLPs, the role of other 
TLR members and details of effector pathways yielding protective immunity to C. difficile is 
unknown.  
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5.2 The Role of Toll-Like Receptors in C. difficile Infection 
 
In the present study, the potential role of TLR family in the recognition of C. difficile was 
investigated by employing TLR-transfected-HEK293, a human embryonic kidney cell-line. 
Stably transfected HEK293 cells with one or two TLR genes were infected with bacterial 
culture, supernatant and PFA-fixed C. difficile strains of R20291, 630, M68, and CF5 at an 
MOI of 10. IL-8 secretion was measured as the biological readout of TLR activation. Specific 
ligands known to activate each TLR, TNF-α (125 ng/ml); Lactobacillus rhamnosus GG (LGG), 
a Gram-positive facultative anaerobe; 630 Δerm tcdA tcdB (A-B-), an isogenic mutant of 
strain 630, and CD37, a non-toxigenic C. difficile strain (MOI 10) were used as controls.  
 
5.2.1 IL-8 Response to C. difficile Infection by HEK293 Cells 
 
As non-transfected HEK293 cells are likely to express endogenous TLRs, it was critical to 
determine the contribution of these receptors in providing basal IL-8 secretion levels in 
response to C. difficile. Each individual TLR ligand was also tested as the magnitude of 
response may reflect the degree of corresponding TLR expression (Figure 5.1 a). 
Uninfected HEK293 cells spontaneously secreted IL-8 in the range of ~25 pg/ml. Upon C. 
difficile infection, only strains 630 and CD37 showed a modest induction. Amongst the TLR 
ligands tested, FLA-ST (S. typhimurium Flagellin, TLR5 receptor ligand) was the only agonist 
to yield significant IL-8. TNF-α was included as an independent indicator of the ability of 
HEK293 cells to produce IL-8. The observations obtained from this study complemented 
available information as HEK293 cells naturally express TLR5 (Rhee et al., 2009) and TNF-α 
promotes an inflammatory response (Figure 5.1 a).  
Non-transfected cells were also stimulated with bacterial supernatant and PFA-fixed 
bacteria (Figure 5.1 b). Strains CD37 and 630 Δerm tcdA tcdB supernatants caused greater 
induction amongst the strains tested, interestingly upon PFA fixation, all strains induced 
more IL-8 compared to their non-fixed counterpart but PFA-fixed strains 630 and 630 Δerm 
tcdA tcdB caused elevated levels of IL-8 secretion. Overall, cells stimulated with PFA-fixed 
bacteria induced greater level of IL-8 than cells infected with bacterial culture or 
supernatant. 
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Figure 5.1. IL-8 response of non-transfected HEK293 cells to C. difficile infection and TLR 
ligands. Non- transfected HEK293 cells were infected with C. difficile bacterial culture at an 
MOI of 10, and stimulated with TLR ligands to for 8 h. Strains CD37, 630 Δerm tcdA tcdB, 
and LGG and TNF-α (125 ng/ml) were positive controls (a). Cells were also infected with 
bacterial culture, supernatant, and PFA-fixed bacteria at an MOI of 10 and IL-8 secretion 
was measured at 8 h post-infection (b). Data represent mean ± SEM, n=3. ^p<0.05, ^^p<0.01 
and ^^^p<0.001 represent significant difference from uninfected control cells and ***p<0.001 
represents significant PFA-fixed difference from bacterial culture and supernatant. P values 
were obtained using ANOVA with Bonferroni post-test analysis.  
 
(a) 
(b) 
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5.2.2 Recognition of C. difficile by TLR2/6-transfected HEK293 Cells  
 
TLR2 is involved in the recognition of a wide range of MAMPs including lipopeptides, 
peptidoglycan, and lipoteichoic acid. TLR2 generally forms heterodimers with TLR1 or TLR6. 
Specifically, TLR2/1 heterodimer recognises triacylated lipopetides from Gram-negative 
bacteria, whereas the TLR2/6 heterodimer recognises diacylated lipopeptides from Gram-
positive bacteria (Kawai et al., 2010).  
As C. difficile is a Gram-positive bacterium, an initial study was performed using TLR2/6-
transfected cells to assess bacterial recognition. Cells were infected with bacterial culture, 
supernatant, and PFA-fixed bacteria and IL-8 was quantified (Figure 5.2). Uninfected TLR2/6 
cells secreted <30 pg/ml IL-8 in a spontaneous manner. Bacterial culture and PFA-fixed 
bacteria caused significant induction with strain M68 being the most potent inducer (Figure 
5.2 a). Interestingly, the difference between non-fixed and PFA-fixed bacteria was no longer 
significant. These preliminary observations indicated that MAMPs involved in C. difficile 
interaction(s) with TLR2 are variable amongst the strains tested to an extent that a 
differential IL-8 response could be documented. Bacterial supernatants remained poor 
inducers of IL-8 (Figure 5.2 b). The TLR2/6 agonist FSL 1, induced >1500 pg/ml IL-8, 
indicating experiments conducted at an MOI of 10 did not completely saturate TLR2 
receptor occupancy (Figure 5.2 c).  
 
 
 
 
(a) 
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Figure 5.2. C. difficile-mediated IL-8 response in TLR2/6-transfected HEK293 cells. Cells 
were infected with bacterial culture and PFA-fixed bacteria and IL-8 secretion was 
measured at 8 h (a). Comparison of bacterial culture and corresponding supernatant in 
mediating IL-8 (b). Stimulated cells with TLR2/6 receptor ligand, FSL 1 showed an IL-8 
induction of >1500 pg/ml (c). Data represent mean ± SEM, n=3. *p<0.05 and ***p<0.001 
(ANOVA with Bonferroni post-test) represent significant bacterial culture difference from 
supernatant.   
 
 
 
 
 
(c) 
(b) 
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5.2.3 IL-8 Response to C. difficile Infection by TLR5-transfected HEK293 
Cells 
 
TLR5 recognises bacterial flagellin, it was important to determine whether C. difficile 
flagellin was able to activate TLR5. In this study TLR5-transfected HEK293 cells were co-
cultured with bacterial culture, supernatant, and PFA-fixed bacteria at an MOI of 10 and IL-
8 induction was measured at 8 h post-infection.  
Uninfected TLR5-transfected cells secreted ~15 pg/ml IL-8. It was noted that C. difficile 
strains ranged in their ability to activate TLR5 as IL-8 levels varied between 100-400 pg/ml. 
Also as observed previuosly, PFA-fixed bacteria induced significantly higher levels of IL-8 
(Figure 5.3 a). Infected cells with C. difficile supernatants secreted <100 pg/ml IL-8, while 
630 Δerm tcdA tcdB bacterial culture and supernatant caused ~1000 pg/ml IL-8 induction 
(Figure 5.3 b). Cells stimulated with TLR5 receptor ligand, FLA-ST expressed 1000 pg/ml IL-8 
(Figure 5.3 c). 
 
 
 
 
(a) 
161 
 
 
 
 
 
Figure 5.3. IL-8 secretion in response to TLR5 activation by C. difficile. TLR5-transfected 
cells were infected with bacterial culture and PFA-fixed C. difficile at an MOI of 10, and IL-8 
expression was measured at 8 h (a). IL-8 release in response to bacterial culture and 
corresponding supernatant (b). IL-8 expression detected in cells stimulated with TLR5 
agonist FLA-ST (c). Data represent mean ± SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 
represent significant PFA-fixed difference from bacterial culture. P values were obtained 
using ANOVA with Bonferroni post-test analysis.    
 
 
 
 
 
 
(b) 
(c) 
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5.2.4 Role of TLR2-CD14 and TLR4-CD14 HEK293 Transfected Cells in 
Recognising C. difficile Strains 
 
CD14 is a glycosylphosphatidylinositol (GPI)-anchored receptor, which is a component of 
TLR2 and TLR4 complexes that facilitates ligand binding and signalling efficacy (Kawai et al., 
2010). It is known that HEK293 cells lack endogenous CD14 expression therefore, it was 
important to observe whether CD14 transfection of HEK293 cells increased levels of IL-8 
secretion. 
CD14-transfected cells were infected with bacterial culture, supernatant, and PFA-fixed C. 
difficile strains (Figure 5.4). Uninfected cells showed <40 pg/ml IL-8 expression. Bacterial 
culture-infected cells showed an induction of IL-8 between 200-300 pg/ml and co-cultured 
cells with supernatant secreted 100-200 pg/ml IL-8. A considerable elevation in IL-8 
induction was detected in cells infected with PFA-fixed bacteria ranging from 700-900 
pg/ml.  
 
 
 
 
 
Figure 5.4. C. difficile-induced IL-8 secretion by CD14-transfected HEK293 cells. HEK293-
CD14 transfected cells were infected with MOI 10 of bacterial culture, supernatant, and 
PFA-fixed and IL-8 secretion was measured at 8 h. Data represent mean ± SEM, n=3. 
***p<0.001 (ANOVA with Bonferroni post-test) represents significant PFA-fixed difference 
from bacterial culture and supernatant.                   
163 
 
After confirming the basal level of IL-8 secretion in CD14-transfected cells, HEK293 
transfected cells with TLR2-CD14, and TLR4-CD14 receptors were utilised to investigate C. 
difficile recognition by these complexes. 
TLR2-CD14-transfected HEK293 cells were stimulated with C. difficile bacterial culture, 
supernatant, and PFA-fixed. Uninfected cells showed an induction <40 pg/ml, upon 
bacterial culture stimulation 200-500 pg/ml IL-8 expression was detected, while PFA-fixed 
bacteria induced a considerable amount of IL-8 (1500-2000 pg/ml) (Figure 5.5 a). Cells co-
cultured with bacterial supernatant secreted 150-300 pg/ml IL-8 (Figure 5.5 b). 
Evidently, PFA-fixed bacteria caused a significant amount of IL-8 expression compared to 
bacterial culture, on the other hand, no significant difference was observed in cells infected 
with supernatant compared to bacterial culture.  
Similar infection was conducted to examine the role of TLR4-CD14 complex in recognition 
of C. difficile strains, although this series of experiments were performed in the absence of 
MD-2 a co-receptor. Less than 40 pg/ml IL-8 was detected in uninfected cells, while 
bacterial culture caused 100-300 pg/ml and PFA-fixed 400-800 pg/ml IL-8 expression (Figure 
5.6 a). Bacterial supernatant stimulation caused an induction of 50-100 pg/ml IL-8 (Figure 
5.6 b). HKLM and LPS were used respectively as TLR2-CD14 and TLR4-CD14 agonist, showed 
IL-8 secretion more than 1000 pg/ml (Figure 5.6 c).   
Notably, IL-8 induction upon PFA-fixed stimulation was significantly higher than bacterial 
culture, while no significant difference was detected between bacterial culture and 
supernatant. 
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Figure 5.5. IL-8 secretion by TLR2-CD14 complex in response to C. difficile stimulation. 
TLR2-CD14-transfected cells were infected with bacterial culture and PFA-fixed C. difficile 
(MOI 10) and IL-8 expression was measured at 8 h (a). Bacterial culture and supernatant 
mediated IL-8 release (b). Data represent mean ± SEM, n=3. *p<0.05 and ***p<0.001 
represent significant PFA-fixed difference from bacterial culture, and significant difference 
of bacterial culture from supernatant. P values were obtained using ANOVA with Bonferroni 
post-test analysis. 
               
 
 
(a) 
(b) 
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Figure 5.6. C. difficile-induced IL-8 secretion by TLR4-CD14 complex. Deficient MD-2 TLR4-
CD14 cells were infected with MOI 10 of C. difficile bacterial culture and PFA-fixed (a). Cells 
stimulated with bacterial culture and supernatant (b). IL-8 expression in response to TLR2-
CD14 and TLR4-CD14 ligands respectively, HKLM and LPS (c). Data represent mean ± SEM, 
n=3. **p<0.01 and ***p<0.001 (ANOVA with Bonferroni post-test) represent significant PFA-
fixed difference from bacterial culture.   
(a) 
(b) 
(c) 
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5.2.5 TLR2/1 Heterodimer Activation in Response to C. difficile 
Stimulation 
 
As mentioned previously, TLR2/1 heterodimer recognises bacterial triacyl lipopeptide in 
order to trigger an inflammatory response. TLR2/1-transfected HEK293 cells were infected 
with C. difficile strains as described before and IL-8 secretion was measured after 8 h 
infection.  TLR2/1 uninfected cells showed <10 pg/ml IL-8 and 30-50 pg/ml was detected in 
cells infected with bacterial culture. Cells stimulated with PFA-fixed bacteria secreted 60-
130 pg/ml IL-8 (Figure 5.7 a). 10-20 pg/ml IL-8 expression was measured as a result of 
stimulation with bacterial supernatant (Figure 5.7 b). TLR2/1 receptor ligand, Pam3CSK4 
caused ~150 pg/ml IL-8 (Figure 5.7 c).   
In comparison between different stimuli, PFA-fixed bacteria caused a significant induction 
of IL-8 compared to bacterial culture. On the other hand, only strains M68, CF5, and CD37 
showed a significant difference with bacterial supernatant. 
 
 
 
 
 
(a) 
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Figure 5.7. C. difficile-induced IL-8 response by TLR2/1-transfected HEK293 cells. Cells 
were co-cultured with bacterial culture and PFA-fixed bacteria at an MOI of 10 (a). IL-8 
secretion in response to bacteria culture and supernatant (b). Stimulated cells with TLR2/1 
receptor ligand Pam3CSK4 and TNF-α showed an IL-8 induction ranging from 150-400 pg/ml 
(c). Data represent mean ± SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 represent significant 
PFA-fixed difference from bacterial culture and significant bacterial culture difference from 
supernatant. P values were obtained using ANOVA with Bonferroni post-test analysis.     
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5.2.6 Role of TLR9-transfected Cells in Recognition of C. difficile 
 
TLR9 has shown to respond to bacterial CpG DNA. To verify whether C. difficile is recognised 
by TLR9, transfected cells were infected with C. difficile strains as described. Uninfected 
TLR9-transfected cells showed a secretion <30 pg/ml, expression increased to 40 pg/ml in 
response to infection with bacterial culture and <50 pg/ml IL-8 was detected upon PFA-
fixed bacteria (Figure 5.8 a), while bacterial supernatant caused 5-25 pg/ml IL-8 induction 
(Figure 5.8 b).  Cells stimulated with ODN2006, a TLR9 agonist and TNF-α showed 150-200 
pg/ml IL-8 secretion (Figure 5.8 c).  
No significant difference in IL-8 secretion was observed between bacterial culture and PFA-
fixed bacteria. Although R20291, 630, and M68 bacterial cultures showed a significant 
increase in IL-8 compared to bacterial supernatant but the responses were not significantly 
higher than uninfected cells.  
Taken all together, PFA-fixed C. difficile was the most significant activator of TLR-
transfected HEK293 cells, excluding TLR9. Further, C. difficile strains caused considerable 
activation of TLR2/6, TLR5, and TLR2-CD14, as detected by IL-8 induction compared to 
TLR4-CD14, TLR1/2, and TLR9.  
 
 
 
 
(a) 
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Figure 5.8. IL-8 secretion in response to C. difficile stimulation by TLR9. C. difficile bacterial 
culture and PFA-fixed were used at an MOI of 10 to infect TLR9-transfected cells (a). IL-8 
secretion in response to bacterial culture and supernatant (b). IL-8 expression detected in 
cells stimulated with TLR9 agonist ODN2006 (c). Data represent mean ± SEM, n=3. **p<0.01 
and ***p<0.001 (ANOVA with Bonferroni post-test) represent significant bacterial culture 
difference from supernatant.    
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5.3 Conclusions  
 
The detection of pathogens by the host is achieved through the families of PRRs that 
recognise conserved molecular structures of microbes and induce production of innate 
effector molecules. TLRs are one of the major receptors, which have been proven to be 
crucial for recognition of microbes by the innate immune system and for bridging the 
innate and acquired immune response (Netea et al., 2004; Wells et al., 2011).  
In the current study, recognition of C. difficile by a specific TLR was investigated using 
HEK293 cells, which were stably transfected with one or two TLR genes. Bacterial-induced 
IL-8 was measured as the biological readout of TLR stimulation.  
Bacterial cultures and supernatants of C. difficile strains caused a minimum induction of IL-8 
by untransfected HEK293 cells, while PFA-treated bacteria were able to trigger a better 
activation and significant release of IL-8; whether or not secreted toxins by live bacteria 
have a role in suppressing TLR signalling remains to be determined. Interestingly, no 
significant difference was observed in recognition of C. difficile bacterial culture and PFA-
fixed by TLR2/6, signifying that TLR2 is likely involved in recognition of C. difficile 
peptidoglycan-related molecules. 
 TLR5 appeared to respond to PFA-fixed bacteria more strongly than bacterial culture, while 
no significant difference was detected between TLR5 cells infected with bacterial culture 
and supernatant indicating that the supernatant may contain shed flagellin triggering 
similar responses to bacterial culture. Further, cells stimulated with 630 Δerm tcdA tcdB 
bacterial culture and supernatant showed increased IL-8 secretion compared to other 
strains. Although the reason for this phenomenon at present is unknown, one may 
speculate that as strain 630 Δerm was produced by continues subculturing it might 
influence expressed phenotypes consequently affecting its recognition by TLR5. 
C. difficile bacterial culture and supernatant stimulated TLR2-CD14 and TLR4-CD14 
complexes in a similar extent. On the other hand, PFA-fixed bacteria stimulated TLR2-CD14 
2-3 times more than it stimulated TLR4-CD14. Although TLR2/1 heterodimer exhibited a 
significant level of IL-8 release in response to PFA-fixed bacteria and bacterial culture 
nevertheless showed a weak recognition of C. difficile strains compared to TLR2/6. Finally, 
TLR9 stimulation with C. difficile showed that TLR9 had no role in recognition of this 
bacterium and its components.  
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5.3.1 Summary 
 
Overall, it was observed that: 
 PFA-fixed bacteria were able to trigger a significant activation of examined TLRs 
compared to bacterial culture and supernatant.  
 C. difficile was recognised specifically with TLR2/6 and TLR5. 
 TLR2-CD14 complex may play a role in C. difficile recognition, while the role of 
TLR4-CD14 was not conclusive due to lack of MD-2 co-receptor. 
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Chapter 6  
Clostridium difficile-mediated    
Dendritic Cell Activation   
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6.1 Introduction 
 
The GI mucosa is in constant interaction with the luminal micro-environment and is 
monitored by a highly adaptable host defence system in which sentinels such as DCs, 
macrophages and IECs together monitor the microbial environment and coordinate 
immune responses to danger signals (Niess & Reinecker, 2005; Kelsall, 2008). In the 
intestinal mucosa, DCs are located in the PPs and lamina propria. DCs in PPs perform two 
important task; uptake of antigen after its transcytosis across the FAE, this is mediated by 
immature DCs, and T and B cells activation by mature DCs in T cell areas. Furthermore, PP 
DCs promote the differentiation of B cells into IgA-secreting cells (Iliev et al., 2007; Kelsall, 
2008). 
DCs can produce an array of cytokines such as IL-10, IL-6, IL-12 and its family members IL-23 
and IL-27. The IL-12 family of cytokines have a central role in Th1 responses. IL-12 is a 
heterodimer formed by two subunits; p35 and p40. Although IL-12 was identified as a 
unique heterodimeric cytokine, it was recognised that the IL-12p35 subunit is homologous 
to type I cytokines, such as IL-6, and that the IL-12p40 is structurally related to the soluble 
IL-6 receptor (IL-6Rα) (Trinchieri, 2003). IL-23 and IL-27 are two other IL-12 family members. 
IL-23 is composed of two covalently linked subunits: IL-23p19, which was identified on the 
basis of its homology with IL-6 and the p35 chain, and is distantly related to IL-12p40. IL-23 
enhances Th17 cell activity by acting on differentiated Th17 cells, which express the IL-23 
receptor chain. IL-27 is a heterdimeric cytokine composed of an IL-27p28 (p28) and Epstein 
Barr virus induced gene 3 (EBI3) subunits. The p28 subunit is homologous to IL-12p35 and 
IL-6, whereas EBI3 structurally resembles the IL-12p40 subunit and shares homology with 
IL-6Rα. Although, IL-27 is similar to IL-12 and IL-23 it is unique in that the p28 and EBI3 
subunits are not held together by disulphide bonds. IL-27 promotes early commitment of 
naive T cells to the Th1 cell-lineage and also modulates pro- and anti-inflammatory 
activities (Hunter, 2005; Goriely et al., 2008; Gee et al., 2009). 
To date, a limited number of studies have examined the role of C. difficile in DC activation 
and maturation, and subsequent initiation of acquired immunity. In 2006, Ausiello et al. 
showed that C. difficile SLPs from clinical isolates were able to induce the release of 
significant amounts of IL-1β and IL-6, and maturation of human DCs. The authors showed 
that SLPs caused Th1/Th2 polarisation as evidenced by comparable levels of IFN-γ and IL-5 
induction. They concluded that SLPs by perturbing the fine balance of inflammatory and 
regulatory cytokines may play a role in the pathogenicity of C. difficile. The same group in a 
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recent study compared the immunomodulatory activities of purified SLPs from 
hypervirulent-epidemic strains (ribotype 027 and 001) versus non-hypervirulent-epidemic 
strains (ribotype 012). They detected high levels of IL-1β and IL-6 secretion, and also IL-10 
but not IL-12p70, while in the previous study they reported higher amounts of IL-12p70 
than IL-10. Overall, the results suggested that SLPs from hypervirulent-epidemic strains 
trigger similar inflammatory responses as to non-hypervirulent-epidemic strains, thus, SLP-
mediated immunity is not ribotype specific (Bianco et al., 2011).  
So far, no studies have shown the impact of C. difficile itself on DC activation and 
subsequent T cell immunity, thus, the aim of this study was to investigate the ability of C. 
difficile strains to modulate the function of human and murine DCs in the induction of pro- 
or anti-inflammatory cytokines and to evaluate T cell response in C. difficile-primed murine 
DCs. Studies have begun to highlight how C. difficile toxins mediate excess IL-1β secretion 
leading to tissue damage, these studies have mainly been investigated in macrophages. In 
the present study how C. difficile may modulate DC inflammasome activation and 
subsequent IL-1β was assessed.  
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6.2 Murine Bone-marrow-derived Dendritic Cell (BMDC) 
Immune Response(s) to C. difficile Strains 
 
Dendritic cells are key elements linking innate and adaptive immune responses to infection. 
Immature DCs respond to pathogen-derived products by initiating a maturation program 
that induces their migration to lymphoid organs and ultimately leads to the presentation of 
antigens associated with MHC molecules, the expression of co-stimulatory molecules and 
the secretion of cytokines that activate antigen-specific T cells (Niedergang & Kweon, 2005).  
In this study, C. difficile-mediated effects on DCs and subsequent DC driven-T cell immunity 
was initially investigated in the murine model as it provides a genetically homogenous 
model system to decipher host-pathogen interactions. BMDCs were harvested from 
C57BL/6 mice and stimulated with C. difficile strains R20291 (Hypervirulent), 630 (A+B+) and 
M68 and CF5 (A-B+). In these series of experiments LPS from E. coli was utilised as a 
reference stimulus.  
 
6.2.1 Dendritic Cell Maturation Induced by C. difficile Strains 
 
DCs can broadly exist in two main states of maturation; immature and mature or activated, 
with respect to their function as APCs and capacity to induce a primary immune response. 
Maturation or activation of DCs occurs after exposure to pathogens, when DCs migrate to 
secondary lymphoid organs and express molecules such as, MHC-peptide complexes, co-
stimulatory molecules, chemokines, and inflammatory cytokines, which enable DCs to 
interact with T cells so as to initiate an acquired immune response (Wilson & O’Neill, 2003).  
To investigate whether C. difficile can influence the expression of cell surface markers, 
BMDCs were infected with C. difficile bacterial cultures at an MOI of 10. At 8 h post-
infection, expression of co-stimulatory molecules CD80, CD86, MHC class II and CD40 was 
investigated by flow cytometry and presented as the mean fluorescence intensity (MFI) fold 
increase of the marker-specific antibody (Figures 6.1 a-d). 
Cells infected with strain R20291 and M68 showed an approximate 1.5-fold increase in 
CD80 up-regulation, with CF5 causing a modest ≥ 1-fold increase. In comparison, 630-
mediated CD80 up-regulation was significantly higher than that observed with the other 
strains (Figure 6.1 a).  
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Strains R20291 and 630 caused ≥ 1.5-fold up-regulation of CD86 molecule, whilst M68 
showed <1.5-fold CD86 change. Once more, CF5 caused significantly less CD86 up-
regulation exhibiting ≥ 1-fold increase (Figure 6.1 b). 
MHCII, a mature DC marker was up-regulated <2-fold in response to R20291 and ≥ 1-fold to 
strain 630. M68 and CF5 caused similar MHCII fold increase (2-fold), while CF5 showed a 
significant increase compared to strain 630 (Figure 6.1 c). 
CD40 was modulated less than 2-fold in response to stimulation with strain R20291, strain 
630 showed ≥ 1-fold increase. Strain M68 caused similar CD40 fold change as R20291 (≤ 2), 
while CD40 was enhanced 3-fold in response to CF5 (Figure 6.1 d). 
In summary, this data suggested that C. difficile strains caused a moderate up-regulation of 
co-stimulatory molecules CD80 and CD86, as well as surface expression of MHC class II and 
accessory cell molecule CD40. While, strain CF5 showed the least modulation of CD80 and 
CD86, it induced comparatively higher up-regulation of MHCII and CD40. 
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Figure 6.1. C. difficile induces maturation of BMDCs by modulating cell surface markers. 
BMDCs were infected with C. difficile bacterial cultures at an MOI of 10. At 8 h post-
stimulation, cells were labelled with mouse CD80, CD86, MHCII and CD40 antibodies and 
analysed by flow cytometry (a). The level of surface expression was quantified and 
presented as MFI fold increase (b-e). 1 μg/μl LPS was utilised as a reference stimulus. Data 
represent mean ± SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 represent significant 
difference from uninfected cells and ^p<0.05, ^^p<0.01 and ^^^p<0.001 represent significant 
inter-strain difference. P values were obtained using ANOVA with Bonferroni post-test 
analysis.   
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6.2.2 C. difficile-mediated Cytokine Gene Expression in BMDC 
 
The interaction between DCs and pathogens are of prime importance in establishing an 
appropriate immune response. To investigate C. difficile-mediated inflammatory cytokine 
mRNA expression, BMDCs were infected with C. difficile bacterial cultures at an MOI of 10. 
Gene expression of IL-12 family (IL-12, IL-23, and IL-27) subunits (IL-12: p35/p40; IL-23: 
p19/p40; IL-27: EBI3/p28), IL-10, IL-6, and IL-1β was measured by quantitative real-time 
PCR at 2, 4, 6, and 8 h post-infection and presented as a fold increase relative to uninfected 
control cells (Figure 6.2 a-h).  
Infected cells were examined for expression of IL-12 subunits; p35/p40. All strains induced 
p35 expression in a time-dependent manner (Figure 6.2 a). The expression increased 
progressively peaking at 6 h post-infection although magnitude of expression varied 
between strains. Strains R20291 and CF5 caused a significant p35 modulation at 6 and 8 h 
compared to 630 and M68 (Figure 6.2 a).   
P40 subunit, which is shared by IL-12 and IL-23 cytokines, exhibited a 3-fold increase in 
response to bacterial infection at 2 h (Figure 6.2 b). P40 expression also increased 
progressively and reached its peak at 6 h thus following the same profile as p35 expression. 
At 8 h a moderate decrease was observed with all four strains. Interestingly, as seen for 
p35, R20291 and CF5 showed a significant increase in p40 at 6 and 8 h post-infection 
compared to strain 630 and M68 (Figure 6.2 b).  
Expression of p19, a subunit unique to IL-23 showed 25-fold increase at 2 h and was 
enhanced further reaching maximum levels at 4 h (Figure 6.2 c). It is worth noting that p19 
exhibited the highest fold-induction in this family of cytokines. Between 4 and 6 h, unlike 
the increase observed for p35 and p40, the expression profile varied amongst the various 
strains. The expression levels decreased in all four strains at 8 h post-infection. R20291 
caused significant p19 mRNA expression at 4, 6, and 8 h post-infection when compared 
with the other strains (Figure 6.2 c).  
Expression of EBI3 and p28, IL-27 subunits were observed in C. difficile infected cells. A very 
modest induction in EBI3 was noted at 2 h, expression reached its maximum at 6 h with a 
moderate increase ranging between 2.5 to 4-fold. At 8 h, EBI3 mRNA level declined in cells 
infected with R20291 and 630. R20291 was statistically significant at 6 and 8 h compared to 
strain 630, while CF showed a significant increase at 8 h compared to 630 (Figure 6.2 d).  
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In contrast, infected cells showed a better response to p28 induction (Figure 6.2 e). A 4.5-
fold increase was observed at 2 h, mRNA expression increased gradually and reached its 
peak at 6 h, the increase measured ranged between 40 and 220-fold. At 8 h p28 mRNA 
expression declined in all four strains. Yet again, R20291 showed significant gene 
expression at 4, 6, and 8 h, while CF5 was statistically significant at 6 and 8 h compared to 
strains 630 and M68 (Figure 6.2 e). 
C. difficile infection modulated DC anti-inflammatory response as measured by IL-10 
production (Figure 6.2 f). A marked increase in IL-10 mRNA expression was detected as 
early as 2 h. At 4 h, IL-10 expression increased further and this continued till 8 h. At 8 h, all 
strains showed an increase in IL-10, while CF5 caused statistically significant mRNA 
expression compared to 630 (Figure 6.2 f). 
C. difficile Infected cells showed increase in IL-6 expression at 2 h (Figure 6.2 g) mRNA 
expression increased steadily up to 6 h post-infection. At 8 h, IL-6 mRNA levels showed a 
moderate decline in all four strains; furthermore, no significant inter-strain difference was 
detected at any examined time-points (Figure 6.2 g).  
Measurement of IL-1β gene expression showed ~20-fold increase in C. difficile infected cells 
at 2 h (Figure 6.2 h). IL-1β expression was up-regulated further at 4 h. At 6 h, strains 
R20291, 630, and M68 showed increased modulation, whereas CF5 remained unchanged. 
No significant inter-strain difference was detected in IL-1β gene expression at any time-
points measured (Figure 6.2 h). 
Taken all together, this data indicated that C. difficile strains mediated changes in pro-
inflammatory mRNA expression which showed maximal response between 4 and 6 h post-
infection, and declined by 8 h. In contrast, IL-10 gene expression continued to show a 
significant increase at 8 h. Strains R20291 and CF5 were statistically significant in 
modulating p35, p40, and p28 gene expression at 6 and 8 h compared to strains 630 and 
M68. 
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Figure 6.2. Cytokine mRNA expression in response to C. difficile infection in BMDCs. 
BMDCs were infected with C. difficile cultures at an MOI of 10. Gene modulation of IL-12 
family subunits; p35 (a), p40 (b), p19 (c), EBI3 (d), and p28 (e), as well as IL-10 (f), IL-6 (g) 
and IL-1β (h) were measured by real-time PCR and normalised to uninfected control cells 
and presented as a fold increase. Reactions for each sample were conducted in duplicate. 
Data represent mean ± SEM, n=3. */^p<0.05, **/^^p<0.001, and ***/^^^p<0.001 represent 
significant inter-strain difference. P values were obtained using ANOVA with Bonferroni 
post-test analysis.  
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6.2.3 C. difficile-induced Cytokine Production by BMDC  
 
Dendritic cells upon interaction with bacteria characteristically release a range of both pro-
and anti-inflammatory cytokines. Following assessment of cytokine gene expression in 
response to C. difficile infection, cytokine protein secretion was investigated. BMDCs were 
infected with C. difficile cultures at an MOI of 10 and induction of IL-12 family (IL-12, IL-23, 
and IL-27), IL-10, TNF-α, and IL-1β cytokines was measured 8 h post-infection (Figures 6.3 a-
f).  
IL-12 was detected at a basal level of ~10 pg/ml in uninfected control cells. R20291 
enhanced IL-12 secretion up to 80 pg/ml, while strain 630 caused ~35 pg/ml induction. 
Strain M68 mediated intermediate levels, whereas CF5 exhibited significant IL-12 release 
(>200 pg/ml) compared to the other strains (Figure 6.3 a).  
IL-23 was almost undetectable in uninfected control cells. Upon infection with R20291 
significant increase in IL-23 was observed, whilst 630 caused more modest increase. M68 
and CF5 induced between 300 and 400 pg/ml of IL-23. This data clearly showed the 
differential capacity of the various C. difficile strains to modulate IL-23 (Figure 6.3 b).  
IL-27 release in uninfected control BMDC was low (~6 pg/ml). R20291 showed greater 
ability to induce IL-27 when compared to the 630 (180 versus 50 pg/ml). M68 was as 
equipotent as R20291, while CF5 enhanced IL-27 secretion to ~350 pg/ml. CF5 showed a 
significant IL-27 release compared to the other strains (Figure 6.3 c).  
Uninfected control BMDCs did exhibit spontaneous IL-10 secretion. Infection with R20291 
caused a 7 to 8-fold increase in IL-10 protein levels with a 3 to 4-fold seen in response to 
strain 630. Strain M68 showed similar ability as R20291, while strain CF5 caused 
significantly marked increase in IL-10 compared to other strains (Figure 6.3 d).  
Uninfected BMDCs secrete TNF-α, this level increased upon infection with strain R20291 to 
a significant level (7000 pg/ml). Strain 630 was less potent (~6000 pg/ml) while M68 and 
CF5 induced similar levels to strain R20291 (Figure 6.3 e).     
Low levels (~15 pg/ml) of IL-1β were measured in uninfected BMDC. Upon infection with 
strain R20291, IL-1β secretion increased to >3000 pg/ml, whilst 630 caused less. Strain M68 
exhibited similar IL-1β induction as R20291 (>3000 pg/ml) while CF5 showed significantly 
less ability to modulate IL-1β. Amongst the various cytokines tested, IL-1β was the first 
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cytokine where the examined bacterial strains showed marked variation in their ability to 
modulate a pro-inflammatory cytokine (Figure 6.3 f).  
In summary, strain CF5 induced significant amounts of IL-12 family and IL-10 compared to 
the other strains and yet, at the same time was least inducer of IL-1β. The APCs such as 
BMDCs clearly have the ability to detect and mount differential responses to individual C. 
difficile strains, thus fine tuning their response(s) to each stimulus. 
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Figure 6.3. Cytokine induction by BMDCs in response to C. difficile infection. BMDCs were 
infected with C. difficile cultures at an MOI of 10. IL-12 (a), IL-23 (b), IL-27 (c), IL-10 (d), TNF-
α (e), and IL-1β (f) were measured by ELISA at 8 h post-infection. 1 μg/μl LPS was utilised as 
a reference stimulus. Data represent mean ± SEM of duplicate samples and are 
representative of three individual experiments. */^p<0.05, **/^^p<0.01 and ***/^^^p<0.001 
represent significant difference from uninfected cells and significant inter-strain difference. 
P values were obtained using ANOVA with Bonferroni post-test analysis.   
(e) 
(d) 
(f) 
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6.3 The Inflammasome Activation Mediated by C. difficile 
 
The inflammasome is a caspase-activating complex that mediates the activation of caspase-
1, which is the enzyme responsible for cleaving inactive pro-IL-1β and IL-18 into their 
bioactive form. This process is linked with secretion of the bioactive form. The molecular 
platform for caspase-1 activation includes NLR family members such as; NLRP1, NLRP3 
(NALP3) and NLRC4 (IPAF) and AIM2 (absent in melanoma 2). All four proteins recognise 
microbial products and upon engagement each can trigger initiation of inflammasome 
formation in an independent manner. An adaptor protein, ASC (apoptosis-associated speck-
like protein containing a CARD domain) is common to all these inflammasome platforms. 
ASC contains an N-terminal pyrin domain and a C-terminal CARD domain, both enabling 
ASC to recruit other pyrin- and CARD-containing domains through protein-protein 
interactions linking NLRs to caspase-1 (Yu & Finlay, 2008; Franchi et al., 2009).  
Caspase-1 is present in the cytosol of phagocytic cells as an inactive zymogen. Caspase-1 is 
activated by auto-proteolytic cleavage leading to the generation of two subunits (10 and 20 
kDa). Mature IL-1β and IL-18 have been linked to many immune reactions, including the 
recruitment of inflammatory cells to the site of infection, production of IFN-γ and 
enhancement of the cytolytic activity of natural killer cells (Lamkanfi et al., 2007; Yu & 
Finlay, 2008; Franchi et al., 2009). 
Recently, Ng et al. reported that C. difficile toxins (40 μg/ml TcdA and 2.5 μg/ml TcdB) 
trigger inflammasome-dependent release of IL-1β. They showed that inhibition of 
inflammasome signalling through deletion of ASC, completely abrogated caspase-1 
activation and IL-1β processing in vitro, and significantly reduced toxin-induced intestinal 
injury in vivo, concluding an ASC-dependent activation of the inflammasome by C. difficile 
toxins (Ng et al., 2010). 
Although toxins clearly activate the inflammasome complex, what is unclear is whether the 
bacterial cell itself participates in these reactions. Also the individual components involved 
during C. difficile-mediated IL-β release are not defined yet. The aim of this study was to 
investigate the potential role of C. difficile bacterial components in triggering the activation 
of the inflammasome.  
 
 
189 
 
6.3.1 Caspase-1 Activation in Response to C. difficile Strains 
 
To assess whether C. difficile-induced IL-1β processing was caspase-1 dependent, BMDCs 
from wild-type (WT) C57BL/6 (genetically Nlrp1 deficient), Nod2-/-, Ipaf-/-, Nlrp3-/-, and ASC-/- 
mice were infected with C. difficile cultures at an MOI of 10. At 8 h post-infection cell 
extracts were analysed for the extent of caspase-1 activation and IL-1β release (Figure 6.4 
a-k). Pro-caspase-1 was detected as a 45 kDa propeptide and active caspase-1 as a 10 kDa 
subunit, while pro-IL-1β and IL-1β are 31 kDa and 17 kDa size proteins respectively. In these 
experiments ATP was used as a positive control to activate the inflammasome (Figure 6.4 a-
k).  
Pro-caspase-1 and pro-IL-1β were detected in uninfected control WT and knock-out (KO) 
BMDCs (Figure 6.4 a-j). Infection with C. difficile strains caused release of active caspase-1 
(Figure 6.4 a), and mature IL-β in WT BMDCs (Figure 6.4 b).  
Similar results, detecting pro- and active caspase-1 were observed in Nod2-/- (Figure 6.4 c), 
Ipaf-/- (Figure 6.4 e), and Nlrp3-/- (Figure 6.4 g) infected BMDCs, followed by the detection of 
pro-IL-1β and release of mature IL-1β in Nod2-/- (Figure 6.4 d), Ipaf-/- (Figure 6.4 f), and 
Nlrp3-/- (Figure 6.4 h).  
Pro-caspase-1 and pro-IL-1β were detected in ASC-/- uninfected control and C. difficile 
infected BMDCs. In contrast, caspase-1 activation and IL-1β production were completely 
absent in infected ASC-/- cells (Figure 6.4 i & j).  
Taken all together, this data suggested that C. difficile strains induced mature IL-1β in a 
caspase- and ASC-dependent manner consistent with inflammasome activation. 
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Figure 6.4. C. difficile triggers caspase-1 activation and IL-1β secretion. BMDCs from WT 
mice (a-b) and mice deficient in Nod2 (c-d), Ipaf (e-f), Nlrp3 (g-h) and ASC (i-j) were infected 
with C. difficile bacterial cultures at an MOI of 10. Immunoblotting was used to detect pro- 
and active caspase-1 (45 & 10 kDa, respectively) and pro- and mature IL-1β (31 & 17 kDa, 
respectively) release in cell extracts at 8 h post-infection. ATP (5 mM) was used as a 
stimulator of inflammasome activation. β-actin (45 kDa) was used as a loading control (k).   
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6.3.2 C. difficile-induced IL-1β Secretion 
 
IL-1β, produced by activated macrophages, monocytes, and DCs is a potent pro-
inflammatory cytokine and a key immune modulator, controlling both the induction of 
localised inflammation as well the recruitment and activation of the adaptive immune 
response. Induction of IL-1β in response to C. difficile infection was investigated by utilising 
BMDCs from WT (C57BL/6, genetically Nlrp1 deficient), Nod2, Ipaf, Nlrp3, and ASC KO mice. 
Cells were infected with C. difficile strains and 017 ribotype strains including: CF2, CF3, 
CD586, CD636, and CD816 at an MOI of 10 and IL-1β induction in response to infection was 
measured at 8 h post-infection (Figure 6.5 a-d).   
Uninfected WT, Nod2-/-, Ipaf-/-, Nlrp3-/-, and ASC-/- control BMDCs showed a basal level of 
<20 pg/ml IL-1β (Figure 6.5 a-d). Upon infection with R20291 ≥ 2000 pg/ml IL-1β was 
secreted in WT, Nod2-/-, and Ipaf-/- cells. Similar IL-1β secretion was observed in response to 
strains 630 and M68. In contrast, CF5 caused significantly less release of IL-1β compared to 
the other strains. It was originally hypothesised that CF5 causes minimal IL-1β secretion due 
to lack of caspase-1 activation, however as seen earlier CF5 is equipotent in causing 
caspase-1 activation when compared to the other strains (Figure 6.5 a), so a molecular 
explanation of how CF5 infection leads to minimal IL-1β secretion remains unknown. 
Elevated levels of IL-1β however were observed in Nod2-/- and Ipaf-/- infected cells (450, 600 
pg/ml; respectively) compared to WT BMDCs (80 pg/ml), which was not statistically 
significant (Figure 6.5 a).  
The effect of C. difficile in the activation of the inflammasome leading to IL-1β release was 
examined using Nlrp3-/- and ASC-/- BMDCs. Strain R20291 caused release of 1700 pg/ml IL-
1β in Nlrp3 KO DCs, while 630 induced >2000 pg/ml and M68 showed ~2600 pg/ml IL-1β 
secretion. Strain CF5 yet again caused significantly less IL-1β when compared with the other 
strains (~780 pg/ml). R20291, 630, and M68-induced IL-1β response in ASC deficient BMDCs 
were significantly less compared to WT and Nlrp3-/- cells (<50 pg/ml) (Figure 6.5 b). 
As CF5-induced IL-1β to a significantly less extent, five ribotype 017 strains including CF2, 
CF3, CD586, CD636, and CD816 were employed to investigate whether ribotype 017 strains 
shared the property of reduced IL-1β secretion with CF5. WT BMDCs infected with CF5 and 
ribotype 017 strains showed 40-110 pg/ml IL-1β release, indicating these strains share the 
ability of being weak inducer of IL-1β compared to R20291, 630 and M68. The induction of 
IL-1β was increased in infected Nod2-/- cells with ribotype 017 strains (80-280 pg/ml) as was 
194 
 
observed with CF5. This increase in IL-1β responses was not statistically significant. CF5 
caused 600 pg/ml IL-1β release in infected Ipaf-/- cells, similar responses were detected in 
cells infected with ribotype 017 strains (Figure 6.5 c). Stimulation of Nlrp3 deficient BMDCs 
with ribotype 017 strains and CF5 induced efficient IL-1β secretion (ranging between 150-
700 pg/ml) but the responses were markedly attenuated in ASC-/- BMDCs (Figure 6.5 d). 
This study showed that C. difficile strains triggered the IL-1β release by activating an ASC-
containing inflammasome and that they caused IL-1β processing in the examined three cell 
types Nod2-/-, Ipaf-/-, and Nlrp3-/-, ruling out critical roles for these NLRs in the activation of 
the inflammasome. Also it was observed that ribotype 017 strains excluding M68, caused 
the least IL-1β release in infected WT DCs but unexpectedly Nod2, Ipaf and Nlrp3 deficiency 
enhanced potency of these strains leading to increased levels of IL-1β secretion. 
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Figure 6.5. C. difficile toxins trigger IL-1β release by activating an ASC-containing 
inflammasome. BMDCs from WT C57BL/6 (genetically Nlrp1 deficient) mice and mice 
deficient in Nod2, Ipaf (Nlrc4), Nlrp3, and ASC were infected with C. difficile strains as well 
as five ribotype 017 strains at an MOI of 10. IL-1β release was measured by ELISA at 8 h 
post-infection. 1 μg/μl LPS was utilised as a reference stimulus. Data represent mean ± 
SEM, n=4. ***p<0.001 represents significant WT difference from ASC-/-, ^^^p<0.001 
represents significant Nlrp3-/- difference from ASC-/-, ###p<0.001 represent significant CF5 
difference from strains R20291, 630, and M68, ~~p<0.01 represents significant WT 
difference from Ipaf-/-, and +p<0.05 represents significant strain CF5 difference from 
ribotype 017 strains. P values were obtained using ANOVA with Bonferroni post-test 
analysis.  
 
 
 
 
 
 
 
 
 
(d) 
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6.4 Innate Immune Response of Human Dendritic Cells to C. 
difficile Strains 
 
The murine model of C. difficile infection showed that C. difficile strains were able to 
modulated murine BMDC cytokine responses. Human DCs were utilised to determine 
whether similar mechanisms were at play during C. difficile-mediated human DC activation. 
Human monocyte-derived DCs were infected with C. difficile cultures at an MOI of 10 and 
induction of IL-12, IL-10, and IL-1β cytokines were measured at 8 h post-infection (Figures 
6.6 a-c).  
Cells infected with R20291 showed <400 pg/ml IL-12 secretion, while strains 630 and M68 
showed median induction of ~140 pg/ml. CF5-induced IL-12 was similar to that observed 
with R20291 (~400 pg/ml) showing significant IL-12 increase compared to uninfected cells, 
however, no significant inter-strain difference was observed (Figure 6.6 a). Although, strains 
630, M68 and CF5 showed similar trend of IL-12 secretion with that observed in BMDC 
data, R20291 caused significantly high levels of IL-12 in human DCs compared to murine 
DCs.  
Infected cells were also examined for induction of anti-inflammatory IL-10 (Figure 6.6 b). IL-
10 expression was increased in response to infection with R20291 reaching to median 500 
pg/ml. Similar IL-10 induction was detected in DCs infected with 630, M68 and CF5. All 
strains were statistically significant compared to uninfected control cells and no inter-strain 
difference was detected (Figure 6.6 b). Comparatively, strain CF5 caused significantly higher 
secretion of IL-10 in BMDC compared to the other strains (p<0.001) while human DCs 
showed similar IL-10 response to all four strains.  
Furthermore, C.difficile-induced IL-1β was measured in infected cells (Figure 6.6 c). 
Minimum level of IL-1β detected in uninfected control cells was 18 pg/ml. IL-1β induction 
was increased significantly in response to R20291 infection (750 pg/ml) while cells infected 
with 630 and M68 showed similar level of IL-1β secretion (380 pg/ml). In comparison, strain 
CF5 caused the least expression of IL-1β (150 pg/ml) (Figure 6.6 c). Although no significant 
inter-strain difference in IL-1β response was observed in human DCs, CF5 showed the least 
secretion, the same results were also detected in BMDC showing CF5 caused significantly 
less IL-1β compared to other strains (p<0.001).  
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Figure 6.6. Effect of C. difficile strains on IL-12, IL-10, and IL-1β production by human DC. 
Human DCs obtained from nine healthy donors were stimulated with C. difficile bacterial 
cultures at an MOI of 10. IL-12 (a), IL-10 (b) and IL-1β (c) induction was measured by ELISA 
at 8 h post-infection. 1 μg/μl LPS was utilised as a reference stimulus. **p<0.01 and 
***p<0.001 represent significant difference from uninfected control cells. Data was analysed 
using Mann-Whitney U test.  
(a) 
(b) 
(c) 
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6.5 Role of C. difficile-stimulated Dendritic Cells on T Cell 
Activation 
 
The generation of adaptive immunity begins with DCs capturing microbial antigens in the 
peripheral tissues. Subsequently, DCs migrate to the draining lymph nodes to present the 
processed peptides to naive T lymphocytes in the context of MHC molecules. In transit, DCs 
also undergo a maturation program that enables the cells to stimulate naive T cells. Once 
inside the lymph nodes, DCs migrate to the T cell areas, seek out antigen-specific T cells and 
induce their activation and differentiation into effector cells. Depending on the density of 
the presented peptides, types of expressed co-stimulatory molecules, and secreted 
cytokines by the DCs, naive CD4+ T cells differentiate into either Th1 or Th2 cells (Iwasaki & 
Medzhitov, 2004). Th1 cells can release the signature cytokine IFN-γ and activate 
macrophages, whereas Th2 cells produce IL-4 and drive the immunoglobulin isotype 
switching of B cells to IgG1 and IgE (Rescigno, 2002; Reiner, 2007).  
One of the most critical cytokines produced by DCs for the induction and growth factor of 
polarised Th1 responses is IL-12 insofar as it represses expression of the transcription factor 
GATA-3, a key regulator of Th2 commitment. IL-23, another IL-12 family member, which 
shares use of the p40 subunit of IL-12, drive T cells to express the signature cytokines of the 
IL-17 family members, resulted in the term Th17 cells, but it is now known that they also 
secrete IL-22 (Reiner, 2007). IL-27 is homologous to IL-12 and has a role in the development 
of Th1-cell responses; however, the evidence from in vivo models of parasitic infection has 
revealed the anti-inflammatory properties of IL-27 (Hunter, 2005).  
To date, limited numbers of studies have investigated T cell activation and differentiation in 
response to C. difficile-matured DCs and their cytokine production profile, which are the 
determinants of the balance between Th1/Th2 responses, by utilising primarily C. difficile 
SLPs (Ausiello et al., 2006) or direct interaction of C. difficile toxins with T cells (Daubener et 
al., 1988; Mahida et al., 1998; Solomon et al., 2005; Wanahita et al., 2006). Thus, the aim of 
this study was to investigate the cross-talk of whole bacterial cell activated DCs with T cells. 
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6.5.1 T cell Proliferation in Response to C. difficile-stimulated Dendritic 
Cells 
 
To investigate the proliferative response of T cells to C. difficile-stimulated DCs from WT 
mice, BMDCs were infected with PFA fixed C. difficile strains at an MOI of 50. At 24 h post-
infection C. difficile-stimulated DCs were co-cultured with CFSE-labelled splenocytes of WT 
mice in the presence of anti-CD3/CD28. Co-cultures were analysed after 72-96 h post-
infection by flow cytometry gated on CD4+ cells (Figure 6.7 a), then quantified and 
presented as percentage of divided and undivided cells (Figure 6.7 b). 
CFSE-labelled splenocytes in the absence of DCs (media only), showed no cell division. Co-
cultured splenocytes with DCs in the presence of anti-CD3/CD28 initiated a cell proliferation 
(Figure 6.7 a). No more than 1.5% of cells were proliferated in the absence of DCs (media 
only). Cell division increased to 60% in the presence of uninfected DCs. C. difficile-
stimulated DCs caused 74% cell proliferation; however, cell division resulted by uninfected 
DCs was not statistically different from proliferated cells caused by infected DCs; moreover, 
there was no significant inter-strain difference (Figure 6.7 b). 
Same experiments were performed stimulating BMDCs from WT mice with PFA fixed C. 
difficile strains at an MOI of 50. At 24 h post-infection CFSE-labelled naive CD4+ T cells from 
OT-II transgenic mice were co-cultured with C. difficile-stimulated DCs in the presence of 
OVA323-339. Co-cultures were analysed by flow cytometry after 72-96 h (Figure 6.8 a), then 
results were quantified and presented as percentage of proliferated and un-proliferated 
cells (Figure 6.8 b).  
No cell division was observed in CFSE-labelled naive CD4+ T cells in the absence of DCs 
(media only), however, CD4+ T cells co-cultured with BMDCs initiated a cell division (Figure 
6.8 a). CD4+ T cells in the absence of DCs showed <1% cell division, this percentage was 
enhanced to 68% in the presence of uninfected DCs. CD4+ T cells co-cultured with R20291, 
630, and M68 stimulated DCs proliferated >80%, which was statistically significant 
compared to uninfected DCs (p<0.01). On the other hand, CF5 infected DCs caused 72% 
division that was not significantly different from uninfected DCs (Figure 6.8 b).  
Taken all together, this data suggested that C. difficile-stimulated DCs were able to induce T 
cell proliferation.  
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Figure 6.7. In vitro proliferation of splenocytes in response to C. difficile-stimulated 
BMDCs.  BMDCs from WT mice were infected with PFA fixed C. difficile strains at an MOI of 
50. At 24 h post-infection C. difficile-stimulated DCs were co-cultured with CFSE-labelled 
splenocytes of WT mice in the presence of anti-CD3/CD28. 1 μg/μl LPS was utilised as a 
reference stimulus. Co-cultures were analysed after 72-96 h post-infection by flow 
cytometry gated on CD4+ cells, then quantified and presented as percentage of divided and 
undivided cells. Data was analysed using ANOVA with Bonferroni post-test.  
 
(a) 
(b) 
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Figure 6.8. Naive CD4+ T cell proliferation in response to C. difficile-stimulated BMDCs. 
BMDCs from WT mice were infected with PFA fixed C. difficile strains at an MOI of 50. At 24 
h post-infection CFSE-labelled naive CD4+ T cells from OT-II transgenic mice were co-
cultured with C. difficile-stimulated DCs in the presence of OVA323-339. 1 μg/μl LPS was 
utilised as a reference stimulus. Co-cultures were analysed by flow cytometry after 72-96 h. 
Results were quantified and presented as percentage of proliferated and un-proliferated 
cells. Data was analysed using ANOVA with Bonferroni post-test.  
 
(a) 
(b) 
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6.5.2 Naive CD4+ T Cell Cytokine Response(s) to C. difficile-stimulated 
BMDC 
 
To investigate the ability of C. difficile-stimulated BMDCs to induce a T cell response, naive 
OT-II CD4+ T cells were co-cultured with bacterial-stimulated BMDCs in the presence of 
OVA323-339 for 96 h. Cells were stained for cell surface expression of CD4 and intracellular 
expression of IFN-γ and IL-17. Stained cells were analysed by flow cytometry gated on CD4+ 
cells (Figure 6.9 a). Results were quantified and presented as percentage of cells that 
released intracellular IFN-γ and IL-17 (Figure 6.9 b & c). 
Cells gated on CD4+ cells were displayed in IFN-γ and IL-17 axis. In each graph CD4+ cells 
were shown on the bottom left panel, and IFN-γ+ cells on the top left panel. Cells that were 
positive for IL-17 were shown on the bottom right panel, while cells positive for both IFN-γ 
and IL-17 showed on top right panel (Figure 6.9 a). Figures 5.9 b and c shows percentage of 
IFN-γ+ and IL-17+ cells.   
Less than 3% of T cells co-cultured with uninfected DCs expressed IFN-γ. Upon co-culturing 
with R20291-stimulated BMDCs, IFN-γ induction was increased to 13%. Strain 630 caused 
5% secretion, while 10% IFN-γ release was detected in T cells co-cultured with M68 and 
CF5-stimulated DCs (Figure 6.9 b).  
Approximately 0.5% of T cells expressed IL-17 in response to co-culture with uninfected 
DCs. R20291 and 630 caused <1.5% of cells to induce IL-17, while M68 showed 1.7% of T 
cells to secrete IL-17, which was significantly higher than that observed with CF5 (1%) 
(Figure 6.9 c).   
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Figure 6.9. Intracellular IFN-γ and IL-17 staining in CD4+ naive T cells stimulated with C. 
difficile infected BMDC. Naive OT-II CD4+ T cells were co-cultured with C. difficile-stimulated 
BMDCs in the presence of OVA323-339 for 96 h. Cells were stained for cell surface expression 
of CD4 and intracellular expression of IFN-γ and IL-17, then analysed by flow cytometry 
gated on CD4+ cells and displayed in IFN-γ and IL-17 axis. In each graph CD4+ cells were 
shown on the bottom left panel, and IFN-γ+ cells on the top left panel. Cells that were 
positive for IL-17 were shown on the bottom right panel, and cells positive for both IFN-γ 
and IL-17 showed on top right panel (a). 1 μg/μl LPS was utilised as a reference stimulus. 
Quantified results were presented as percentage of IFN-γ+ (b) and IL-17+ (c) cells. Data 
represent mean ± SEM, n=3. */^p<0.5, **/^^p<0.01 and ***/^^^p<0.001 represent significant 
difference from uninfected controls and significant inter-strain difference. P values were 
obtained using ANOVA with Bonferroni post-test analysis.  
(b) 
(c) 
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6.5.3 Splenocytes Cytokine Response(s) to C. difficile-stimulated BMDC 
 
To investigate the cytokine production, splenocytes from WT mice were co-cultured with 
WT BMDCs (stimulated with PFA fixed C. difficile strains for 24 h) in the presence of anti-
CD3/CD28. At 96 h post-co-culture, supernatants were collected to detect IFN-γ, IL10, IL-
17A, IL-2, and IL-4 levels (Figure 6.10 a-e). 
Uninfected DCs showed 60 pg/ml IFN-γ secretion. Levels increased to 1000 pg/ml in 
response to R20291-stimulated BMDCs, which was significantly higher than that observed 
with strain 630 (400 pg/ml). Strain M68 showed >700 pg/ml IFN-γ release, while CF5 
induced 1000 pg/ml IFN-γ secretion (Figure 6.10 a).  
Approximately 200 pg/ml of IL-10 was detected in uninfected cells. Upon co-culture with 
R20291-stimulated BMDCs IL-10 secretion was increased to 2000 pg/ml. Strains 630, M68, 
and CF5 induced similar levels. No significant inter-strain difference in IL-10 induction was 
observed (Figure 6.10 b).  
IL-17A was detectable (145 pg/ml) in uninfected cells. The induction was increased to 
~1800 pg/ml in response to R20291 and 630-stimulated BMDCs. M68 showed 1500 pg/ml 
IL-17A release, whilst CF5 caused 520 pg/ml. It was detected that CF5-induced IL-17A was 
significantly less than strains R20291 and 630 (Figure 6.10 c).  
Detected IL-2 in uninfected cells was <40 pg/ml. Strains R20291 and M68 caused ~100 
pg/ml IL-2 secretion. Strain 630 showed a significant IL-2 induction compared to R20291 
and M68. Further, IL-2 secretion was significantly increased in response to CF5 when 
compared with the other strains (1000 pg/ml) (Figure 6.10 d).  
Splenocytes co-cultured with uninfected cells showed <20 pg/ml IL-4. Similar levels of IL-4 
secretion was detected in response to R20291, 630, and M68 ranging between 35-70 
pg/ml. Strain CF5 caused the highest IL-4 release (~100 pg/ml), which was statistically 
significant compared to the other strains (Figure 6.10 e).   
This data suggested that C. difficile can stimulate BMDCs to mount a strong IFN-γ, IL-10 and 
IL-17 cytokine responses in murine splenocytes. Interestingly, strain CF5 showed greater 
propensity for IL-2 and IL-4 production compared to other strains, adding weight to the 
suggestion that crosstalk between C. difficile and the host immune outcome is finely tuned 
at the molecular level. 
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Figure 6.10. Cytokine response of splenocytes stimulated with C. difficile infected BMDC. 
BMDCs from WT mice were infected with PFA fixed C. difficile strains at an MOI of 50. At 24 
post-infection, stimulated DCs were co-cultured with splenocytes from WT mice in the 
presence of anti-CD3/CD28. Supernatants were collected after 96 h co-culture and 
measured by ELISA for IFN-γ (a), IL-10 (b), IL-17A (c), IL-2 (d), and IL-4 (e) induction. 1 μg/μl 
LPS was utilised as a reference stimulus. Data represent mean ± SEM, n=3. */^p<0.05, 
**/^^p<0.01 and ***/^^^p<0.001 represent significant difference from uninfected cells and 
significant inter-strain difference. P values were obtained using ANOVA with Bonferroni 
post-test analysis.   
 
 
(d) 
(e) 
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6.6 Conclusions  
 
Dendritic cells are hematopoietic cells that belong to the APC family, which have a central 
role in both the priming of adaptive immune responses and the induction of self-tolerance. 
The mechanisms that are used by DCs to translate their environment so that facilitate 
lymphocytes activation, are represented in the concept of DC maturation. DC exists in two 
functional states, immature and mature, with only a mature DC having the ability to prime 
an immune response (Reis e Sousa, 2006). DCs can take up an array of antigens, process 
and present them in the form of peptides bound to both MHC class I and class II molecules. 
DCs undergo a process of maturation and migrate to secondary lymphoid organs where 
they stimulate naive T cells (Rescigno, 2002). Depending on the conditions, DCs can 
stimulate the outgrowth and activation of a variety of T cells, which affect the immune 
response differently. DCs are able to influence CD4+ naive T cells to differentiate into IFN-γ-
producing Th1 cells, or into IL-4-expressing Th2 cells (Banchereau & Steinman, 1998).  
In this study, C. difficile-mediated DC activation was established in murine model system. 
The maturation of murine BMDCs in response to infection with C. difficile was examined. 
Also the gene expression of IL-12 family subunits, IL-10, IL-6, and IL-1β was determined in a 
time-dependent-manner. The role of C. difficile strains in cytokine protein induction was 
examined in murine and human DCs. C. difficile-mediated activation of the inflammasome 
was determined by detecting active caspase-1 and mature IL-1β in infected BMDCs from 
WT, Nod2-/-, Ipaf-/-, ASC-/-, and Nlrp3-/- mice. IL-1β protein secretion was further investigated 
in response to C. difficile and ribotype 017 strains. Finally, T cell activation and proliferation 
was examined in response to stimulated murine BMDCs with PFA fixed C. difficile strains.  
It was observed that stimulation of BMDCs with C. difficile strains caused differential up-
regulation of the co-stimulatory molecules CD80, CD86 and cell surface markers MHCII and 
CD40. Compared to uninfected cells, strains R20291, 630, and M68 caused statistically 
significant up-regulation of co-stimulatory molecules CD80 and CD86. In contrast, CF5 
showed the highest CD40 fold increase. Lee et al. (2009) have shown that the expression of 
cell surface molecules CD80, CD86, MHCII, and CD40 on immature murine DCs were 
increased after exposure to 100 ng/ml purified TcdA and postulated that C. difficile TcdA 
can promote the maturation of DCs. However, in the current study strain M68 caused 
comparatively same levels of cell surface markers up-regulation to that observed with 
R20291 and 630. Furthermore, CF5 showed similar potential to R20291 and M68 in 
modulation of MHCII and CD40. Moreover, it has been shown that SLPs (35 μg/ml) from C. 
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difficile are able to induce maturation of human DCs by up-regulation of MHCII, CD83, and 
CD80 (Ausiello et al., 2006) therefore, it can be hypothesised that multiple factors are at 
play in C. difficile-mediated DC maturation. 
DCs produce various cytokines and chemokines upon interaction with bacteria. Cells 
infected with C. difficile strains showed maximal gene expression of IL-12p35, IL-12/IL-
23p40, IL-23p19, IL-27p28 & EBI3, IL-6, and IL-1β between 4 and 6 h post-infection 
indicating early sensing of C. difficile by DCs. On the contrast, IL-10 mRNA expression 
showed a significant up-regulation only at 8 h post-infection. It was also noted that strains 
R20291 and CF5 caused a significant gene modulation compared to strains 630 and M68. In 
addition, CF5 showed the highest IL-10 and the least IL-1β gene expression at 8 h 
correspondent to that observed with their protein secretion suggesting that CF5 mediates 
more anti-inflammatory response than pro-inflammatory compared to other strains.  
Gene expression analysis of the IL-12 cytokine family subunits revealed that C. difficile 
strains caused a significant IL-23p19 up-regulation compared to IL-12 and IL-27 subunits. 
Further on this note, it was detected that C. difficile infection caused a significant IL-23 
cytokine induction compared to the other IL-12 family members in BMDCs, hence the 
increased gene expression of IL-23p19 might be accountable for the predominant IL-23 
secretion leading to potent Th17 immunity.  
It was also noted that strains R20291 and M68 caused comparable protein expression of IL-
12 family, whilst CF5 showed the highest secretion; strain 630 was the least inducer of IL-12 
family cytokines. Further, infected BMDCs released larger amount of IL-23 and IL-27 
compared to IL-12 highlighting that C. difficile strains exhibit differential ability in 
modulating DC IL-12 family members which is likely to impact on downstream T cell 
immunity. The splenocytes co-cultured with stimulated BMDCs showed significant IFN-γ 
response compared to IL-4 induction, indicating that C. difficile promotes a shift in Th1/Th2 
balance toward Th1-dominant immunity. Also significant IL-17A secretion indicated that C. 
difficile infection mediates strong Th17 immunity as well as Th1, although the magnitude of 
the responses maybe strain-specific.  
Direct interaction between C. difficile toxins and T cells however has been controversial, 
while some studies argue that toxins only interact with monocytes and not with T cells 
(Daubener et al., 1988; Wanahita et al., 2006), there are investigations linking occurrence 
of T cell apoptosis following exposure to TcdA as a consequence of a direct interaction 
(Mahida et al., 1998; Solomon et al., 2005).   
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The current study showed that human and murine DCs released comparatively more IL-10 
in response to C. difficile infection than IL-12. In contrary, Ausiello and co-workers (2006) 
showed that C. difficile SLP-treated human monocyte-derived DCs secreted greater 
amounts of IL-12p70 than IL-10 and induced a mixed Th1/Th2 orientation of immune 
response in naive CD4 T cells. Thus, one may suggest that C. difficile cellular components 
may contribute differentially to the pathogenicity of the bacteria by perturbing the fine 
balance of pro- and anti-inflammatory responses.   
Ng et al. (2010) have previously highlighted the toxin-dependent release of IL-1β due to 
activation of the inflammasome in response to purified TcdA and TcdB. A study by Ausiello 
and colleagues has also suggested that C. difficile SLPs can cause IL-1β secretion from 
human DC. Taken together, one may speculate that several immunogenic structural 
determinants of C. difficile likely activate this pathway. Results gathered from human and 
murine DCs in this study clearly showed that strains R20291, 630, and M68 elicited a 
significant IL-1β release. In contrast, strain CF5 caused the least pro-inflammatory IL-1β 
response.  
Further investigation revealed that C. difficile strains activated caspase-1 and triggered IL-
1β release in infected DCs from WT mice as well as DCs deficient in Nod2, Ipaf, and Nlrp3. 
Hasegawa and co-workers have already shown that Nod1 deficient mice are more 
susceptible to C. difficile infection than Nod2 deficient mice. They suggested that Nod1 
directly recognises C. difficile and induces the recruitment of neutrophils to the site of the 
infection in order to clear the bacteria consequently triggering pro-inflammatory responses 
and in particular IL-1β (Hasegawa et al., 2011).  
Although strain CF5 consistently caused minimal IL-1β responses, western blot results 
showed that this strain is as equipotent as other strains in activating caspase-1, thus it 
remains to be answered how CF5 elicits the least IL-β secretion. Further examination of five 
additional ribotype 017 strains also showed that these strains share the ability of being a 
weak inducer of IL-1β. However it is unknown how strain M68 exhibits a potent IL-1β 
response; furthermore it is not clear why Nod2, Ipaf and Nlrp3 deficiency enhanced 
potency of CF5 and 017 ribotype strains leading to increased levels of IL-1β secretion.  
Inhibition of the inflammasome signals through genetic deletion of ASC markedly decreased 
active caspase-1 expression and mature IL-1β secretion in all four strains indicating that C. 
difficile infection leads to an ASC-dependent inflammasome activation. Although it has 
been reported that caspase-1 activation and IL-1β secretion in response to C. difficile toxins 
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from Nlrp3-/- macrophages show reduction by 50% compared to WT cells (Ng et al., 2010) 
the current study showed no significant difference in caspase-1 activation or IL-β release 
from Nlrp3 deficient DCs compared to WT BMDCs.  
Taken all together, C. difficile strains caused up-regulation of co-stimulatory molecules of 
BMDCs leading to a predominant IL-10 secretion compared to IL-12 family cytokines. It was 
also shown that C. difficile strains may promote more Th1/Th17 responses, despite a 
significant IL-10 secretion known to suppress IL-12 and IL-23 induction. Additionally, C. 
difficile strains activated the inflammasome in an ASC-dependent manner.  
 
6.6.1 Summary 
 
The work presented in this chapter showed that: 
 C. difficile strains caused differential up-regulation of the co-stimulatory molecules 
CD80, CD86, MHCII and CD40. 
 BMDCs infected with C. difficile strains showed maximal IL-12, IL-23 and IL-27 
subunits, IL-6 and IL-1β gene expression between 4-6 h post-infection, while IL-10 
mRNA expression was significantly up-regulated only at 8 h. 
 Infected BMDCs released greater amount of IL-23 and IL-27 compared to IL-12. 
 Strain CF5 showed the highest IL-10 and the least IL-1β gene and protein expression 
amongst the strains. 
 C. difficile infected human DCs showed similar trend in IL-12, IL-10 and IL-1β 
secretion to that observed with BMDCs. 
 Significant IFN-γ and IL-17A responses by stimulated splenocytes indicated that C. 
difficile infection mediates Th1/Th17 immunity. 
 C. difficile strains triggered the inflammasome in an ASC-dependent manner leading 
to caspase-1 activation and IL-1β release. 
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Chapter 7  
Clostridium difficile Toxin-dependent 
and Independent Effects on Dendritic 
Cell Function  
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7.1 Introduction  
 
Dendritic cells play important roles in innate and adaptive immune responses (Steinman, 
1991) by performing functions such as phagocytosis and antigen presentation. 
Furthermore, a subset of intestinal LP DCs has been identified, which are capable of taking 
up bacterial antigens by transepithelial dendrites. This DC subset, most likely activates 
innate immune pathway(s) involved in protecting the mucosa from luminal microorganisms 
(Niess et al., 2005).  Additionally, mucosal DCs have a unique ability to induce T cell 
differentiation in the gut (Bilsborough & Viney, 2004) thus regulating the degree of 
inflammation and preserving gut immune homeostasis (Rimoldi et al., 2005; Ausiello et al., 
2006).  
The interactions between C. difficile and DCs leading to toxin-induced inflammation have 
not yet been fully identified. Lee and co-workers demonstrated that the exposure of 
immature mouse BMDCs to C. difficile purified TcdA (100 ng/ml) results in rapid 
chronological activation of p38 MAPK, IKK and NF-κB pathways leading to DC maturation 
and up-regulation of neutrophil-attracting chemokine CXCL2 gene expression (Lee et al., 
2009).  
As C. difficile toxin mutants have only recently become available, the aim of this study was 
to delineate the role of toxins in C. difficile-driven murine and human DCs innate immune 
responses and also examine the hypothesis that C. difficile toxins are the major drivers of 
inflammasome activation. In these series of experiments R20291 and 630 toxin mutant 
strains (kindly provided by Prof. Minton, University of Nottingham) were utilised comprising 
of R20291 tcdA (A-B+, CDT+), R20291 tcdB (A+B-, CDT+), R20291 cdtA and R20291 cdtB (A+B+ 
with mutation in one of the cdtA/cdtB binary toxin gene subunit) (unpublished data). Strain 
630 isogenic mutants were constructed using 630 Δerm (erythromycin sensitive derivative 
of strain 630, Hussain et al., 2005) as the parent strain by the ClosTron system targeting 
intron insertions to tcdA and tcdB at nucleotide positions 1584 and 1511, respectively 
(Kuehne et al., 2010). Toxin mutant stains included 630 Δerm tcdA (A-B+), 630 Δerm tcdB 
(A+B-), and 630 Δerm tcdA tcdB (A-B-). 
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7.2 Cytotoxicity of C. difficile Toxin Mutants 
 
Prior to co-culture studies, all toxin mutants were examined for their cytotoxicity potential 
by utilising HT-29 and Vero cell-lines as described previously (Chapter 3). HT-29 and Vero 
cells are susceptible to both TcdA and TcdB; however, HT-29 cells are known to be more 
sensitive to TcdA, while Vero cells are more sensitive to TcdB (Torres et al., 1992).  
The cytopathic effect (CPE) of TcdA on HT-29 cells was quantified by infecting semi-
confluent HT-29 cells with 2-fold dilutions of filter-sterilised bacterial supernatants at 
starting MOI of 500 (Figure 7.1). Minimum cytotoxic activity was detected in uninfected 
control cells. Cells infected with R20291 tcdA and R20291 tcdB caused a modest 
cytotoxicity, showing significantly less cell toxicity when compared to the parental strain 
R20291. In contrast, R20291 cdtA exhibited the highest cell intoxication, while strain 
R20291 cdtB showed similar cell toxicity to the parental strain R20291; however, no 
significant difference in cytotoxicity was observed amongst strain R20291 and its binary 
toxin mutants (Figure 7.1 a). 
Cells infected with strain 630 Δerm showed an increase in cytotoxicity compared to 
uninfected control cells, although this was not statistically significant (Figure 7.1 b). Strain 
630 Δerm tcdA caused an enhanced level of cell intoxication, while 630 Δerm tcdB exhibited 
comparable cell toxicity to strain 630 Δerm. Cells infected with the A-B- double-toxin mutant 
(630 Δerm tcdA tcdB) caused minimum cytotoxicity. No significant inter-strain difference in 
cytotoxicity was observed amongst 630 isogenic mutants (Figure 7.1 b).  
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Figure 7.1. C. difficile secreted toxins exert varying cytotoxic potential on HT-29 cells. 
Semi-confluent HT-29 cells were co-cultured with 2-fold dilutions of filter-sterilised 
bacterial culture supernatants of R20291 (a) and 630 (b) toxin mutants. The end-point titre 
of each dilution series was scored at 8 h post-infection. Data presented as the mean ± SEM, 
n=3. *p<0.05, **p<0.01 and ***p<0.001 represent significant difference from uninfected 
control cells, and ^p<0.05 represents significant difference from the parental strain. P values 
were obtained using ANOVA with Bonferroni post-test analysis. 
 
 
 
 
(b) 
(a) 
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Role of TcdB in cell intoxication was investigated by conducting similar co-culture 
experiments using Vero cells. Confluent monolayers were infected with 2-fold dilutions of 
filter-sterilised supernatants of stationary phase bacterial cultures at starting MOI of 500, 
CPE was scored at 8 h post-infection (Figure 7.2). Compared to the parental strain R20291, 
R20291 tcdA exhibited an enhanced level of cytotoxicity; however, this was not statistically 
significant. On the contrary, significantly less cell intoxication was observed with R20291 
tcdB when compared to the parental strain. Elevated levels of cytotoxicity were also 
detected in cells infected with strains R20291 cdtA, and R20291 cdtB, which were not 
statistically different from the WT strain R20291 (Figure 7.2 a).  
Cells infected with 630 Δerm showed significant cell intoxication compared to uninfected 
control cells. Similar cytotoxicity to the A+B+ parental strain was observed with A-B+ mutant 
strain (630 Δerm tcdA). The A+B- mutant strain (630 Δerm tcdB) showed statistically reduced 
cell toxicity compared to the parental strain. Also, compared to the 630 Δerm, a 
significantly less cytotoxicity was detected with the double-toxin mutant strain (630 Δerm 
tcdA tcdB) (Figure 7.2 b).  
Taken all together, HT-29 cells showed no particular sensitivity to TcdA, and A-B+ strains 
showed similar cell toxicity to A+B- strains. On the other hand, TcdB sensitive Vero cells 
showed the least cytotoxicity when infected with A+B- strains. While R20291 binary toxin 
mutants caused significant cytotoxicity in both cell-lines, the least cell toxicity was detected 
with the double-toxin mutants.  
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Figure 7.2. C. difficile secreted toxins exert varying cytotoxic potential on Vero cells. Vero 
cell monolayers were co-cultured with 2-fold dilutions of filter-sterilised bacterial culture 
supernatants of R20291 (a) and 630 (b) toxin mutants. The end-point titre of each dilution 
series was scored at 8 h post-infection. Data presented as the mean ± SEM, n=3. **p<0.01 
and ***p<0.001 represent significant difference from uninfected control cells, and ^p<0.05 
and ^^p<0.01 represent significant difference from the parental strain. P values were 
obtained using ANOVA with Bonferroni post-test analysis.   
 
 
 
 
 
(b) 
(a) 
219 
 
7.3 Adherence of C. difficile Toxin Mutants to Human Intestinal 
Epithelial Cells (IECs) 
 
To investigate the contribution of toxins to the process of bacterial adherence to IEC, 
R20291 and 630 toxin mutants were labelled with FITC and analysed by flow cytometry 
(Figure 7.3 & 7.5). FITC-labelled bacteria were co-cultured with Caco-2 cells at an MOI of 
250. Bacterial adherence was analysed by flow cytometry at 6 h post-infection (Figure 7.4 a 
& 7.6 a), and presented as change in MFI (Figure 7.4 b & 7.6 b).  
Uninfected control cells showed a minimum MFI value (~5), which was similar to that 
observed with unlabelled bacterial infected cells (Figure 7.4 b). R20291 toxin mutants 
adhered to Caco-2 cells at the same level as the parental strain R20291 (MFI ~150), 
exhibiting no significant inter-strain difference (Figure 7.4 b).   
Similar experiments were also conducted to investigate the adherence of strain 630 
isogenic mutants to Caco-2 cells. Uninfected control cells showed a minimum MFI value 
(~5), similar to that observed with unlabelled bacterial infected Caco-2 cells (Figure 7.6 b). 
Toxin mutant strains showed similar adherence levels to the parental strain 630 Δerm and  
no significant difference  was detected amongst the individual (A-B+, A+B-) and the double 
toxin (A-B-) mutant strains (MFI ~100-125) (Figure 7.6 b).  
Collectively, this data suggested that bacterial adherence to Caco-2 cells was toxin 
independent.   
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Figure 7.3. C. difficile R20291 toxin mutant strains show similar distribution of unlabelled 
and FITC-labelled bacteria. The FITC-labelling of the bacteria was seen as a shift of the 
bacteria along the FL1 axis in the histogram display mode, showing unlabelled (left peak) 
and FITC-labelled C. difficile (right peak). The fluorescence signal of the labelled population 
showed no overlap with unlabelled population indicating that the whole population was 
labelled. This data is the representative of three individual experiments. 
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Figure 7.4. C. difficile toxins do not contribute to C. difficile adherence to Caco-2 cells. 
FITC-labelled bacteria were co-cultured with Caco-2 cells at an MOI of 250. Flow cytometric 
analysis of Caco-2 cells alone and after incubation with FITC-labelled C. difficile toxin 
mutant strains showed bacterial association as a shift of adhered bacteria to Caco-2 cells 
along the FL1 axis in the histogram display. Data is representative of three separate 
experiments (a).  Results were quantified as change in MFI. Data represent mean ± SEM, 
n=3. ***p<0.001 (ANOVA with Bonferroni post-test) represents significant difference from 
uninfected cells (b).   
(b) 
(a) 
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Figure 7.5. C. difficile 630 toxin mutant strains show similar distribution of unlabelled and 
FITC-labelled bacteria. The FITC-labelling of the bacteria was seen as a shift of the bacteria 
along the FL1 axis in the histogram display mode, showing unlabelled (left peak) and FITC-
labelled C. difficile (right peak). The fluorescence signal of the labelled population showed 
no overlap with unlabelled population indicating that the whole population was labelled. 
This data is the representative of three individual experiments. 
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Figure 7.6. Strain 630 TcdA and TcdB do not affect bacterial adherence levels to Caco-2 
cells. FITC-labelled bacteria were co-cultured with Caco-2 cells at an MOI of 250. Flow 
cytometric analysis of Caco-2 cells alone and after incubation with FITC-labelled C. difficile 
toxin mutants showed bacterial association as a shift of adhered bacteria to Caco-2 cells 
along the FL1 axis in the histogram display. Data is representative of three separate 
experiments (a). Data represent mean ± SEM, n=3. ***p<0.001 (ANOVA with Bonferroni 
post-test) represents significant difference from uninfected cells (b). 
(b) 
(a) 
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7.4 Regulation of BMDC Immune Response(s) by C. difficile 
Toxin Mutant Strains  
 
To determine C. difficile toxin-mediated effects BMDCs were harvested from C57BL/6 mice 
and stimulated with bacterial cultures of R20291 WT and toxin mutants R20291 tcdA (A-B+), 
R20291 tcdB (A+B-), R20291 cdtA (A+B+, CDTa-), R20291 cdtB (A+B+, CDTb-), and isogenic 
mutants of 630 Δerm included 630 Δerm tcdA (A-B+), 630 Δerm tcdB (A+B-), 630 Δerm tcdA 
tcdB (A-B-). All co-culture studies were conducted at an MOI of 10.  
 
7.4.1 Dendritic Cell Maturation in Response to Infection with C. difficile 
Toxin Mutant Strains 
 
Dendritic cells are known to up-regulate co-stimulatory molecules upon contact with 
bacterial components. To investigate whether C. difficile toxins can influence DC 
maturation, the expression of co-stimulatory molecules CD80, CD86, as well as MHC class II 
and CD40 was investigated by flow cytometry (Figures 7.7-7.10). 
Cells infected with R20291 showed 1.5-fold increase in CD80. R20291 toxin mutants caused 
similar levels of CD80 modulation (≥ 1.5-fold) (Figure 7.7 a). Strain 630 Δerm showed 1.5-
fold change in CD80 and 630 Δerm tcdA caused <1.5-fold increase, while 630 Δerm tcdB up-
regulated CD80 ~2-fold. The double toxin mutant 630 Δerm tcdA tcdB showed <1.5-fold 
CD80 modulation. Strain 630 Δerm toxin mutant strains were not significantly different 
from the parental strain; however, strain 630 Δerm tcdB showed a significant difference 
from 630 Δerm tcdA (p<0.05) and 630 Δerm tcdA tcdB (p<0.01) (Figure 7.7 b). 
Strains R20291 and R20291 tcdA both caused ≥ 1.5-fold modulation in CD86. CD86 was up-
regulated ≥ 2-fold with R20291 tcdB and the binary toxin mutants, which were statistically 
different from the parental strain (Figure 7.8 a). Strain 630 Δerm showed ~2-fold increase, 
while CD86 showed minimal impact in response to 630 Δerm tcdA (<1.5-fold). 630 Δerm 
tcdB showed similar level of CD86 up-regulation as the parental strain, whereas 630 Δerm 
tcdA tcdB exhibited >1-fold CD86 modulation. The TcdA and the double toxin mutant 
strains were significantly different from the parental strain, furthermore, 630 Δerm tcdB 
showed a higher CD86 fold increase when compared with 630 Δerm tcdA (p<0.01) and 630 
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Δerm tcdA tcdB (p<0.001), also 630 Δerm tcdA up-regulated CD86 significantly more than 
the double toxin mutant (p<0.01) (Figure 7.8 b).  
MHCII, a mature DC marker increased <2-fold in response to WT R20291 and toxin mutants 
showed no significant difference compared to the parental strain (Figure 7.9 a). Strain 630 
Δerm caused >1.5-fold MHCII modulation, which was not changed in response to TcdA toxin 
mutant strain. The TcdB toxin mutant showed <1.5 fold increase, whilst the double toxin 
mutant up-regulated the MHCII ~2-fold. Strain 630 Δerm toxin mutants were not 
significantly different from the parental strain and also no significant inter-strain difference 
was observed (Figure 7.9 b).  
A 2-fold increase in CD40 was detected in response to R20291. A similar response was 
observed with R20291 toxin mutant strains, showing no significant difference from the 
parental strain and also no inter-strain difference was detected (Figure 7.10 a). 
Approximately 2-fold increase of CD40 was seen with strain 630 Δerm and >1.5-fold in 
response to 630 Δerm tcdA. CD40 expression was significantly less in response to TcdB 
mutant compared to the parental strain, whilst the double toxin mutant showed >1.5-fold 
CD40 up-regulation (Figure 7.10 b).  
This data suggested that R20291 toxin mutants showed similar CD80, MHCII, and CD40 up-
regulation, while 630 Δerm tcdB caused significant modulation of CD80 and CD86 
compared to the TcdA and the double toxin mutants. On the other hand, the 630 Δerm 
toxin mutants showed similar up-regulation of MHCII and CD40.   
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Figure 7.7. C. difficile up-regulates DC surface marker CD80. BMDCs were infected with 
R20291 and 630 Δerm isogenic mutants at an MOI of 10. After 8 h stimulation, cells were 
labelled with mouse CD80 antibody and analysed by flow cytometry (a). The level of surface 
expression was quantified and presented as MFI fold increase (b-c). Data represent mean ± 
SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 represent significant difference from uninfected 
cells and #p<0.05 and ##p<0.01 represent significant inter-strain difference. P values were 
obtained using ANOVA with Bonferroni post-test analysis.   
(b) 
(c) 
(a) 
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Figure 7.8. C. difficile induces maturation of DCs by modulating CD86. BMDCs were 
infected with toxin mutants of R20291 and 630 Δerm at an MOI of 10. At 8 h post-
stimulation, cells were labelled with mouse CD86 antibody and analysed by flow cytometry 
(a). The level of surface expression was quantified and presented as MFI fold increase (b-c). 
Data represent mean ± SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 represent significant 
difference from uninfected cells, ^p<0.05, ^^p<0.01 and ^^^p<0.001 represent significant 
difference from the parental strain, and ##p<0.01 and ###p<0.001 represent significant inter-
strain difference. P values were obtained using ANOVA with Bonferroni post-test analysis.   
(b) 
(c) 
(a) 
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Figure 7.9. C. difficile up-regulates co-stimulatory molecule MHCII. BMDCs were infected 
with R20291 and 630 Δerm isogenic mutants at an MOI of 10. After 8 h stimulation, cells 
were labelled with mouse MHCII antibody and analysed by flow cytometry (a). The level of 
surface expression was quantified and presented as MFI fold increase (b-c). Data represent 
mean ± SEM, n=3. *p<0.05 (ANOVA with Bonferroni post-test) represents significant 
difference from uninfected cells.  
 
 
 
(c) 
(b) 
(a) 
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Figure 7.10. C. difficile up-regulates CD40 a DC surface marker. BMDCs were infected with 
toxin mutants of R20291 and 630 Δerm at an MOI of 10. At 8 h post-stimulation, cells were 
labelled with mouse CD40 antibody and analysed by flow cytometry (a). The level of surface 
expression was quantified and presented as MFI fold increase (b-c). Data represent mean ± 
SEM, n=3. *p<0.05, **p<0.01 and ***p<0.001 represent significant difference from uninfected 
cells and ^p<0.05 represents significant difference from the parental strain. P values were 
obtained using ANOVA with Bonferroni post-test analysis.  
 
(b) 
(b) 
(a) 
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7.4.2 Cytokine Production by Dendritic Cells in Response to C. difficile 
Toxin Mutant Strains 
 
To assess the potential role of C. difficile toxins in modulating DC innate immune response 
BMDCs were infected with R20291 and 630 Δerm toxin mutant strains at an MOI of 10. IL-
12 family (IL-12, IL-23, and IL-27), IL-10, TNF-α, and IL-1β cytokines were measured at 8 h 
post-infection (Figures 7.11-7.16).  
Basal IL-12 levels were ~10 pg/ml in uninfected control cells. Infection with strain R20291 
enhanced IL-12 secretion to ~80 pg/ml. Cells infected with R20291 toxin mutants showed 
induction which was not statistically different from the parental strain (Figure 7.11 a). 
Induction in response to strain 630 Δerm was less potent when compared to R20291. Strain 
630 Δerm toxin mutants were not significantly different from the parental strain (Figure 
7.11 b). 
 Uninfected control DCs secreted very low levels of IL-23. Upon infection with R20291, 
marked induction in IL-23 was noted (Figure 7.12 a). R20291 isogenic mutant strains 
secreted IL-23 to a similar extent. 630 Δerm caused IL-23 release which was 4 to 5-fold less 
than that observed with R20291, the toxin mutant strains again had minimal impact (Figure 
7.12 b).  
The basal level of IL-27, another IL-12 family member, in uninfected control cells was 
<10pg/ml. Infection with R20291 increased IL-27 to ~180 pg/ml. Toxin mutant strains 
increased IL-27 to a similar extent as seen with the parental strain (Figure 7.13 a). Very 
modest increase in IL-27 was noted in response to 630 Δerm, again toxin mutant strains 
were not statistically different from the parental strain (Figure 7.13 b).  
Taken together, C. difficile strains R20291 and 630 showed distinct abilities in modulating 
IL-12 family members. Strains R20291 and 630 caused marked increase in IL-23, with an 
intermediate effect on IL-27. Interestingly, the least induction was noted for IL-12. 
Importantly, the absence of individual toxins had no significant effect on this family of 
cytokines.  
Infection with strain R20291 showed ~5-fold increase in IL-10 release. The toxin mutant 
strains showed IL-10 responses in a similar range (Figure 7.14 a). Similar data was noted in 
response to strain 630 Δerm (Figure 7.14 b). The toxin mutant strains of both R20291 and 
630 Δerm did not show any significant difference from the parental strains. Interestingly, 
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unlike the differential IL-12 family response observed above, both R20291 and 630 Δerm 
induced IL-10 to a similar extent.  
A basal level of <60 pg/ml TNF-α was detected in uninfected control cells. The level was 
increased upon infection with R20291 to ~7000 pg/ml. Similar responses were detected 
with R20291 isogenic mutants (Figure 7.15 a). Cells infected with 630 Δerm caused >4000 
pg/ml TNF-α secretion. The TcdA toxin mutant showed a significantly reduced level of TNF-
α induction compared to the 630 Δerm, while the level of TNF-α released by the TcdB toxin 
mutant was similar to the parental strain (~4000 pg/ml). On the other hand, a significantly 
low expression of TNF-α was detected in response to the double toxin mutant (~1850 
pg/ml) when compared to the parental strain. It was also observed that the induction of 
TNF-α by 630 Δerm tcdB was significantly higher than 630 Δerm tcdA (p<0.01) and 630 
Δerm tcdA tcdB (p<0.001) (Figure 7.15 b).               
IL-1β secretion was also investigated in response to C. difficile toxins. A basal level of ~15 
pg/ml IL-1β was detected in uninfected control BMDCs. Upon infection with R20291, IL-1β 
release markedly increased. Similar responses were detected with R20291 toxin mutant 
strains (Figure 7.16 a). Cells infected with 630 Δerm showed 1300 pg/ml IL-1β secretion, 
infection with the TcdA toxin mutant strain caused significantly less release, in contrast 630 
Δerm tcdB showed IL-1β secretion similar to the parental strain. Importantly, the double 
toxin mutant was a very poor agonist for IL-1β secretion (p<0.01) (Figure 7.16 b).  
In summary, studies investigating C. difficile-BMDC interactions suggested that BMDC IL-12 
and IL-10 responses to C. difficile infection were not modulated by the individual toxins. 
R20291 consistently induced greater cytokine responses compared to strain 630. TNF-α and 
IL-1β levels were not affected by the absence of individual R20291 toxins. The absence of 
TcdA and TcdB in the 630 Δerm double toxin mutant had the biggest impact on IL-1β 
secretion, thus highlighting a major role for the toxins in modulating this specific cytokine. 
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Figure 7.11. BMDCs IL-12 induction in response to C. difficile infection. BMDCs were 
infected with R20291 and 630 Δerm isogenic mutant strains at an MOI of 10. Secretion of 
IL-12 was measured by ELISA at 8 h post-infection. Data represent mean ± SEM of duplicate 
samples and are representative of three individual experiments. *p<0.05 and **p<0.01 
represent significant difference from uninfected cells. p values were obtained using ANOVA 
with Bonferroni post-test analysis.   
 
(b) 
(a) 
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Figure 7.12. IL-23 release in response to C. difficile infection by BMDCs. Murine DCs were 
infected with R20291 and 630 Δerm toxin mutants at an MOI of 10. Secretion of IL-23 was 
measured by ELISA after 8 h infection. Data represent mean ± SEM of duplicate samples 
and are representative of three individual experiments. *p<0.05, **p<0.01 and ***p<0.001 
represent significant difference from uninfected cells. P values were obtained using ANOVA 
with Bonferroni post-test analysis.   
 
(b) 
(a) 
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Figure 7.13. IL-27 secretion by BMDCs in response to C. difficile infection. Murine DCs 
were infected with isogenic mutants of R20291 and 630 Δerm at an MOI of 10. Release of 
IL-27 was measured by ELISA at 8 h post-infection. Data represent mean ± SEM of duplicate 
samples and are representative of three individual experiments. *p<0.05 and **p<0.1 
represent significant difference from uninfected cells. P values were obtained using ANOVA 
with Bonferroni post-test analysis.  
 
(b) 
(a) 
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Figure 7.14. IL-10 release in response to C. difficile infection by murine DCs. BMDCs were 
infected with R20291 and 630 Δerm toxin mutants at an MOI of 10. Production of IL-10 was 
measured by ELISA after 8 h infection. Data represent mean ± SEM of duplicate samples 
and are representative of three individual experiments. *p<0.05 and **p<0.01 represent 
significant difference from uninfected cells. P values were obtained using ANOVA with 
Bonferroni post-test analysis.  
 
(b) 
(a) 
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Figure 7.15. TNF-α production in response to C. difficile infection. Murine DCs were 
infected with toxin mutant strains of R20291 and 630 Δerm at an MOI of 10. Release of 
TNF-α was measured by ELISA after 8 h infection. Data represent mean ± SEM of duplicate 
samples and are representative of three individual experiments. ***p<0.001 represents 
significant difference from uninfected cells, ^^^p<0.001 represents significant difference 
from the parental strain, and ##p<0.01 and ###p<0.001 represent significant inter-strain 
difference. P values were obtained using ANOVA with Bonferroni post-test analysis.  
 
(b) 
(a) 
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Figure 7.16. IL-1β release in response to C. difficile infection. BMDCs were infected with 
R20291 and 630 Δerm toxin mutant strains at an MOI of 10. Secretion of IL-1β was 
measured by ELISA after 8 h infection. Data represent mean ± SEM of duplicate samples 
and are representative of three individual experiments. ***p<0.001 represents significant 
difference from uninfected cells, ^p<0.05 and ^^p<0.01 represent significant difference from 
the parental strain, and #p<0.05 and ##p<0.01 represent significant inter-strain difference. P 
values were obtained using ANOVA with Bonferroni post-test analysis.  
 
 
 
 
(b) 
(a) 
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7.4.3 C. difficile Toxin-mediated IL-1β Secretion 
 
C. difficile strains activate the inflammasome and cause the induction of mature IL-1β in a 
caspase- and ASC-dependent manner (Chapter 6). Here, the role of individual toxins in 
mediating IL-1β secretion was further investigated in BMDCs by utilising mutant strain that 
lacked individual toxins (Figure 7.16). Since no difference was noted in R20291 toxin mutant 
strains, one may conclude that as the mutant strains lacked only one toxin, presence of the 
remaining two toxins was sufficient to release bioactive IL-1β. This suggestion is likely to 
hold, as the deletion of both toxins as seen in the 630 Δerm double toxin mutant did indeed 
lose the ability to mediate IL-1β release. Although all three C. difficile toxins (TcdA, TcdB 
and CDT) are likely to activate the inflammasome resulting in IL-1β release in an 
independent manner, how each toxin may engage the various components of the 
inflammasome is not known. To gain better insight into these mechanism(s) BMDCs from 
WT (C57BL/6, genetically Nlrp1 deficient), Nod2, Ipaf, Nlrp3, and ASC deficient mice were 
infected with R20291 and 630 Δerm toxin mutant strains at an MOI of 10 and IL-1β 
response was measured at 8 h post-infection (Figure 7.17 a-d).   
Uninfected WT, Nod2-/-, Ipaf-/-, Nlrp3-/-, and ASC-/- control BMDCs showed a basal level of 
<20 pg/ml IL-1β (Figure 7.17 a-d). Infection with WT R20291 caused IL-1β secretion to 
increase to ~2000 pg/ml in WT, Nod2-/-, and Ipaf-/- BMDCs (Figure 7.17 a). The IL-1β levels 
from Nod2-/-and Ipaf-/- cells in response to R20291 isogenic mutants were not statistically 
different from the WT BMDC (Figure 7.17 a).  
The Nlrp3 KO cells infected with strain R20291 showed 1700 pg/ml IL-1β secretion, whilst 
its isogenic mutants caused ~2500 pg/ml. The ASC deficient cells released <60 pg/ml IL-1β 
in response to R20291 and the toxin mutants exhibited significantly reduced levels of IL-1β 
when compared with WT and Nlrp3-/- cells (Figure 7.17 b). 
The WT, Nod2-/- and Ipaf-/- DCs infected with 630 Δerm released ~1800-2200 pg/ml IL-1β. 
The Nod2 KO BMDCs infected with the TcdA toxin showed marked reduction compared to 
the parental strain, whereas the TcdB toxin mutant strain was similar to WT. Infection with 
the double toxin mutant had minimal effect. The Ipaf deficient BMDC showed reduced IL-1β 
in response to the TcdA toxin mutant, while the TcdB mutant was similar to WT. 
Statistically, no significant difference in IL-1β expression from Nod2 and Ipaf KO cells in 
response to 630 Δerm and its isogenic mutants was detected when compared with the WT 
BMDCs (Figure 7.17 c).  
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The Nlrp3 KO cells infected with 630 Δerm showed >2000 pg/ml IL-1β release, while similar 
IL-1β secretion was detected in response to the TcdA and TcdB toxin mutants. The IL-1β 
expression from ASC deficient BMDC in response to 630 Δerm, 630 Δerm tcdA, and 630 
Δerm tcdB was significantly reduced (<40 pg/ml) compared to WT and Nlrp3-/- cells. 
Furthermore, the double toxin mutant mediated minimal IL-1β release in Nlrp3-/- and ASC 
deficient BMDCs (Figure 7.17 d).  
This data indicated that C. difficile toxins trigger the release of mature IL-1β as the secretion 
of IL-1β was completely abrogated with the double toxin mutant. Activation of the 
inflammasome and release of IL-1β was ASC dependent ruling out a potential role for Nod2, 
Ipaf and Nlrp3 NLRs in C. difficile-mediated inflammasome activation.  
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(b) 
(a) 
(c) 
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Figure 7.17. C. difficile toxins trigger IL-1β release by activating an ASC-containing 
inflammasome. BMDCs from WT (C57BL/6 genetically Nlrp1 deficient) mice and mice 
deficient in Nod2, Ipaf (Nlrc4), Nlrp3, and ASC were infected with R20291 and 630 Δerm 
toxin mutants at an MOI of 10. IL-1β release was measured by ELISA at 8 h post-infection. 1 
μg/μl LPS was utilised as a reference stimulus. Data represent mean ± SEM, n=4. *p<0.05, 
**p<0.01 and ***p<0.001 represent significant WT difference from ASC-/- and ^^^p<0.001 
represents significant Nlrp3-/- difference from ASC-/-. P values were obtained using ANOVA 
with Bonferroni post-test analysis.  
 
 
 
 
 
 
 
 
 
 
(d) 
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7.5 Human Dendritic Cell Innate Immune Response(s) to C. 
difficile Toxin Mutant Strains  
 
The murine model of C. difficile infection showed that C. difficile toxins modulated BMDC 
cytokine responses in a toxin-dependent and independent way. Next we wished to know if 
similar mechanism(s) were at play during C. difficile mediated human DC activation. Human 
monocyte-derived DCs were infected with strains R20291 and 630 Δerm toxin mutants at 
an MOI of 10 and induction of IL-12, IL-10, and IL-1β cytokines were measured at 8 h post-
infection (Figures 7.18-7.20). 
Cells infected with strain R20291 showed <400 pg/ml IL-12 induction (Figure 7.18 a). DCs 
infected with R20291 toxin mutant strains showed IL-12 median induction in the range of 
100-250 pg/ml (Figure 7.18 a). Strain 630 Δerm caused ~75 pg/ml IL-12, while its isogenic 
mutants induced 110-240 pg/ml (Figure 7.18 b). No significant difference was detected in 
IL-12 expression in response to both R20291 and 630 Δerm toxin mutants when compared 
with the parental strains, thus mirroring the response seen in BMDC.  
Uninfected control human DCs can spontaneously secrete IL-10. The expression increased 
in response to WT R20291 and the toxin mutant strains (Figure 7.19 a). Cells infected with 
630 Δerm showed less induction compared to WT R20291 (Figure 7.19 b). Human DC IL-10 
expression in response to C. difficile infection showed a similar trend to that observed in 
BMDCs. The toxin mutant strains did not show any significant difference in IL-10 release 
compared to their WT counterparts.  
Infection with strain R20291 caused marked IL-1β release, whilst the isogenic mutants 
showed a range of responses (Figure 7.20 a). The lack of TcdA or TcdB did not significantly 
affect IL-1β secretion. Interestingly, unlike the data generated in BMDC, human DC showed 
a trend for less IL-1β release in response to CdtA and CdtB mutants suggesting a potentially 
greater role for CDT in C. difficile-mediated inflammasome activation. Infection with strain 
630 Δerm caused 200 pg/ml IL-1β secretion and ~120-210 pg/ml in response to 630 Δerm 
toxin mutants. Further, unlike the data obtained with BMDC significant reduction of IL-1β 
was not detected in response to the double toxin mutant strain (Figure 7.20 b). Both 
R20291 and 630 Δerm toxin mutant strains showed no significant difference in IL-1β 
response compared to the parental strains.  
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Figure 7.18. Effect of C. difficile toxins on IL-12 production by human DC. Human 
monocyte-derived DCs obtained from nine healthy donors were stimulated with R20291 (a) 
and 630 Δerm (b) toxin mutants at an MOI of 10. IL-12 secretion was measured by ELISA at 
8 h post-infection. *p<0.05 and **p<0.01 represent significant difference from uninfected 
control cells. Data was analysed using Mann-Whitney U test.  
 
(a) 
(b) 
244 
 
 
 
 
 
Figure 7.19. Effect of C. difficile toxins on IL-10 synthesis by human DC. Human monocyte-
derived DCs obtained from nine healthy donors were stimulated with R20291 (a) and 630 
Δerm (b) isogenic mutants at an MOI of 10. IL-10 production was measured by ELISA at 8 h 
post-infection. **p<0.01 and ***p<0.001 represent significant difference from uninfected 
cells. Data was analysed using Mann-Whitney U test. 
 
 
(a) 
(b) 
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Figure 7.20. Effect of C. difficile toxins on human DC IL-1β secretion. Human monocyte-
derived DCs obtained from nine healthy donors were stimulated with R20291 (a) and 630 
Δerm (b) toxin mutants at an MOI of 10. IL-1β release was measured by ELISA at 8 h post-
infection. **p<0.01 and ***p<0.001 represent significant difference from uninfected control 
cells. Data was analysed using Mann-Whitney U test.  
 
 
 
 
 
 
(a) 
(b) 
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7.6 Conclusions  
 
Immature DCs found in all peripheral tissues are able to efficiently capture microbial 
antigens (Steinman, 2007). In the gut, exposed DCs to bacterial products are known to 
mature and migrate to T cell areas of secondary lymphoid organs, where they activate 
naive T cells (Niess & Reinecker, 2006). Although the process of DC maturation is important 
to the pathogenesis of CDI, the role of C. difficile toxins in mediating disease through DC 
maturation is less defined.  
In the current study, in vitro cell cytotoxicity assays were conducted by utilising the R20291 
and 630 Δerm toxin mutants then the role of C. difficile toxins in bacterial adherence to IEC 
was investigated. Toxin-mediated DC activation and maturation was examined in murine 
model system. The induction of IL-12 family members, anti-inflammatory IL-10, pro-
inflammatory TNF-α and IL-1β cytokines were measured. Toxin-mediated inflammasome 
activation and IL-1β secretion was determined in infected BMDCs from WT, Nod2-/-, Ipaf-/-, 
ASC-/-, and Nlrp3-/- mice and finally, human monocyte-derived DCs were utilised to evaluate 
the cytokine production in response to C. difficile toxins.  
In this study, the cytotoxicity assay showed that compared to the parental strain R20291, 
both R20291 tcdA and R20291 tcdB caused similar and significantly low cytotoxicity in 
infected HT-29 cells. HT-29 cells infected with 630 Δerm tcdA and tcdB showed relatively 
higher cell toxicity compared to R20291 tcdA and tcdB, although same trend was observed 
detecting A-B+ strains being potentially more toxic than A+B- strains in HT-29 cells, even 
though  630 Δerm toxin mutants were not significantly different from the parental strain in 
causing cell toxicity. These findings were unexpected as HT-29 cells are known to be more 
sensitive to TcdA moreover it was not clear why R20291 tcdB exhibited significantly 
reduced cell toxicity.  
Furthermore, HT-29 cells infected with R20291 cdtA showed an enhanced but not 
significantly different cytotoxicity effects compared to the parental strain, while R20291 
cdtB caused similar cell intoxication to the parental strain. It was not anticipated that 
deletion of the enzymatic compartment (CDTa) may cause enhanced cell toxicity. This 
matter requires further investigation and obtaining the triple toxin mutant will elucidate 
this phenomenon.  
Expectedly, 630 Δerm double toxin mutant showed the least cytotoxicity in HT-29 cells.  
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On the other hand, more sensitivity to TcdB was detected with Vero cell cytotoxicity assay. 
Cells infected with R20291 tcdA showed increased cell toxicity, similar effect was also 
detected with both R20291 cdtA and cdtB mutants however the enhanced cytotoxicity 
levels were not statistically significant to the parental strain. Whereas, R20291 tcdB showed 
significantly reduced cell toxicity compared to R20291. Furthermore, 630 Δerm tcdA 
showed more cytotoxicity but not statistically significant compared to the parental strain. 
Considerably less cell intoxication was detected with TcdB mutant strain, while the double 
toxin mutant showed the least cell toxicity when compared to 630 Δerm.  
In 2009, Lyras et al. in a cytotoxicity assay using HT-29 showed that 630 Δerm tcdA mutants 
were significantly less toxic than the WT strain (630 Δerm). Vero cell cytotoxicity assay also 
showed that detected cytotoxic activity was predominantly TcdB-mediated, hence the tcdA 
mutants showed the same cytotoxic phenotype as the WT strain. In 2010, Kuehne and co-
workers successfully constructed the first double toxin mutant strain of C. difficile, which 
showed no cytotoxic activity towards either HT-29 or Vero cells. They reported that 
compared to the parental strain (630 Δerm), tcdA mutant caused reduced toxicity in HT-29 
cells, although the difference was not significant. Similar degree of cytotoxicity in Vero cells 
was also seen with this mutant. On the other hand, they detected that compared to the 
parental strain, the tcdB mutant showed increased toxicity in HT-29 cells, which was not 
statistically significant, and a similar level of toxicity in Vero cells. Both authors reasoned 
that the observed increased TcdA expression in A+B- mutant strains was due to the 
mutation of tcdB. They showed by quantitative RT-PCR that the expression of TcdA was 
increased 3.3-fold compared to the WT/parental strain however the basis for this increased 
expression of TcdA is not known.  
Moreover, these two studies showed very contradictory results. While Lyras et al. detected 
a significant decrease in HT-29 cell toxicity with tcdA mutants compared to the parental 
strain, Kuehne et al. observed reduced but not statistically different outcome. The same 
discrepancy was also seen in Vero cell cytotoxicity assay. In an article in 2011, Kuehne and 
co-workers discussed a number of factors that needed to be considered in comparing these 
two studies, the most important difference was related to the employed strains. Whilst the 
parent strain employed in both studies was strain 630, the mutants were generated using 
different isolates. As generation of mutants relies on the ability to select resistance to 
erythromycin, a requirement that disqualifies the use of strain 630 as it carries a functional 
copy of ermB. Therefore, both studies employed independently isolated derivative strain of 
630, which was sensitive to this antibiotic. While Kuehne et al. utilised strain 630 Δerm 
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generated after 30 repeated subculture of strain 630 in non-selective media leading to 
specific deletion of ermB, Lyras et al. isolated another erythromycin sensitive strain, 
through an undisclosed number of subcultures of strain 630 and designated the strain 630E. 
A preliminary comparison showed that the 630 Δerm and 630E have clear phenotypic 
differences such as; strain 630E is non-motile, lacks flagella, and has a more severe glucose 
response, affecting the level of produced toxin in the presence of this carbon source.  
The current study is the first one to employ the R20291 toxin mutants, thus the reason why 
the tcdB mutant that has been shown to produce 3.3-fold more TcdA caused significantly 
less cell toxicity compared to the parental strain is not known. Moreover, although in this 
study the same 630 Δerm toxin mutants was utilised as those of Kuehne and co-workers, 
630 Δerm tcdA mutant showed increased cell toxicity in HT-29 and 630 Δerm tcdB exhibited 
a significantly reduced cytotoxicity in Vero cells, which were not observed in the study by 
Kuehne et al. The answer may reside with the in vitro model, either employed cell culture 
conditions or cell confluence could influence the outcome. Also in the current study the 
cytotoxic activity was not confirmed using toxin neutralisation assay. 
In 1988, Borriello et al. reported that in a clindamycin-induced disease in the Syrian 
hamster model there was a correlation between variable efficiencies of gut colonisation by 
different C. difficile strains and their abilities to associate with regions of the GI tract, 
spanning the jejunum to the colon. They suggested that it might be partly due to strains 
differential ability to produce toxins however they explored the idea that factors other than 
toxin production might be responsible too. Later Drudy et al. (2001) in a flow cytometric 
analysis of C. difficile adherence showed that toxigenic and non-toxigenic strains adhere 
equally to primary colonic epithelial cells and intestinal cell-lines nevertheless binding to 
primary cells were significantly greater than adherence to Caco-2 or HT-29 cells. In the 
current study, similar in vitro results were also observed with R20291 and 630 isogenic 
mutants. Compared to the parental strain R20291, toxin mutants exhibited similar levels of 
adherence to Caco-2 cells and no inter-strain difference was detected (Figure 7.4). Toxin 
mutants of 630 Δerm, single or the double toxin mutants also showed comparable 
adherence levels to the parental strain 630 Δerm, indicating additional bacterial factors 
involved in binding to the intestinal epithelia other than toxins (Figure 7.6). 
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The role of toxins was further investigated by examining their effects on DC activation. 
Strain R20291 toxin mutants caused up-regulation of cell surface markers CD80, MHCII, and 
CD40 in similar levels compared to the parental strain. However, R20291 tcdB, and binary 
toxin mutants showed a significant increase in CD86 modulation when compared to the 
R20291. On the other hand, 630 Δerm tcdB exhibited a significant CD80 and CD86 fold 
increase compared to 630 Δerm tcdA and the double toxin mutant, although this was not 
statistically significant compared to the parental strain. MHCII was up-regulated in response 
to all 630 Δerm toxin mutants, while similar result was detected with CD40, 630 Δerm tcdB 
showed a significantly less CD40 modulation compared to the 630 Δerm. It has been 
already shown that the expression of cell surface molecules such as CD40, CD80, CD86, and 
MHCII on immature murine DCs were increased in response to 100 ng/ml TcdA leading to 
hypothesise that C. difficile TcdA can promote DC maturation (Lee et al., 2009), although in 
the current study a strong MHCII and CD40 up-regulation was detected with the double 
toxin mutant strain indicating that DC surface markers were modulated in a toxin-
dependent and independent manner. 
Following DC maturation upon interaction with bacteria, DCs release an array of cytokines 
and chemokines. Cells infected with R20291 toxin mutants showed no significant increase 
in secretion of IL-12 family cytokine, IL-10, TNF-α, and IL-1β compared to the parental strain 
signifying a toxin independent induction of these cytokines. Similar outcome was also 
detected with 630 Δerm isogenic mutants showing no significant difference in expression of 
IL-12 family cytokine and IL-10 when compared to the WT strain. However, while 630 Δerm 
tcdB caused comparable amounts of pro-inflammatory TNF-α and IL-1β to the parental 
strain, 630 Δerm tcdA and the double toxin mutant strains induced significantly less TNF-α 
and IL-1β, suggesting that TcdA may possibly be the potent inducer of these pro-
inflammatory cytokines. It is not clear why differential TNF-α and IL-1β expression was seen 
in response to R20291 tcdA and 630 Δerm tcdA, nevertheless the impact of R20291 binary 
toxin in host response modulation cannot be disregarded.  
Additionally, human monocyte-derived DCs infected with R20291 and 630 Δerm toxin 
mutants showed no significant difference in induction of IL-12, IL-10 and IL-1β cytokines 
compared to the parental strains and no inter-strain difference was detected. Although 
human peripheral blood monocytes are widely used, the in vitro generated DCs do not 
demonstrate the same ability and behaviour as ex vivo isolated DCs.  
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Ng et al. (2010) have already shown that C. difficile infection leads to the activation of the 
inflammasome and IL-1β secretion in a toxin-dependent way. In this study, it was also 
observed that C. difficile strains caused differential induction of IL-1β, detecting the least IL-
1β expression in response to strain CF5. Therefore, the role of toxins in the release of 
mature IL-1β caused by the activation of the inflammasome was investigated in DCs 
infected with R20291 and 630 Δerm isogenic mutants. DCs from Nod2, Ipaf, and Nlrp3 
deficient mice, infected with R20291 toxin mutants showed no significant difference in IL-
1β response compared to the WT DCs however the secretion of IL-1β was significantly 
decreased in ASC KO DCs. Similar responses were also detected in Nod2, Ipaf, and Nlrp3 
deficient mice infected with 630 Δerm toxin mutants, exhibiting no significant difference in 
IL-1β secretion compared to that observed with WT DCs and deletion of ASC abrogated the 
release of IL-1β. Furthermore, the double toxin mutant caused the least induction of IL-1β 
in all tested cell types. 
Collectively, C. difficile caused DC activation and cytokine production in a toxin-dependent 
and independent fashion indicating that multiple bacterial factors may play a role in 
initiating an innate immune response. Nonetheless, C. difficile toxins were clearly 
responsible for activation of the inflammasome in an ASC-dependent manner. 
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7.6.1 Summary 
 
This chapter demonstrated that: 
 Toxin mutant strains exerted varying cytotoxic potential on HT-29 and Vero cells. 
 The double toxin mutant strain showed the least cell cytotoxicity compared to 
other toxin mutants. 
 C. difficile adherence to IEC was toxin independent. 
 BMDC surface markers were modulated in a toxin-dependent and independent 
manner. 
 BMDCs infected with R20291 and 630 Δerm toxin mutants showed toxin-
independent secretion of IL-12 family cytokines and IL-10. 
 Strain 630 Δerm tcdA and the double toxin mutant induced significantly less pro-
inflammatory TNF-α and IL-1β. 
 Human DCs infected with toxin mutant strains showed similar trend in IL-12 and IL-
10 secretion to that observed with BMDCs however the double toxin mutant 
caused comparable IL-1β release as the parental strain. 
 C. difficile toxins activated the inflammasome and triggered IL-1β release in an ASC-
dependent manner.   
 
252 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8  
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C. difficile is recognised as the primary cause of infectious diarrhoea in hospitalised patients 
(Kelly & LaMont, 2008). In the last decade, the incidence, severity and recurrences of C. 
difficile infection (CDI) have increased considerably, particularly with the emergence of 
hypervirulent strains (Stabler et al., 2009; Khanna et al., 2012). CDI is a toxin-mediated 
disease; the majority of strains express two exotoxins (TcdA & TcdB) which are the most 
extensively studied virulence factors. The mechanisms by which TcdA and TcdB induce 
enterotoxicity have been well established by utilising purified/recombinant toxins both in 
vitro in an array of cell types and in vivo animal models of infection. Until recently our 
understanding of C. difficile pathogenesis was greatly hindered due to the lack of available 
tools for the construction of chromosomal mutants as C. difficile is difficult to manipulate 
genetically. At the commencement of the present study no isogenic mutant strains were 
available, the initial studies were therefore conducted utilising four different C. difficile 
strains including R20291 (hypervirulent strain, A+B+CDT+), a fully sequenced strain 630 
(A+B+) and two variant strains, M68 and CF5 (A-B+). This study commenced aiming to 
elucidate the role of the bacterial cell and its native toxins (in the context of infection) in 
modulating host immunity; these experiments laid the foundation to improve our 
understanding of how the host may raise differential immune and non-immune responses 
to A+B+ versus A-B+ strains. Nonetheless, availability of R20291 and 630 toxin mutant strains 
later on in the project, allowed a better understanding of the role toxins play in C. difficile 
infection.  
The colonic epithelium is the first target tissue of C. difficile. The ability to disrupt tight 
junctions and to breach the intestinal epithelial barrier is one of the most direct events 
attributed to TcdA and TcdB in the intestine (Feltis et al., 2000). These toxins are 
glucosyltransferases that mono-glucosylate Rho GTPases (Just et al., 1995). As Rho proteins 
play an important role in tight junction (TJ) assembly, their inactivation by the toxins causes 
the loss of epithelial barrier function and re-organisation of filamentous actin structure 
(Hecht et al., 1988; Halabi-Cabezon et al., 2008). C. difficile toxins also possess apoptogenic 
properties, which may contribute to the inflammatory process induced by this bacterium 
(Fiorentini et al., 1998; Brito et al., 2002). Studies have shown that C. difficile toxin-induced 
apoptosis depends on glucosylation of Rho GTPases leading to activation of caspases and is 
independent of the effect on the actin cytoskeleton (Qa’Dan et al., 2002; Gerhard et al., 
2008). Additionally, C. difficile may gain access to the underlying lamina propria and 
submucosa, to act directly on other cell types once the epithelial barrier is breached 
(Mahida et al., 1998; Solomon et al., 2005).   
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The current study showed that strains R20291, 630, and M68 caused an extensive TJ 
disruption in infected T84 cell-lines which was concomitant with increased TEER loss and 
enhanced barrier permeability, detected as FITC-dextran flux (Figures 4.11-4.14). Co-culture 
experiments showed that R20291 induced the highest levels of IL-8 compared to the other 
strains. Whilst, similar amount of IL-8 was detected in response to strains 630 and M68, 
CF5-infected cells released the lowest quantity. Strains R20291, 630 and M68 also induced 
significant levels of apoptosis/necrosis in infected Caco-2 cells, although disruption of the 
epithelium and cell death was detected with CF5, it was to the lesser extent compared to 
other strains. These series of experiments showed that hypervirulent R20291 was 
inherently more potent compared to strains 630, M68 and CF5. While, 630 and M68 had 
the potential to induce comparatively similar responses, strain CF5 initiated the least effect. 
It was hypothesised that CF5 owes its low potency to differential TcdB glucosylation 
property, although strain CF5 was observed to produce more toxin than M68 (Figure 3.6). 
Studies have shown that toxins of some C. difficile strains and particularly TcdB have 
inherent variability (Chaves-Olarte et al., 2003; Stabler et al., 2008; Lanis et al., 2010). Strain 
M68 significantly glucosylated Rac1 compared to CF5, nonetheless further investigation is 
required to identify the underlying mechanisms responsible for the differences in activity 
between the two forms of this toxin. Also comparison of M68 and CF5 completed 
sequences may shed a light on observing any possible sequence variation. 
A severe inflammatory response with a marked neutrophil accumulation is a key 
characteristic of the clinical pathophysiology of CDI (Johnson & Gerding, 1998; Kelly & 
LaMont, 1998). Neutrophil recruitment to the site of the infection is a complex and 
multistep process (Springer, 1994), which is driven by a local production of an array of 
chemoattractants and activated cytokines that establish a chemotactic gradient. IL-8 is a 
potent pro-inflammatory chemokine that predominantly exerts its effects on neutrophils 
(Hoch et al., 1996). Analysis of mucosal responses revealed that C. difficile strains evoked a 
robust inflammatory cytokine response in colonic tissues, eliciting a strong induction of IL-8 
and comparatively weak IL-17A (Figure 4.15). This response suggested that IL-8 may play a 
pivotal role in mediating neutrophil recruitment necessary for containment of the infection. 
Additionally, C. difficile infection caused a strong IL-1β and IFN-γ secretion, release of pro-
inflammatory cytokines is a critical activation event in C. difficile-mediated inflammation. IL-
1β has been reported to increase both IL-8 secretion by TcdA-treated HT-29 cells and 
promote intercellular adhesion molecule-1 (ICAM-1)-dependent neutrophil adhesion, two 
molecules that are important in neutrophil chemoattraction, adhesion and subsequent 
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inflammation (Kelly et al., 1994; Tixier et al., 2005). Furthermore, it has been shown that 
IFN-γ has an essential role in TcdA-induced enteritis by enhancing TNF-α, MIP (Macrophage 
inflammatory protein)-1α, MIP-2 and ICAM-1 secretion (Ishida et al., 2004). This data 
showed that M68 initiated inflammatory responses in infected paediatric colonic biopsies 
to a similar extent as R20291 and 630, while CF5 caused significantly less pro-inflammatory 
IL-1β, IFN-γ and inflammatory IL-17A release. This study could be further developed to 
establish host differential responses to C. difficile and its toxins by employing toxin mutant 
strains and providing an anaerobic environment for bacteria by utilising Ussing chambers.  
Although C. difficile toxins have been suggested to initiate IL-8 secretion nevertheless the 
present study demonstrated that bacterial whole cell cultures induced considerably more 
IL-8 release than bacterial supernatants (potential source of secretory toxins) in Caco-2 and 
HT-29 cells, indicating that additional, as yet undefined cell-associated bacterial factors may 
be involved in triggering IEC innate immunity alongside the toxins. Moreover, it was 
observed that C. difficile was recognised by a number of TLRs, specifically with TLR2/6 and 
TLR5 (Figures 5.2-5.3). In addition to the known effect of C. difficile mediated IL-8 secretion 
via TJ disruption, our observations define a second potential mechanism of how C. difficile 
recognition by host TLRs may mediate IEC IL-8 responses. It is still unclear how C. difficile 
induce chemokine and cytokine production. While several studies have suggested both 
Rho-dependent and independent cytokine release mechanisms (Warny et al., 2000; Yeh et 
al., 2008; Sun et al., 2009), others have proposed the involvement of NF-κB or MAPK p38 in 
the cytokine secretion (Castagliuolo et al., 1998; Jefferson et al., 1999; Kim et al., 2006b). 
There are reports showing NF-κB not being involved in TcdB-mediated IL-8 production, 
while it plays an important role in TcdA-mediated IL-8 secretion. 
C. difficile is an anaerobic bacterium therefore there are limitations with co-culture studies. 
This thesis described providing an anaerobic environment for bacteria by employing an 
Ussing vertical chamber system. This series of experiments showed a significant increase in 
secretion of pro-inflammatory IL-8 and TNF-α, and antimicrobial hBD-2 accompanied by a 
rapid TEER loss when strains R20291, 630 and M68 were co-cultured under anaerobic 
conditions compared to cultures under an aerobic environment. It was hypothesised that 
observed increase in cytotoxic and cytopathic effects were as a result of optimal condition 
for bacterial growth. However, it is yet to be determined whether these effects were a 
result of increased bacterial viable count and/or bacterial adherence. Interestingly, the 
strain CF5 showed an increase in TEER loss when cultured under anaerobic conditions 
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however no significant increase in cytokine response was detected compared to cultures 
under an aerobic environment.  
Utilising an in vitro murine model of infection suggested that C. difficile had the ability to 
promote bone-marrow-derived DCs (BMDCs) maturation, which was supported by up-
regulation of the co-stimulatory molecules CD80 and CD86, as well as the cell surface 
markers MHCII and CD40. Further, infected BMDCs released larger amounts of IL-23 and IL-
27 compared to IL-12 highlighting that C. difficile strains exhibit differential ability in 
modulating DC IL-12 family members which is likely to impact downstream T cell immunity. 
BMDCs infected with strains R20291 and M68 expressed similar levels of IL-12 family 
cytokines, 630 was the least inducer while the highest secretion was observed in response 
to CF5. Previous studies have shown IL-1β release in response to C. difficile toxins and SLPs, 
in here data obtained from human and murine DCs clearly showed that strains R20291, 630 
and M68 elicited a significant IL-1β secretion. In contrast, CF5 caused the least pro-
inflammatory IL-1β response. As IL-1β is known to be involved in the neutrophil recruitment 
during CDI this data could provide potential insights into the pathophysiological 
mechanisms of these strains. Also a robust anti-inflammatory IL-10 was induced in response 
to strain CF5 which may indicate why CF5 infected hosts typically remain clinically 
asymptomatic. 
T cell activation was investigated to identify whether C. difficile-stimulated mature DCs had 
the potential to prime and influence T cell responses. C. difficile strains induced strong IFN-γ 
secretion compared to IL-4, indicating the ability of C. difficile in promoting a shift in 
Th1/Th2 balance toward Th1-dominant immunity. Further, a robust IL-17A expression in 
response to R20291, 630 and M68 indicated that these strains mediate potent Th1/Th17 
immunity. Although strain CF5 caused the highest IL-23 protein expression, it showed the 
least propensity for IL-17A production and caused the highest IL-4 secretion compared to 
other strains promoting more Th1/Th2 responses. Thus, strain CF5 may tune the fine 
balance of Th1/Th2 immunity affecting antibody responses and in particular IgG which 
assists toxin neutralisation.  
The process of DC maturation is important to the pathogenesis of CDI however the role of 
C. difficile toxins in mediating disease via DC maturation is less clear. This study showed 
that R20291 and 630 Δerm toxin mutant strains did not exert a significant impact on BMDC 
CD80, MHCII and CD40 expression compared to the parental strains although an effect on 
CD86 was observed. Further, data presented in Figures 7.11 – 7.16 indicated that C. difficile 
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may engage in toxin-independent mechanism(s) to regulate BMDC IL-12 family and IL-10 
responses, and yet, toxin-dependent mechanism(s) are likely to be critical regulators of IL-
1β secretion. However, the notion why 630 Δerm tcdA was less potent in IL-1β induction is 
still unknown. It could be hypothesised that either TcdB is an essential C. difficile virulence 
factor in triggering CDI or the significantly increased IL-1β secretion in response to 630 
Δerm tcdB is due to increased TcdA expression attributed to tcdB mutation. Therefore, 
although strains R20291 and 630 toxin mutants provided a unique potential to gain a better 
understanding of the role of toxins nevertheless, R20291 triple toxin mutant can facilitate 
comprehensive and comparative investigation of C. difficile toxins.    
Moreover, C. difficile activated the caspase-1 and triggered IL-1β secretion in BMDCs in an 
ASC-containing inflammasome. The ASC-dependent activation of the inflammasome has 
been reported by Ng et al. (2010) showing contribution of IL-1β to toxin-induced 
inflammation and intestinal injury in vivo. They also observed that TcdA and TcdB not only 
trigger IL-1β release but also induce ASC-dependent pyroptosis. Caspase-1 dependence is a 
key feature of pyroptosis, which ultimately results in the release of pro-inflammatory 
intracellular contents, including IL-1β. They suggested that C. difficile triggered NLRP3 
inflammasome activation and IL-1β release. However, glibenclamide a NLRP3 inhibitor did 
not completely abolish the toxin-induced IL-1β release, also they were unable to show a 
significant role for NLRP1, 2, 6, 12 and Ipaf in the toxin-induced inflammasome activation 
concluding other NLRs may contribute to activation of the inflammasome. The current 
study showed strains R20291, 630 and their toxin mutants together with M68 caused IL-1β 
processing in Nod2, Ipaf and Nlrp3 deficient BMDCs, ruling out critical roles for these NLRs 
in triggering the inflammsome. Hasegawa and co-workers (2011) have already shown that 
Nod1 deficient mice are more susceptible to C. difficile infection than Nod2 deficient mice 
suggesting a protective role for Nod1 against C. difficile by recruiting neutrophil to clear the 
bacteria. Therefore, a further investigation is required to identify the NLR(s) responsible for 
C. difficile-induced inflammasome activation in DCs and macrophages.  
Also, even though strain CF5 consistently caused minimal IL-1β responses, western blot 
results (Figure 6.4) showed that this strain is as equipotent as other strains in activating 
caspase-1, thus it remains to be answered how CF5 elicits the least IL-1β secretion. 
Furthermore, it is unclear why Nod2, Ipaf and Nlrp3 deficiency enhanced potency of CF5 
leading to increased levels of IL-1β compared to WT BMDCs.  
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Taken all together, C. difficile strains have the potential to elicit differential immune 
responses based on a cell type they encounter. Also distinct toxin-dependent and 
independent effects on host immunity were observed indicating a potential role for other 
bacterial virulence factors such as the capsule, SLPs, flagella, pili and hydrolytic enzymes in 
engaging host-pathogen interactions.   
Despite the progress that have been made in understanding the molecular mechanisms of 
TcdA and TcdB, many fundamental questions remain unanswered regarding the 
involvement and contribution of the bacteria itself and its virulence factors in the onset and 
progression of the CDI. The nature of the specific receptors for TcdA, TcdB and binary toxin 
is still unknown and it is not clear why TcdA and TcdB present such a diverse biological 
activity while they share high amino acid sequence identity, similar domain structures and 
act in a similar molecular mode, yet display different enterotoxic potential. Also the 
respective roles of TcdA, TcdB, and binary toxin in the host inflammatory response(s) and 
pathogenesis still remain undefined.  
Given the increasing emergence of hypervirulent strains and community-acquired CDI, 
further investigations will improve our understanding of this bacterium, leading to a better 
containment of the associated disease.  
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